{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyMBKLRYvhuga5wd0j2fRKN2",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/Sugandaram/Akaike-Technologies-Assignment-Submission/blob/main/NLP_Tweeter__Assignment.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hPyeucmUGJ4i",
        "outputId": "52470879-2547-449a-e0a7-8414908743f2"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting googletrans==4.0.0-rc1\n",
            "  Downloading googletrans-4.0.0rc1.tar.gz (20 kB)\n",
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Collecting httpx==0.13.3\n",
            "  Downloading httpx-0.13.3-py3-none-any.whl (55 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m55.1/55.1 KB\u001b[0m \u001b[31m3.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: idna==2.* in /usr/local/lib/python3.8/dist-packages (from httpx==0.13.3->googletrans==4.0.0-rc1) (2.10)\n",
            "Collecting httpcore==0.9.*\n",
            "  Downloading httpcore-0.9.1-py3-none-any.whl (42 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m42.6/42.6 KB\u001b[0m \u001b[31m2.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: certifi in /usr/local/lib/python3.8/dist-packages (from httpx==0.13.3->googletrans==4.0.0-rc1) (2022.12.7)\n",
            "Collecting rfc3986<2,>=1.3\n",
            "  Downloading rfc3986-1.5.0-py2.py3-none-any.whl (31 kB)\n",
            "Collecting hstspreload\n",
            "  Downloading hstspreload-2023.1.1-py3-none-any.whl (1.5 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.5/1.5 MB\u001b[0m \u001b[31m26.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting sniffio\n",
            "  Downloading sniffio-1.3.0-py3-none-any.whl (10 kB)\n",
            "Collecting chardet==3.*\n",
            "  Downloading chardet-3.0.4-py2.py3-none-any.whl (133 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m133.4/133.4 KB\u001b[0m \u001b[31m10.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting h2==3.*\n",
            "  Downloading h2-3.2.0-py2.py3-none-any.whl (65 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m65.0/65.0 KB\u001b[0m \u001b[31m3.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting h11<0.10,>=0.8\n",
            "  Downloading h11-0.9.0-py2.py3-none-any.whl (53 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m53.6/53.6 KB\u001b[0m \u001b[31m4.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting hpack<4,>=3.0\n",
            "  Downloading hpack-3.0.0-py2.py3-none-any.whl (38 kB)\n",
            "Collecting hyperframe<6,>=5.2.0\n",
            "  Downloading hyperframe-5.2.0-py2.py3-none-any.whl (12 kB)\n",
            "Building wheels for collected packages: googletrans\n",
            "  Building wheel for googletrans (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for googletrans: filename=googletrans-4.0.0rc1-py3-none-any.whl size=17414 sha256=71dacdb799720bba2aae1c6d7c4e4d852756dd77a3390032133ca64bafcb52e6\n",
            "  Stored in directory: /root/.cache/pip/wheels/a9/25/af/715361fa79594524c89c75d293def652045f3fdce6ca398712\n",
            "Successfully built googletrans\n",
            "Installing collected packages: rfc3986, hyperframe, hpack, h11, chardet, sniffio, hstspreload, h2, httpcore, httpx, googletrans\n",
            "  Attempting uninstall: chardet\n",
            "    Found existing installation: chardet 4.0.0\n",
            "    Uninstalling chardet-4.0.0:\n",
            "      Successfully uninstalled chardet-4.0.0\n",
            "Successfully installed chardet-3.0.4 googletrans-4.0.0rc1 h11-0.9.0 h2-3.2.0 hpack-3.0.0 hstspreload-2023.1.1 httpcore-0.9.1 httpx-0.13.3 hyperframe-5.2.0 rfc3986-1.5.0 sniffio-1.3.0\n"
          ]
        }
      ],
      "source": [
        "!pip install googletrans==4.0.0-rc1"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import nltk\n",
        "nltk.download('averaged_perceptron_tagger')\n",
        "import nltk\n",
        "nltk.download('stopwords')\n",
        "nltk.download('brown')\n",
        "nltk.download('wordnet')\n",
        "nltk.download('punkt')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fOvhFFbLGNcl",
        "outputId": "05c0d605-6e7b-445b-f66d-6e3995bc01a4"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package averaged_perceptron_tagger to\n",
            "[nltk_data]     /root/nltk_data...\n",
            "[nltk_data]   Unzipping taggers/averaged_perceptron_tagger.zip.\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n",
            "[nltk_data] Downloading package brown to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/brown.zip.\n",
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n",
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 2
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Importing Pandas to work with dataframe\n",
        "import pandas as pd     \n",
        "\n",
        "#Importing numpy for working with numpy arrays and other functions\n",
        "import numpy as np      \n",
        "\n",
        "#Importing json for reading the json file of tweets\n",
        "import json\n",
        "\n",
        "import re\n",
        "\n",
        "#Elimination of Stop words\n",
        "from nltk.corpus import stopwords \n",
        "from nltk.util import ngrams \n",
        "\n",
        "#Counting the frequency\n",
        "from collections import Counter\n",
        "\n",
        "#NLP Toolkit\n",
        "import nltk\n",
        "\n",
        "\n",
        "# For visualization:\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns\n",
        "\n",
        "#Importing Translator from googletrans for tweet translation purpose\n",
        "from googletrans import Translator"
      ],
      "metadata": {
        "id": "zkd511qzGQ1S"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "with open('tweets.json') as jfile:\n",
        "  \n",
        "  df = json.load(jfile)"
      ],
      "metadata": {
        "id": "4uiGzMYaGcFK"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "v1KznneJGoc3",
        "outputId": "1915f853-f1e5-4af2-9c80-9ea4a0b3d258"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'1374140386071961602': {'tweet_author': 'Hematopoiesis News',\n",
              "  'tweet_text': '⚕️ Scientists conducted a Phase II study of acalabrutinib in patients with relapsed/refractory #CLL who were ibrutinib-intolerant, and found an overall response rate of 73%. \\nhttps://t.co/eJ6m4QpC5P https://t.co/kuZz6ZO47r'},\n",
              " '1374032432173842437': {'tweet_author': 'Michael Wang, MD',\n",
              "  'tweet_text': 'This phase 2 Acalabrutinib-Venetoclax (AV) trial that is still in recruitment phase will study how well venetoclax and acalabrutinib works in MCL patients who either relapsed or non-respondent to the initial therapy.\\n\\nhttps://t.co/gg0G9At23N'},\n",
              " '1373902876553048065': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#NICE backs #AstraZenecas #Calquence for #CLL https://t.co/Vb5lPDoGrA'},\n",
              " '1373656782367813635': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': '#acalabrutinib is a valuable option in pts intolerant to #ibrutinib. Further valuable data to help decision making in #CLL \\n\\nEarly View | Haematologica https://t.co/Z2kCLZaX0D'},\n",
              " '1372941634334232586': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'NICE has recommended the use of acalabrutinib for patients with treatment-naïve chronic lymphocytic leukemia. Find out more here https://t.co/6OuJptLCIN #lymsm #lymphoma'},\n",
              " '1372927482278539265': {'tweet_author': 'David Ledger',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/JOPNLNID5R https://t.co/9pwY4NKP4s'},\n",
              " '1372911723305394179': {'tweet_author': 'N Wales Cancer Forum',\n",
              "  'tweet_text': 'This is England for now - these decisions usually come to Wales too. \\nMore info\\n\\n https://t.co/SR5TU0ZSHH https://t.co/OFdwEdlav6'},\n",
              " '1372888121159868423': {'tweet_author': 'European Pharmaceutical Review',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic #leukaemia.\\n#oncology #drugapprovals #pharma #healthnews\\nFind out more here: https://t.co/qYUft2Cn8b https://t.co/Sxve6NGGX3'},\n",
              " '1372866915081797632': {'tweet_author': 'Graham Collins',\n",
              "  'tweet_text': 'Superstar @tobyeyre82 responding to the excellent news of NICE approval of acalabrutinib in frontline CLL for FCR / BR unsuitable patients. https://t.co/lACvpOtrWx'},\n",
              " '1372825553837944834': {'tweet_author': 'CLL Ireland',\n",
              "  'tweet_text': 'CLL patients all know the drug Ibrutinib and yesterday in the UK Acalabrutinib was approved and now a new drug Pirtobrutinib is making a big impact for relapsed patients in recent #clinicaltrials\\n@cancertrials_ie @CllSociety @LAL_NI @BloodCancerIRL\\nhttps://t.co/murr3KPhsZ'},\n",
              " '1372788676191608837': {'tweet_author': 'Mice Ideas',\n",
              "  'tweet_text': 'Optimal Management of High-Risk CLL with Acalabrutinib\\n19 March 2021 | 7.00 pm - 8.30 pm\\n\\nSpeaker 1 - Dr P G Subramanian, Mumbai \\nSpeaker 2 - Group Captain (Dr) Harshit Khurana, Pune\\n\\nChair: Dr S H Advani, Mumbai\\nModerator: Dr M B Agarwal, Mumbai\\n\\nLink: https://t.co/ou2dEMfIcE https://t.co/nvAeDoMRll'},\n",
              " '1372662881230188555': {'tweet_author': 'Farooq A Wandroo',\n",
              "  'tweet_text': 'Acalabrutinib for all forms of CLL, NICE today.get ready  @SwbhPharmacy @StevenShanu @HojanSenya\\n@SWBH_RandD @Oncology_at_AZ https://t.co/pG1GaUtZ5j'},\n",
              " '1372583112723533827': {'tweet_author': 'Leukaemia Care',\n",
              "  'tweet_text': 'It has been announced today (Thursday 18th March) that The National Institute for Health and Care Excellence (NICE) have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in England.'},\n",
              " '1372558560543047693': {'tweet_author': 'Helen Oram',\n",
              "  'tweet_text': 'NICE has recommended the use of acalabrutinib, as a monotherapy option for adults with:\\n•a 17p\\xa0deletion or TP53\\xa0mutation, or\\n•no 17p\\xa0deletion or TP53\\xa0mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable. https://t.co/ntYG8VLKyZ'},\n",
              " '1372549029767299076': {'tweet_author': 'HealthWatch',\n",
              "  'tweet_text': 'A brand new oral treatment, Acalabrutinib, taken as a twice daily tablet, for untreated  blood cancer, chronic lymphocytic leukaemia, has today (Thursday 18 March 2021) been recommended for NHS use by NICE.\\nhttps://t.co/nLoyYbepRA'},\n",
              " '1372529109805510658': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/P6fy1o0mTi'},\n",
              " '1372528985691746305': {'tweet_author': 'Pharma Trader',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/V0wjoKqqTm'},\n",
              " '1372528101335265284': {'tweet_author': 'Everything Pharma',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/8RAQ6sLJIs'},\n",
              " '1372526440680333314': {'tweet_author': 'IJPSonline',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/hKPfa0IW6N'},\n",
              " '1372519291635998731': {'tweet_author': 'Iceberg Vision',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/6b1RYaHRxX'},\n",
              " '1372515771205742604': {'tweet_author': 'PharmaTimes',\n",
              "  'tweet_text': 'NICE backs AstraZeneca’s Calquence for CLL https://t.co/FTEaEMFSW7 #pharma #lifesciences'},\n",
              " '1372510731795492867': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia https://t.co/osJpzYCezE #CLL #leusm #hematology'},\n",
              " '1372490442911141897': {'tweet_author': 'Pharma News',\n",
              "  'tweet_text': 'TARGETED ORAL MONOTHERAPY CALQUENCE (ACALABRUTINIB) RECOMMENDED BY NICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)\\nhttps://t.co/tJ2w5zcKD3\\n#PharmaNews #ClinicalResearchNews #BiotechNews #LifeSciencesNews #MedicalNews #HealthcareNews #PharmiwebNews https://t.co/wYA5UUOJqo'},\n",
              " '1372475756845137920': {'tweet_author': 'CLL Ireland',\n",
              "  'tweet_text': 'As the UK approve new treatments for #CLL with Acalabrutinib now available. Ireland falls far behind.\\nPatients need better options. \\n@JanRynne @DonnellyStephen @HSELive @davidcullinane @hseNCCP @paulreiddublin @IPPOSI @PaulMcauliffe @RoisinShortall https://t.co/tW2zAInOlp'},\n",
              " '1372473228938084360': {'tweet_author': 'pharmaphorum',\n",
              "  'tweet_text': '.@NICEComms backs NHS use for @AstraZeneca’s Calquence for new leukaemia indication, and @DaiichiSankyo’s cholesterol-lowering drugs Nilemdo and Nustendi #heor https://t.co/PqFk7N9pCi'},\n",
              " '1372473109287215104': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': '#Acalabrutinib @NICEComms approved for 1L #CLL in UK\\n- All pts considered unfit for FCR or BR\\n- All pts TP53 mut/del\\n- All relapsed CLL\\n\\nEnjoyed talking about this with @CLLSupport Chair of Trustees Marc Auckland on Sky News this am. \\n\\nGreat news for our #CLL pts! @bloodcancer_uk https://t.co/Sh0iIDgKel'},\n",
              " '1372447809467777025': {'tweet_author': 'Lymphoma Papers',\n",
              "  'tweet_text': 'Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study #lymphoma #lymsm https://t.co/NrxD4YK0zm'},\n",
              " '1372240588527968259': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study https://t.co/iVdJs3l0Z0 #CLL #leusm #hematology'},\n",
              " '1371884004950089733': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'Congress| #EBMT21 | @michaelwangmd, @MDAndersonNews, discussed results of the ZUMA-2 study in R/R mantel cell lymphoma by morphology and prior BTKi exposure to ibrutinib and/or acalabrutinib. He concluded that all subgroups drew clinical benefit from KTE-X19 treatment. #lymsm https://t.co/vufXrfRbgD'},\n",
              " '1371398643236925441': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) for treatment of chronic lymphocytic leukaemia (CLL) https://t.co/mR2qsZwCZX'},\n",
              " '1370026180603117580': {'tweet_author': 'Osgood',\n",
              "  'tweet_text': 'Calquence Commercial Had A REALLY PRETTY Lady In it @CHANEL @TwitterSupport A nurse I think'},\n",
              " '1367801199638896640': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma https://t.co/I42benJlRg #MCL #lymsm #hematology'},\n",
              " '1367440609896710145': {'tweet_author': 'Thiago Carvalho',\n",
              "  'tweet_text': \"'Solidarity negotiated with Astra-Zeneca to test its cancer drug acalabrutinib, which dampens the immune system. Investigators changed treatment protocols to include the medicine, but then the company decided not to give the green light.'\\n\\nhttps://t.co/x65mJlnv42\"},\n",
              " '1366770231289536522': {'tweet_author': 'Kartos Therapeutics',\n",
              "  'tweet_text': 'ICYMI, please view our #ASH20 TiP poster presentation about a new study that will explore the combination of KRT-232 (MDM2i) + acalabrutinib in patients with R/R B-Cell malignancies. https://t.co/g5uOottDLo. Find out more at https://t.co/sgbNXj8zNx #LYMSM #CLL #DLBCL'},\n",
              " '1365755830574977026': {'tweet_author': 'Apoli Naria',\n",
              "  'tweet_text': 'IQVIA RDS Argentina S.R.L. representa en Argentina a \\n1. Janssen Vaccines &amp; Prevention B.V.\\n2. Pharma B.V.\\n3. AstraZeneca AB\\n4. Amgen Inc.\\n\\nACALABRUTINIB\\nApremilast\\nLanadelumab\\nAbatacept-remdesivir-infliximab-mesilato de cenicriviroc\\n\\nhttps://t.co/KuRUk5RKIY\\n\\ncc:  @spitta1969'},\n",
              " '1365449441398915076': {'tweet_author': 'Michael Wang, MD',\n",
              "  'tweet_text': 'Maria, we appreciate you!\\nOur group has passed 4 FDA inspections. In 2013, we led Ibrutinib FDA approval; in 2017, we led acalabrutinib FDA approval and in 2020, we led Brexucarbatagene Autoleucel FDA approval. Without your leadership and our wonderful team, not possible! https://t.co/FPUMj4qaq2'},\n",
              " '1364491860954259459': {'tweet_author': 'Cardio-Targets',\n",
              "  'tweet_text': 'The role of acalabrutinib in adults with chronic lymphocytic leukemia https://t.co/xv81it4zeO'},\n",
              " '1364304315838582793': {'tweet_author': 'Lymphoma Papers',\n",
              "  'tweet_text': 'The role of acalabrutinib in adults with chronic lymphocytic leukemia #lymphoma #lymsm https://t.co/LVp7uro7so'},\n",
              " '1364302784938475521': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: The role of acalabrutinib in adults with chronic lymphocytic leukemia https://t.co/XRlUn5eVpU #CLL #leusm #hematology'},\n",
              " '1364189928133976069': {'tweet_author': 'Cardio-Targets',\n",
              "  'tweet_text': 'The role of acalabrutinib in adults with chronic lymphocytic leukemia. https://t.co/aPrU50bG9R'},\n",
              " '1364169662267682820': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: The role of acalabrutinib in adults with chronic lymphocytic leukemia. https://t.co/YAnuxMbr89 #CLL #leusm #hematology'},\n",
              " '1364019275279654912': {'tweet_author': 'Jeff Sharman',\n",
              "  'tweet_text': 'The role of CD20 in addition to BTK inhibitors is not a closed story.  We previously published obinutuzumab benefit with acalabrutinib (https://t.co/klsjuwWfDM).  \\n\\nNow we show, Ublituximab to Ibrutinib has benefit in 17P #TGTherapeutics @anthonymatomd \\n\\nhttps://t.co/l7qRcv0uDS'},\n",
              " '1363455819493310464': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma https://t.co/KpdyK3KvOO #MCL #lymsm #hematology'},\n",
              " '1362729902856941568': {'tweet_author': 'IM Médico',\n",
              "  'tweet_text': 'Acalabrutinib alcanza el objetivo primario de eficacia en comparación con ibrutinib en LLC @AstraZenecaES       \\n https://t.co/4VTn1Bsx5O'},\n",
              " '1362727073329131520': {'tweet_author': 'FirstWord Pharma',\n",
              "  'tweet_text': \"Physician Views Preview: Digging into the impressive US launch of AstraZeneca's Calquence $AZN https://t.co/MV4LVMUuQb\"},\n",
              " '1361822683227389957': {'tweet_author': 'CancerNetwork®, Home of the Journal ONCOLOGY®',\n",
              "  'tweet_text': '#ICYMI: Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program.\\nhttps://t.co/m89J49LBfC'},\n",
              " '1360604941971316737': {'tweet_author': 'Tom Henry, MBA, RPh, CPh',\n",
              "  'tweet_text': 'CLL Research: Acalabrutinib – An Analysis of Cardiovascular\\xa0Events https://t.co/sPoUZ0fDnp'},\n",
              " '1360504470883475456': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Comparing acalabrutinib to standard treatments in patients with chronic lymphocytic l... https://t.co/tLXIunsT1a via @medivizor #Leukemia'},\n",
              " '1360378272148815874': {'tweet_author': 'mednetnews',\n",
              "  'tweet_text': 'MCL Survival Likely Affected by Reason for Acalabrutinib\\xa0Discontinuation https://t.co/HSJCzH0Kq2'},\n",
              " '1360319765252886533': {'tweet_author': 'AJMC',\n",
              "  'tweet_text': 'Mantle Cell Lymphoma Survival Likely Affected by Reason for Acalabrutinib Discontinuation: https://t.co/CBfJM8GhPy https://t.co/plFzmtrPzO'},\n",
              " '1359883921979244551': {'tweet_author': 'Patient Worthy',\n",
              "  'tweet_text': 'CALQUENCE Beneficial for CLL, Study Shows https://t.co/zlYXexHKa7 #calquence #CLL #chroniclymphocyticleukemia #rarecancer #treatment @LLSusa'},\n",
              " '1359503020694798338': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: ALICIA (Acalabrutinib in CLL Therapy) https://t.co/xuHPwIu5mO #CLL #leusm #hematology'},\n",
              " '1358937124423290884': {'tweet_author': 'Cat',\n",
              "  'tweet_text': 'https://t.co/NDVz7aYo0K'},\n",
              " '1358840804928876545': {'tweet_author': 'Hemalatha Rangarajan MD',\n",
              "  'tweet_text': '#TCTM21 #gvhdsm #chronicGVHD @StephanieLeeMD Number of registered studies for cGVHD, drugs in these studies, a newer \"itinib\" : oral acalabrutinib https://t.co/CXLx3uWEcv'},\n",
              " '1358182533498871808': {'tweet_author': 'mednetnews',\n",
              "  'tweet_text': 'Mantle Cell Lymphoma Treatment Market By Product Type (Acalabrutinib, JCAR-017) And By End-Users/Application (Hospital, Clinic) Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2021 –\\xa02028 https://t.co/h3S3OG3G7n'},\n",
              " '1358089001689702401': {'tweet_author': 'Bita Fakhri',\n",
              "  'tweet_text': 'In this review, we tried to situate #acalabrutinib among the treatment options for patients with treatment-naive and rel/ref CLL.  https://t.co/ajnFfceVEp'},\n",
              " '1357362376916545538': {'tweet_author': 'NCPE',\n",
              "  'tweet_text': 'Acalabrutinib (Calquence®) | HTA ID: 20063 | National Centre for Pharmacoeconomics | https://t.co/hVpLP5zE5b https://t.co/wi0DvbZXZt'},\n",
              " '1357356433310965761': {'tweet_author': 'JOURNAL ONKOLOGIE',\n",
              "  'tweet_text': 'News von https://t.co/y3RvLBtHWZ – Lesen Sie jetzt den vollständigen Beitrag unter:\\nhttps://t.co/C0MrJSBxlu\\n\\n#Arzt #Schmerz #CLL_Immunchemotherapie #Leukämie #Immuntherapie #Neutropenie #Mutation #Acalabrutinib #Patient #Therapie #Unverträglichkeiten #Zulassung #Studie'},\n",
              " '1357056544454676489': {'tweet_author': 'Oncology Learning Network',\n",
              "  'tweet_text': 'In this video, Dr Danilov, @OHSUNews, discusses the use of #acalabrutinib, (@CalquenceHCP) as a treatment option for #patients with CLL, SLL, and MCL.\\n\\nWatch Here: https://t.co/UULj3g798S\\n\\n#MedEd #MedTwitter #Healthcare https://t.co/0FHgk0h1V1'},\n",
              " '1356950776388739073': {'tweet_author': 'Oncology Learning Network',\n",
              "  'tweet_text': 'In this video interview, Dr Graff, @MercyOneDSM, discusses the evolving treatment landscape for #CLL in recent years, especially with the introduction of #acalabrutinib (Calquence; AstraZeneca).\\n\\nWatch Here: https://t.co/tDq0yoIVV7 https://t.co/0zw9GEAp1W'},\n",
              " '1356497620923998214': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'For the phase 3 trial, investigators set out to evaluate PFS benefit with acalabrutinib versus ibrutinib in previously treated patients with high-risk CLL. #leusm https://t.co/RFP5ZFI9Ua'},\n",
              " '1355979506071330819': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Comparing acalabrutinib to standard treatments in patients with chronic lymphocytic... from @medivizor: https://t.co/tLXIunsT1a #Leukemia'},\n",
              " '1355636954474426374': {'tweet_author': 'TrialSite News',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence Meets Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia\\n\\nhttps://t.co/k6GGKO69lZ\\n\\n#Hematology #Oncology #Acalabrutinib #CLL #PFS #n=533 #AstraZeneca https://t.co/RM308oXVa3'},\n",
              " '1355553403645136897': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib https://t.co/Xn7yfvxE1z'},\n",
              " '1355155741980708864': {'tweet_author': 'Lyfebulb',\n",
              "  'tweet_text': 'Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/QC1WDwWCcp #chronicillness #digitalhealth #Lyfebulb'},\n",
              " '1355017852793856003': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia. #leusm https://t.co/oYihNdET4I'},\n",
              " '1354878082621071361': {'tweet_author': 'The Medical Ed Cons.',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica \\n\\nhttps://t.co/hg4z5BVkTK'},\n",
              " '1354841708723392519': {'tweet_author': 'CancerNetwork®, Home of the Journal ONCOLOGY®',\n",
              "  'tweet_text': 'Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program. | @AstraZeneca \\nhttps://t.co/m89J49LBfC'},\n",
              " '1354542241210101763': {'tweet_author': 'CarnivoresHealth',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/lvZyqYFRzA https://t.co/Ek3TTOltU4'},\n",
              " '1354537187526717445': {'tweet_author': 'Portfolio Penny',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/AAQF9Btz5m https://t.co/1oki6GxPjP'},\n",
              " '1354537173362597892': {'tweet_author': 'FancyFinancy',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/h9uHkFDvpk https://t.co/YSaNwCZglK'},\n",
              " '1354534707250290689': {'tweet_author': 'Robo Schmobo',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/bfn5cRAVG0 https://t.co/qC3sL5xBce'},\n",
              " '1354532137559617536': {'tweet_author': 'Financial Carnivores',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/Showno9jIh https://t.co/Fxx7gKb1Ww'},\n",
              " '1354474488709181441': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'News| Acalabrutinib has met the primary endpoint of non-inferior PFS vs ibrutinib in the phase III ELEVATE-RR trial for R/R CLL. Find out more here https://t.co/QarwKGmNJE #lymsm https://t.co/PIpTt2tbG3'},\n",
              " '1354423095872917504': {'tweet_author': 'NetCancer',\n",
              "  'tweet_text': \"[#AMMHémato]\\nL'acalabrutinib un nouveau traitement chez les patients adultes atteints d’une #Leucémie Lymphoïde Chronique. \\nRetrouvez tous les détails de cette molécule sur notre Findrugs 💻 https://t.co/tvRzX0NLcp\\n\\n#cancer #innovation #informationpatient #hématologie #traitement https://t.co/MLpo9wMwbk\"},\n",
              " '1354238697466687495': {'tweet_author': 'DMGAZ',\n",
              "  'tweet_text': 'A head-to-head study of two #leukemia drugs showed one may be safer relative to side effects associated with cardiac issues. #cardiology #cancer #stroke\\nhttps://t.co/zqsVEGSAyV'},\n",
              " '1354236123413934084': {'tweet_author': 'Amit Patel🇬🇧',\n",
              "  'tweet_text': 'Impact of #CART therapy in those patients with #mantle cell #lymphoma that remain alive in this cohort after #acalabrutinib failure https://t.co/ceS7lsuoiO'},\n",
              " '1354231408223514624': {'tweet_author': 'Blood Advances',\n",
              "  'tweet_text': 'Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib https://t.co/rMiCwSMc1z #CLL https://t.co/vAArexGTfH'},\n",
              " '1354155126689308673': {'tweet_author': 'The Medical Ed Cons.',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica \\n\\nhttps://t.co/hg4z5BVkTK'},\n",
              " '1354135353028997121': {'tweet_author': 'Silas Inman',\n",
              "  'tweet_text': 'Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL https://t.co/HKnmF6nr5m'},\n",
              " '1354120316348465160': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib Shows Noninferior PFS Versus Ibrutinib in High-Risk CLL #leusm https://t.co/ikwuezSI3i'},\n",
              " '1354082212010979330': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'In adults with previously treated, high-risk chronic lymphocytic leukemia, treatment with acalabrutinib was found to be non-inferior to treatment with ibrutinib in terms of progression-free survival. #leusm\\nhttps://t.co/zaH6KhPFKV'},\n",
              " '1354081826583830530': {'tweet_author': 'AnalySource: Premier Drug Pricing Services',\n",
              "  'tweet_text': 'Five things for pharma marketers to know: Tuesday, January 26, 2021 - Roundup - MM&amp;M - Medical Marketing and Media https://t.co/dpi8rn2plu\\n\\n#COVID19 @BoosterShot #Calquence\\n\\n@Merck @statnews @MMMnews @nytimes @endpts @politico @CNBC @moderna_tx @AstraZenecaUS @pfizer https://t.co/PVcoPrgYC9'},\n",
              " '1354072853101084675': {'tweet_author': 'Helix BioPharma',\n",
              "  'tweet_text': \"AstraZeneca said its Calquence had lower rate of atrial fibrillation cases compared with Johnson &amp; Johnson and AbbVie's rival BTK inhibitor Imbruvica in a head-to-head phase 3 chronic lymphocytic leukemia trial! $AZN $JNJ $ABBV #leukemia #pharma \\nhttps://t.co/2n8KV2Mhza\"},\n",
              " '1354067820049539074': {'tweet_author': 'AlphaBronze',\n",
              "  'tweet_text': \"AstraZeneca said its Calquence had lower rate of atrial fibrillation cases compared with Johnson &amp; Johnson and AbbVie's rival BTK inhibitor Imbruvica in a head-to-head phase 3 chronic lymphocytic leukemia trial! $AZN $JNJ $ABBV #leukemia #pharma \\nhttps://t.co/pbHwvaRtai\"},\n",
              " '1354066764825559042': {'tweet_author': 'TrialSite News',\n",
              "  'tweet_text': 'CALQUENCE met Primary Efficacy Endpoint in head-to-head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia\\n\\nhttps://t.co/IVzQpTqGyJ\\n\\n#AstraZeneca #Calquence #Lymphoma #Mantle #Cell #Lymphoma #PFS #CLL #acalabrutinib https://t.co/HSRYADWja1'},\n",
              " '1354047704561758208': {'tweet_author': 'Plexus Ventures',\n",
              "  'tweet_text': '#AZ says #Calquence is a safer drug than #Imbruvica https://t.co/E2rz2ZOOGO via @pharmaphorum #AstraZeneca'},\n",
              " '1354031181269000192': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib https://t.co/hosYReAEo3'},\n",
              " '1354021532763185152': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. https://t.co/n8i8my1hqy #CLL #leusm #hematology'},\n",
              " '1354006590479855617': {'tweet_author': 'BiopharmaAsia',\n",
              "  'tweet_text': 'Calquence approved for the treatment of relapsed or refractory chronic lymphocytic leukaemia in Japan - https://t.co/nmSYYGKfsm'},\n",
              " '1353989515992395776': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against #Ibrutinib in #ChronicLymphocyticLeukemia https://t.co/5pJxyiJgxY'},\n",
              " '1353986275477315585': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #Calquence approved in Japan for the treatment of  #Relapsed or #Refractory #ChronicLymphocyticLeukaemia https://t.co/ALF5oezQ7J'},\n",
              " '1353986043012374530': {'tweet_author': 'Bio_Talent',\n",
              "  'tweet_text': 'Calquence tops Imbruvica in chronic lymphocytic leukaemia study: https://t.co/EcFqJZcqhO\\n\\nFind us at https://t.co/3dDltqR7h2 https://t.co/5D5dyOckdW'},\n",
              " '1353985976792608768': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #Calquence met primary efficacy endpoint in head-to-head trial against #Ibrutinib in #ChronicLymphocyticLeukaemia https://t.co/0hI1lsWQ3e'},\n",
              " '1353985443113664512': {'tweet_author': 'Roberto Bonin',\n",
              "  'tweet_text': 'Calquence ha raggiunto l’endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https://t.co/0xCbBETtfM'},\n",
              " '1353921460171984896': {'tweet_author': 'Taro Shiga',\n",
              "  'tweet_text': 'アストラゼネカのカルケンス®、日本において再発／難治性慢性リンパ性白血病の治療薬として承認取得 https://t.co/NbXvW6Yna5 @PRTIMES_JPより \\n\\n#acalabrutinib #Calquence® \\n#CLL \\n#CardioOnc\\n\\n取り組みがすばらしいですねっ😀\\n名前おぼえるの大変，ホントに... https://t.co/pQ8zeoAltz'},\n",
              " '1353914074472583169': {'tweet_author': 'Susan',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/hdbF9XJQmy'},\n",
              " '1353885369675223045': {'tweet_author': 'BioCentury',\n",
              "  'tweet_text': \"Monday's Quick Takes include Comirnaty's provisional approval in Australia and authorization in Hong Kong; plus priority reviews for Albireo and Iterum, and Calquence meets in Phase III CLL trial https://t.co/NvYD2cGqyP\"},\n",
              " '1353877818380152832': {'tweet_author': 'Endpoints News',\n",
              "  'tweet_text': 'Three years after first launching Calquence as a second generation BTK inhibitor, AstraZeneca continues to tout new data to compete with J&amp;J and AbbVie’s first generation blockbuster Imbruvica. \\n\\nhttps://t.co/tlGdxMdx3O'},\n",
              " '1353836952085258241': {'tweet_author': 'Pharma Top News',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica | BioPharma Dive #PharmaTopNews #OncologyTopNews #Oncology  https://t.co/rE3damFX7X'},\n",
              " '1353836577642962944': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib Approved in Japan for Relapsed/Refractory CLL #leusm https://t.co/3KLyHko5DQ'},\n",
              " '1353834280921800705': {'tweet_author': 'FiercePharma',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/kBg8DCFFmB'},\n",
              " '1353830533491544064': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Outcomes of relapsed mantle cell #lymphoma patients after discontinuing acalabrutinib - Jain - - American Journal of Hematology - Wiley Online Library\\nhttps://t.co/O0qbBGmL3R https://t.co/baT6qqNCKg'},\n",
              " '1353828627717124097': {'tweet_author': 'WebWire',\n",
              "  'tweet_text': 'Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/PmCBCUocGS'},\n",
              " '1353814607492751360': {'tweet_author': 'Tecnomedicina',\n",
              "  'tweet_text': 'Calquence ha raggiunto l’endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https://t.co/Bsv3LYniYl'},\n",
              " '1353798006924046336': {'tweet_author': 'HemOnc Today',\n",
              "  'tweet_text': '🆕  Topline results of randomized phase 3 ELEVATE-RR trial show that acalabrutinib exhibits comparable efficacy and superior safety when compared with ibrutinib for chronic lymphocytic leukemia https://t.co/kuiIbqSlOz #CLL @AstraZeneca https://t.co/r26qeEFL8o'},\n",
              " '1353781577524924416': {'tweet_author': 'BrainSights iOS App',\n",
              "  'tweet_text': 'CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia - Neuro Central via BrainSights for iOS https://t.co/sQAr3EAIyZ'},\n",
              " '1353780477354594305': {'tweet_author': 'Dr Timos Papagatsias',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/8kgb7wPFov #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech'},\n",
              " '1353778216037732354': {'tweet_author': 'NewExpressNews',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial\\xa0showdown https://t.co/ShghMeIhrE'},\n",
              " '1353772372914958336': {'tweet_author': 'BioPharma Dive',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/XobOkLTEUX by @ByJonGardner $AZN $ABBV $JNJ'},\n",
              " '1353752005303537665': {'tweet_author': 'Market Intelligence: Healthcare',\n",
              "  'tweet_text': \"AstraZeneca's Calquence was as effective as Johnson &amp; Johnson's Imbruvica in delaying the progression of a type of blood cancer in a late-stage study\\nhttps://t.co/m6YkcM0N8A \\n$AZN $JNJ https://t.co/lBwf273MRk\"},\n",
              " '1353750800732971010': {'tweet_author': 'Ben Fidler',\n",
              "  'tweet_text': 'AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica https://t.co/HLhOiJmQzY @ByJonGardner $AZN $ABBV $JNJ $MRK $LLY'},\n",
              " '1353749995598475264': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/rmkHEDOpXj'},\n",
              " '1353749330667188224': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'AstraZeneca touts Calquence safety win against Imbruvica in leukemia trial showdown https://t.co/aNpVUGEyZS'},\n",
              " '1353744822947856385': {'tweet_author': 'cafepharma',\n",
              "  'tweet_text': 'AZ says Calquence is a safer drug than Imbruvica https://t.co/rP5BdqUhoe'},\n",
              " '1353743444867481601': {'tweet_author': 'Calgary Herald',\n",
              "  'tweet_text': 'AstraZeneca Says Calquence Approved In Japan For CLL https://t.co/VvdWaQwqay'},\n",
              " '1353742639498190848': {'tweet_author': 'Endpoints News',\n",
              "  'tweet_text': 'Three years after first launching Calquence as a second generation BTK inhibitor, AstraZeneca continues to tout new data to compete with J&amp;J and AbbVie’s first generation blockbuster Imbruvica. By: @Jasonmmast\\n\\nhttps://t.co/tlGdxMv8so'},\n",
              " '1353736022962573312': {'tweet_author': 'David Ledger',\n",
              "  'tweet_text': 'Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/2oWwcmEwbC https://t.co/fZp7ss6Egh'},\n",
              " '1353733848777936896': {'tweet_author': 'Biotech & Tech Stock Focus',\n",
              "  'tweet_text': '$AZN AstraZeneca Reports Positive Phase 3 Results Of Calquence Against Ibrutinib In CLL https://t.co/bc4GDtrXbd'},\n",
              " '1353729595313332230': {'tweet_author': 'Dr Timos Papagatsias',\n",
              "  'tweet_text': \"AstraZeneca's Calquence nabs another win against Imbruvica, but Eli Lilly is on its heels https://t.co/CRIH9rtTtV #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #pharmaceutical #healthcare https://t.co/FepHag53JZ\"},\n",
              " '1353714838787158016': {'tweet_author': 'Corporate News',\n",
              "  'tweet_text': '$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/y0h0eiMRYD'},\n",
              " '1353711478658920448': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': \"AstraZeneca's Calquence nabs another win against Imbruvica, but Eli Lilly is on its heels https://t.co/rr2Rh0Xzyz\"},\n",
              " '1353710232245923840': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL https://t.co/PcXRdX1RYs #CLL #leusm #hematology'},\n",
              " '1353709022336200706': {'tweet_author': 'InvestorsObserver',\n",
              "  'tweet_text': '$AZN +0.8% (reports Calquence met primary efficacy endpoint in a head-to-head trial against ibrutinib; receives approval in Japan for treatment of relapsed or refractory chronic lymphocytic leukemia) \\n\\nhttps://t.co/MDjBoLlE4y'},\n",
              " '1353704850387841024': {'tweet_author': 'Devdiscourse',\n",
              "  'tweet_text': 'BRIEF-AstraZeneca Says Calquence Approved In Japan For CLL https://t.co/fbGcH4txU4'},\n",
              " '1353700939681689600': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia https://t.co/nY5QWDup8o'},\n",
              " '1353688716691304448': {'tweet_author': 'CHItraders',\n",
              "  'tweet_text': \"$AZN AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/9yoennjGjV\"},\n",
              " '1353684379634196480': {'tweet_author': '****',\n",
              "  'tweet_text': 'AwesomeCapital: AstraZeneca: Calquence safer than Imbruvica https://t.co/cXEDyLNqvy'},\n",
              " '1353679151421509633': {'tweet_author': 'Briefing.com',\n",
              "  'tweet_text': '$AZN: AstraZeneca reports Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib; recieves... https://t.co/FVIb69NojY'},\n",
              " '1353678785124700160': {'tweet_author': 'Quant Data',\n",
              "  'tweet_text': \"AstraZeneca's CALQUENCE Met its Primary Efficacy Endpoint\\n\\nRelated Tickers: $AZN\\nRead more at: https://t.co/2zmD10ekY5\"},\n",
              " '1353676688463458309': {'tweet_author': 'PharmaTimes',\n",
              "  'tweet_text': 'Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/rYM3dexyjU #pharmanews #pharma'},\n",
              " '1353676188158488577': {'tweet_author': 'OTC Dynamics, Inc.',\n",
              "  'tweet_text': '$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/WX6BckCEVX'},\n",
              " '1353675874667687936': {'tweet_author': 'Latest News from Business Wire',\n",
              "  'tweet_text': 'CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/FbGmW98yxz https://t.co/5RUxRWogIe'},\n",
              " '1353675668102410242': {'tweet_author': 'IMPharma News',\n",
              "  'tweet_text': 'CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia \\nhttps://t.co/wW4SyfQmgI'},\n",
              " '1353675469418192899': {'tweet_author': 'Crwe World',\n",
              "  'tweet_text': 'CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia https://t.co/Z5lM1bSKso'},\n",
              " '1353675411935399936': {'tweet_author': 'AstraZenecaUS',\n",
              "  'tweet_text': 'Today we announced high-level results from the head-to-head ELEVATE-RR Phase III trial in adults with previously treated, high-risk chronic lymphocytic #leukemia. Learn more: https://t.co/KuCUFoV8mT https://t.co/bjLnjYzuBe'},\n",
              " '1353674732298674178': {'tweet_author': 'Stock Titan',\n",
              "  'tweet_text': '$AZN CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia\\nhttps://t.co/PcJ2mo27hg'},\n",
              " '1353670969932578816': {'tweet_author': 'Gordon Gekko',\n",
              "  'tweet_text': \"AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/E7LKfbW6zG\"},\n",
              " '1353670149241524224': {'tweet_author': 'Investor News',\n",
              "  'tweet_text': \"AstraZeneca's Calquence successful in lymphocytic leukaemia study $AZN https://t.co/MiKEQaiDX9\"},\n",
              " '1353670085190139904': {'tweet_author': 'Stocks tweets',\n",
              "  'tweet_text': \"AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/TvIRCguAEg\"},\n",
              " '1353669340336320512': {'tweet_author': 'Breaking News',\n",
              "  'tweet_text': \"$AZN - AstraZeneca's Calquence successful in lymphocytic leukaemia study https://t.co/tuPuq5E2jw\"},\n",
              " '1353665568767926273': {'tweet_author': 'Soumyajyoti Biswas',\n",
              "  'tweet_text': '$AZN\\nAstraZeneca\\'s Calquence met primary endpoint in head-to-head trial vs. ibrutinib The company states: \"\"Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca\\'s Calquence, or acalabrutinib, met th... https://t.co/9SExNE4WOx'},\n",
              " '1353663982821908480': {'tweet_author': 'pharmaphorum',\n",
              "  'tweet_text': \".@AstraZeneca says Calquence is less likely to cause atrial fibrillation than J&amp;J and AbbVie's market leading BTK inhibitor Imbruvica; also gets green light for the drug in Japan for relapsed chronic lymphocytic #leukaemia #pharma #oncology https://t.co/ckiwpOqQi0 https://t.co/OAjBYm3tEW\"},\n",
              " '1353663947510067201': {'tweet_author': 'Shifting Wealth',\n",
              "  'tweet_text': \"AstraZeneca's Calquence approved in Japan for CLL treatment\\n$AZN\"},\n",
              " '1353663446005518338': {'tweet_author': 'dough',\n",
              "  'tweet_text': '$AZN Calquence head to head study vs Imbruvica in 2L CLL non-inferior PFS with significant reduction in atrial fibrillation.'},\n",
              " '1353662941426561024': {'tweet_author': 'Shifting Wealth',\n",
              "  'tweet_text': \"AstraZeneca's Calquence met primary endpoint in head-to-head trial vs. ibrutinib\\n$AZN\"},\n",
              " '1353655238461251584': {'tweet_author': 'FinanzLinksRatings',\n",
              "  'tweet_text': \"▶ Goldman belässt Astrazeneca auf 'Sell' - Ziel 6575 Pence: NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca angesichts positiver Studiendaten mit dem Medikament Calquence zur Behandlung… https://t.co/LL9o9N95FN AKTIENCHECK\"},\n",
              " '1353655110618943488': {'tweet_author': 'FinanzLinksRatings',\n",
              "  'tweet_text': \"▶ dpa-AFX: Goldman belässt Astrazeneca auf 'Sell' - Ziel 6575 Pence: NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca angesichts positiver Studiendaten mit dem Medikament Calquence zur… https://t.co/s4lCqAL59i FINANZTREFF\"},\n",
              " '1353642661132050432': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'Calquence tops Imbruvica in chronic lymphocytic leukaemia study https://t.co/cEd42RpVQ7'},\n",
              " '1353627828290375680': {'tweet_author': 'LifeProNow-Pharma-Research and News',\n",
              "  'tweet_text': 'Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia\\n\\nhttps://t.co/733f9eYYw5 https://t.co/QjihtiREWu'},\n",
              " '1353624835193249792': {'tweet_author': 'Josekun',\n",
              "  'tweet_text': 'BRIEF-AstraXeneca Says Calquence Approved In Japan For CLL https://t.co/34S4wNhMwz'},\n",
              " '1353624833263853568': {'tweet_author': 'Josekun',\n",
              "  'tweet_text': \"AstraZeneca's leukaemia treatment wins approval in Japan; Calquence meets primary goal https://t.co/qIzMgrqDqg\"},\n",
              " '1353622517492101120': {'tweet_author': 'Jan Ehses',\n",
              "  'tweet_text': '$AZN https://t.co/9QBjQ7D59e'},\n",
              " '1353621966612287488': {'tweet_author': 'Jan Ehses',\n",
              "  'tweet_text': '$AZN https://t.co/xiEvIrVgUT'},\n",
              " '1353620686456188928': {'tweet_author': 'Kevin Jacobs 🇧🇪 🇵🇱 🇮🇹 🇪🇺',\n",
              "  'tweet_text': '$AZN Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia'},\n",
              " '1353618566906523648': {'tweet_author': 'Golden Casino News',\n",
              "  'tweet_text': 'Calquence met primary endpoint against ibrutinib - https://t.co/3dNw2je6hX'},\n",
              " '1353618563358195714': {'tweet_author': 'Golden Casino News',\n",
              "  'tweet_text': 'Calquence approved in Japan for CLL - https://t.co/aY94hrR2MF'},\n",
              " '1353618367190605824': {'tweet_author': 'Kevin Jacobs 🇧🇪 🇵🇱 🇮🇹 🇪🇺',\n",
              "  'tweet_text': '$AZN Calquence Met Primary Endpoint Against Ibrutinib\\n\\n*MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB IN CHRONIC LYMPHOCYTIC\\nLEUKAEMIA\\n\\n*SUPERIOR SAFETY ON KEY SECONDARY ENDPOINT OF ATRIAL FIBRILLATION'},\n",
              " '1353615905092218882': {'tweet_author': 'Sharecast.com',\n",
              "  'tweet_text': \"AstraZeneca reports positive test results, new approval for 'Calquence' https://t.co/mKjcgptvio\"},\n",
              " '1353613727287930880': {'tweet_author': 'EIN Presswire: Pharmaceutical Newswire',\n",
              "  'tweet_text': \"AstraZeneca's leukaemia treatment wins approval in Japan; Calquence meets primary goal https://t.co/Itc96p09KP\"},\n",
              " '1353608619133181952': {'tweet_author': \"Value's Vector\",\n",
              "  'tweet_text': 'LiveSquawk: $AZN | AstraZeneca Plc - Calquence Met Primary Endpoint Against Ibrutinib\\nCalquence Met Primary Efficacy Endpoint In Head-To-Head Trial Against Ibrutinib In Chronic Lymphocytic Leukaemia'},\n",
              " '1353605487414149120': {'tweet_author': 'Devdiscourse',\n",
              "  'tweet_text': 'BRIEF-AstraXeneca Says Calquence Approved In Japan For CLL https://t.co/JJwbaalBwL'},\n",
              " '1353603371576537088': {'tweet_author': 'Devdiscourse',\n",
              "  'tweet_text': 'BRIEF-AstraZeneca Says Calquence Met Primary Endpoint Against Ibrutinib https://t.co/PuDcymtl77'},\n",
              " '1353602178171211777': {'tweet_author': 'Mathan',\n",
              "  'tweet_text': '$AZN | ASTRAZENECA PLC - CALQUENCE MET PRIMARY ENDPOINT AGAINST IBRUTINIB\\nCALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA'},\n",
              " '1353601006378971138': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/VxTrombric'},\n",
              " '1353601002541203456': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence approved in Japan for CLL https://t.co/LivCdCnSXj'},\n",
              " '1353600269460926464': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https://t.co/8brx5cBNuQ'},\n",
              " '1353599509071183872': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia https://t.co/E4z0jbbJCH'},\n",
              " '1353599366431268867': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence met primary endpoint against ibrutinib https://t.co/nb9inloykE'},\n",
              " '1353599249263579136': {'tweet_author': 'LiveSquawk',\n",
              "  'tweet_text': '$AZN | AstraZeneca Plc - Calquence Met Primary Endpoint Against Ibrutinib\\nCalquence Met Primary Efficacy Endpoint In Head-To-Head Trial Against Ibrutinib In Chronic Lymphocytic Leukaemia'},\n",
              " '1353593704649347072': {'tweet_author': 'TYR Kinase papers',\n",
              "  'tweet_text': 'The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia https://t.co/ZdByIV9NGy'},\n",
              " '1351871111802155009': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) https://t.co/S9yRtWE5LY #MCL #lymsm #hematology'},\n",
              " '1351870476574810114': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) https://t.co/bVSRWzHwbx #CLL #leusm #hematology'},\n",
              " '1351038803448889352': {'tweet_author': 'Health Radio Online',\n",
              "  'tweet_text': \"AstraZeneca's New CALQUENCE® Data in Mantle Cell Lymphoma (MCL)\\nRead more: https://t.co/AaHAiq55rn\\n#CALQUENCE #ASH2020 #MantleCellLymphoma\"},\n",
              " '1350884999151693824': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Check out: Comparing acalabrutinib to standard treatments in patients with chronic ly... https://t.co/tLXIunsT1a via @medivizor #Leukemia'},\n",
              " '1350472994313756673': {'tweet_author': 'Aaron Goodman - “Papa Heme”',\n",
              "  'tweet_text': 'This is what happens when you let oncologists design trials for a viral infection.  The following therapies are/were being tested in COVID19 trials\\n\\nRuxolitinib\\nEtoposide\\nIbrutinib\\nSelinexor\\nLenalidomide\\nAcalabrutinib\\nBaricitinib\\nZanabrutinib\\nChest radiation'},\n",
              " '1349838759966216193': {'tweet_author': 'CADTH',\n",
              "  'tweet_text': 'CADTH has issued a final recommendation that #acalabrutinib\\n(#Calquence) be reimbursed with clinical criteria and/or conditions for the treatment of Chronic lymphocytic #leukemia (previously untreated). \\n\\nRead the full recommendation here: https://t.co/dAB8GavDdc https://t.co/z6zFvD33Nw'},\n",
              " '1349688957332811776': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'Great to continue to recruit into the first ever randomised 1L trial in #Richters transformation\\n\\nRCHOP vs RCHOP+acalabrutinib\\n\\nWe are a quarter of the way there! #lymsm #CLL @OUH_Research @AnnaSchuh3 https://t.co/Dvl7pnO5OY'},\n",
              " '1348968100910260225': {'tweet_author': 'Lymphoma Papers',\n",
              "  'tweet_text': 'Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. #lymphoma #lymsm https://t.co/VNtOJXBAl1'},\n",
              " '1348948980126814208': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. https://t.co/aa3xLPsM57 #CLL #leusm #hematology'},\n",
              " '1348738438787379200': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Learn more: Comparing acalabrutinib to standard treatments in patients with chroni... https://t.co/tLXIunsT1a #Leukemia (via @medivizor)'},\n",
              " '1348520236249710596': {'tweet_author': 'Top News Corner',\n",
              "  'tweet_text': 'New post (Acalabrutinib Market Report, Size, Key Players And Global Forecast to 2025) has been published on https://t.co/fdzRB6KRVD - https://t.co/5tIxXQsJ3c https://t.co/fIrPpYDHI0'},\n",
              " '1347474172008665089': {'tweet_author': 'Pharmazeutische Zeitung',\n",
              "  'tweet_text': 'Mit Acalabrutinib kam im Dezember ein neuer Bruton-Tyrosinkinase(BTK)-Hemmer auf den Markt. Der Neuling wird wie das seit 2014 verfügbare Ibrutinib peroral bei Patienten mit chronisch lymphatischer #Leukämie eingesetzt https://t.co/Jjqy1XCUAM'},\n",
              " '1347472919660781575': {'tweet_author': 'RS6',\n",
              "  'tweet_text': 'https://t.co/XTWA2Bz5NB'},\n",
              " '1347180984190595083': {'tweet_author': 'Amar Bhandari',\n",
              "  'tweet_text': 'Global Acalabrutinib Market In-Depth Analysis Report\\xa02020 https://t.co/nX3NfUKGFB'},\n",
              " '1347070826491817984': {'tweet_author': 'Industry News Engine',\n",
              "  'tweet_text': 'Acalabrutinib Market Report Till 2025 | Global Manufacturers\\xa0Analysis https://t.co/T1442apiD3'},\n",
              " '1345837516667154434': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': '“The PFS for patients in the acalabrutinib arms [of the ELEVATE CLL TN trial] outperformed the control, which was obinutuzumab/chlorambucil, by a significant difference,” Dr. Seymour said during this live virtual meeting.\\nhttps://t.co/OZz2ovjCLE #leukemia'},\n",
              " '1345374991446134786': {'tweet_author': 'Medicina e Informazione',\n",
              "  'tweet_text': 'Leucemia linfatica cronica: acalabrutinib è approvato in Europa. Ha dimostrato un beneficio significativo in termini di efficacia e tollerabilità a lungo termine tanto nel trattamento in prima linea quanto nella malattia recidivante o refrattaria\\nhttps://t.co/R1CPilGRTH https://t.co/TqKhOuaiUP'},\n",
              " '1344870978896101376': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL).'},\n",
              " '1344870978480865281': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).'},\n",
              " '1344870977759371266': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870977100910593': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870976811487234': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870975888879623': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870975809101825': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL).'},\n",
              " '1344870975049908227': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870974571819009': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).'},\n",
              " '1344870972692836352': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A See if CALQUENCE can be used to treat your adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).'},\n",
              " '1344870972063531008': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 In a study of 535 chronic lymphocytic leukemia (CLL) patients, 1L CALQUENCE+obinutuzumab demonstrated 90% relative risk reduction (HR=0.10[95% CI: 0.06-0.17], P&lt;0.001) in disease progression or death vs GCIb (obinutuzumab+chlorambucil).'},\n",
              " '1344870969492578304': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is an oral treatment option for adult patients with chronic lymphocytic leukemia (CLL).'},\n",
              " '1344340117452894210': {'tweet_author': 'Joseph Cioccio, DO',\n",
              "  'tweet_text': 'Why might a person with CLL be anemic?\\n1) BM involved (Rai III). Dx - BM Bx\\nTx = venetoclax/obinutuzumab or acalabrutinib +/- obinu\\nFCR*\\n\\n2) AIHA- DX- DAT, ⬆️ t bili, ⬆️ldh, ⬇️hapto, ⬆️ retic\\nTx roids if fail then as above\\n\\n3) PRCA, ⬇️ retics, \\nTx = IST\\n\\n#Cioc_edu /1'},\n",
              " '1344068316353228809': {'tweet_author': 'CureHuntr',\n",
              "  'tweet_text': '#clinicaltrial Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. https://t.co/l6wzhD0nPv'},\n",
              " '1343991464515301385': {'tweet_author': 'VJHemOnc',\n",
              "  'tweet_text': '#Zanubrutinib for ibrutinib/acalabrutinib intolerant R/R B-cell malignancies w/ Ian Flinn of @SarahCannonDocs: https://t.co/jvPhvqOlus\\n\\n#ASH20 @ASH_hematology #HemOnc #Leusm #Leukemia #CLLsm #CTsm'},\n",
              " '1343959049902182400': {'tweet_author': 'TrialBulletin',\n",
              "  'tweet_text': 'Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.: Status: Not yet recruiting, \\nCondition Summary: Primary Central Nervous System Lymphoma (PCNSL) https://t.co/SfBdbbIt6n'},\n",
              " '1343937359734304768': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@SeemaAliBhat1 of @OSUCCC_James discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL\\nhttps://t.co/rTGycOO6dq https://t.co/LtNBss74zI'},\n",
              " '1343180063504740353': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': '“The PFS for patients in the acalabrutinib arms [of the ELEVATE CLL TN trial] outperformed the control, which was obinutuzumab/chlorambucil, by a significant difference,” Dr. Seymour, of @karmanoscancer, said in this live virtual meeting.\\nhttps://t.co/OZz2ovjCLE #CLL #leusm'},\n",
              " '1342866355868086272': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'New: Comparing acalabrutinib to standard treatments in patients with chronic lymphocy... https://t.co/tLXIunsT1a via @medivizor #Leukemia'},\n",
              " '1342203098220130304': {'tweet_author': 'DRUGDOCS',\n",
              "  'tweet_text': '#Calquence Product Monograph, Prescribing Info, Health Technology Assessments and More! \\n\\nAccess Drug Documents 👇'},\n",
              " '1342151826670571522': {'tweet_author': 'Oncology Nursing News',\n",
              "  'tweet_text': 'In case you missed it: Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities, according to data from a pooled analysis across 4 clinical trials. https://t.co/cx3xGOuIh8'},\n",
              " '1340952146997460994': {'tweet_author': 'EmatoInfo',\n",
              "  'tweet_text': '#ASH20 | Nuove importanti conferme sull’utilizzo di #acalabrutinib in combinazione nel trattamento della leucemia linfatica cronica, con risultati significativi in termini di risposta completa e MRD negatività. Le parole di Francesca Romana Mauro. https://t.co/srgFXxx2Ts'},\n",
              " '1340823055371816960': {'tweet_author': 'Oncology Nursing News',\n",
              "  'tweet_text': 'Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities, according to data from a pooled analysis across 4 clinical trials. https://t.co/cx3xGOuIh8'},\n",
              " '1340738181398982657': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Check out Comparing acalabrutinib to standard treatments in patients with chronic lym... https://t.co/tLXIunsT1a via @medivizor #Leukemia'},\n",
              " '1339918478950756355': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Results showed that 17% of 762 patients with CLL who received treatment with the 2nd generation BTK inhibitor as a monotherapy experienced cardiac toxicity of any grade at a median follow-up of 25.9 months. @ASH_hematology #ASH20 https://t.co/PyX4eZaZC3'},\n",
              " '1339578709846732800': {'tweet_author': 'pharmanewsintel',\n",
              "  'tweet_text': \"AstraZeneca's Phase 2 #clinicaltrial found that multiple cell lymphoma patients treated with AstraZeneca’s #cancerdrug, Calquence, remained progression free for an average of 22 months. \\n\\nhttps://t.co/C5Xxpxjt8n\"},\n",
              " '1339432645084684289': {'tweet_author': 'JPubb 日本企業 リリース 医薬品',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血管安全性プロ... 〔12/17 アストラゼネカ〕 https://t.co/isvqYLMTWE'},\n",
              " '1339400282984214528': {'tweet_author': 'PR TIMESビジネス',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血... https://t.co/UAxtcYBcaN'},\n",
              " '1339392438775894018': {'tweet_author': 'PR TIMESニュース',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血... https://t.co/1BZ6NYUWon'},\n",
              " '1339390406853881857': {'tweet_author': 'WMR Tokyo - スタートアップ',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence(R)）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血管安全性プロファイルを評価 https://t.co/rwagDQt79P'},\n",
              " '1339337448543883267': {'tweet_author': 'Ashleigh Walls',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/BuFOYoX5iY #bloodcancerawareness #ad https://t.co/TjcmlppbWN https://t.co/XSJy81zZGo'},\n",
              " '1339280070196621312': {'tweet_author': 'bargainbriana',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/olbLAT1iul #bloodcancerawareness #ad https://t.co/IN8KmIDSIN https://t.co/21brOD585J'},\n",
              " '1339275381170348032': {'tweet_author': 'April Golightly',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/uzjsIfXTb9 #bloodcancerawareness #ad https://t.co/613omF99rh https://t.co/M6FMVHOT2h'},\n",
              " '1339165345291112449': {'tweet_author': 'dough',\n",
              "  'tweet_text': '$AZN LR OP Multiple best-in-class oncology portfolio deserves premium Oncology portfolio includes multiple potentially best-in-class assets, including Tagrisso, Lynparza, Calquence, Enhertu, and Imfinzi https://t.co/KFiGbg5jvi'},\n",
              " '1339017286653448192': {'tweet_author': 'jorge',\n",
              "  'tweet_text': 'Cancer drug as COVID-19 treatment scrapped from WHO Solidarity Trials https://t.co/isO9vJe4js'},\n",
              " '1338970852617019393': {'tweet_author': 'iSanidad',\n",
              "  'tweet_text': '#Investigación 🔎 | Los datos de #acalabrutinib de 4 ensayos clínicos refuerzan su perfil de seguridad cardiovascular en pacientes con #leucemia linfocítica crónica @AstraZenecaES \\n\\nhttps://t.co/c60KOMIBJt'},\n",
              " '1338857609542201344': {'tweet_author': 'iSanidad',\n",
              "  'tweet_text': '🔎 Los datos de #acalabrutinib de 4 ensayos clínicos refuerzan su perfil de seguridad cardiovascular en pacientes con #leucemia linfocítica crónica @AstraZenecaES \\n\\nhttps://t.co/c60KOMIBJt'},\n",
              " '1338710401790472194': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Patients with CLL who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation. @ASH_hematology #ASH20 https://t.co/1bPqyNA0km'},\n",
              " '1338662943920152578': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) - chronic lymphocytic leukaemia (CLL) https://t.co/u3lRYIvDfK'},\n",
              " '1338620216897544192': {'tweet_author': 'Radyo La Verdad 1350',\n",
              "  'tweet_text': 'Kinumpirma ng Department of Health na hindi na gagamitin sa World Health Organization solidarity trial ng therapeutics o mga gamot ang Acalabrutinib. https://t.co/FwV4nC5tzT'},\n",
              " '1338531756996255753': {'tweet_author': 'CURE Magazine',\n",
              "  'tweet_text': 'At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients. https://t.co/w4nltTQFJF'},\n",
              " '1338498441358405634': {'tweet_author': 'Radyo La Verdad 1350',\n",
              "  'tweet_text': 'Acalabrutinib, hindi na gagamitin sa WHO solidarity trial ng therapeutic... https://t.co/FwV4nC5tzT via @YouTube'},\n",
              " '1338438148410392578': {'tweet_author': 'Ronald M. Chavin',\n",
              "  'tweet_text': \"12-14-2020: In a decision announced today by the WHO, bad news for AstraZeneca's blood cancer drug, Calquence (acalabrutinib), for treating COVID-19. AstraZeneca had already announced the failure of Calquence\\nhttps://t.co/8JwlIjSHTd\\nhttps://t.co/AsPNYOtAlF\\nhttps://t.co/HFq8FoNQgc\"},\n",
              " '1338432117890420737': {'tweet_author': 'UNTV News and Rescue',\n",
              "  'tweet_text': 'Acalabrutinib, hindi na gagamitin sa WHO solidarity trial ng therapeutics - DOH  https://t.co/RwKcivPg1p'},\n",
              " '1338395721079300103': {'tweet_author': 'DZBB Super Radyo',\n",
              "  'tweet_text': '5 pasyente, nakumpleto na ang clinical trial ng Avigan bilang gamot sa COVID-19 sa Pilipinas; clinical trial ng cancer drug na Acalabrutinib sa paghanap ng gamot kontra COVID-19, hindi na itinuloy ng @WHO. #SuperBalitaSaHapon https://t.co/Jl7zdrja0g'},\n",
              " '1338371914142724096': {'tweet_author': 'Radyo Agila DZEC 1062 Khz',\n",
              "  'tweet_text': 'Cancer drug na Acalabrutinib,inalis na sa mga gamot na kasama sa WHO solidarity trial https://t.co/PxANQ5oOIa'},\n",
              " '1338368964011782146': {'tweet_author': 'CNN Philippines',\n",
              "  'tweet_text': \"'Nagbigay na ng recommendation ang WHO. It's not going to be part of the Solidarity Trial anymore,' DOH spokesperson Maria Rosario Vergeire says. https://t.co/BogahKfYMH\"},\n",
              " '1338344742917009410': {'tweet_author': 'DZBB Super Radyo',\n",
              "  'tweet_text': 'Paggamit ng cancer drug na Acalabrutinib bilang bahagi ng solidarity trial sa paghanap ng gamot para sa COVID-19, hindi na itinuloy ng World Health Organization o @WHO. | via @Isa_Umali'},\n",
              " '1337659087585239042': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'NEW: Comparing acalabrutinib to standard treatments in patients with chronic lymphocy... https://t.co/tLXIunsT1a via @medivizor #Leukemia'},\n",
              " '1337449313648205825': {'tweet_author': 'This Messy Season Family Blog',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/VRIqUhrkFf. #bloodcancerawareness #ad https://t.co/Y2lMRkOR9k https://t.co/kTaDjk7PUW'},\n",
              " '1337235679139557387': {'tweet_author': '印度孟加拉抗癌药',\n",
              "  'tweet_text': '阿卡替尼 孟加拉耀品国际首仿，\\n用于治疗患有套细胞淋巴瘤（mantlecell lymphoma）且曾接受过至少一次治疗的成人患者。接受Calquence治疗的患者有81%获得了完全缓解或部分缓解\\n\\n剂型/给药途径：口服\\n\\n作用机制：酪氨酸激酶BTK抑制剂，阻断癌细胞增殖和扩散所需要的酶 https://t.co/B01z5Puj4x'},\n",
              " '1337155558802038784': {'tweet_author': 'Cook Eat Go',\n",
              "  'tweet_text': '#ad Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/PkC83TF1kq. #bloodcancerawareness https://t.co/7v16qKmdS5 https://t.co/P0jIZK4Jo4'},\n",
              " '1337102287299350531': {'tweet_author': 'IM Médico',\n",
              "  'tweet_text': 'Los datos de Calquence de 4 ensayos clínicos refuerzan su perfil de seguridad cardiovascular en pacientes con LLC\\n https://t.co/Sz0v1TRM6K'},\n",
              " '1337063133286948866': {'tweet_author': 'William V. Sweeney',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/7q8vWzSwbS #bloodcancerawareness #ad https://t.co/FfjjEHSkg8 https://t.co/IYA4qtCD9F'},\n",
              " '1337041689567846400': {'tweet_author': 'Caryn Bailey',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/FRgJjnX8v5 #bloodcancerawareness #ad https://t.co/uFYQJrBgZt https://t.co/SyejqJn1a8'},\n",
              " '1336828570585468930': {'tweet_author': 'Christi B',\n",
              "  'tweet_text': 'With @CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients with CLL or SLL. Learn more at [https://t.co/Ay3QXBPHkk]. #bloodcancerawareness #ad https://t.co/o9G2s6XEMh https://t.co/1AiGr7uzIf'},\n",
              " '1336828362405392387': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: 17p deletion testing for access to acalabrutinib in patients w/ relapsed or refractory chronic lymphocytic leukaemia https://t.co/3vVU2IFbFi'},\n",
              " '1336799465726996486': {'tweet_author': 'Kami Allen',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/9AavBCJUDc #bloodcancerawareness #ad https://t.co/QUI6rhtA06 https://t.co/3914nA0gz5'},\n",
              " '1336785315873230849': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785315864879106': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785315827130369': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785315814522882': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785315793575936': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785192141393923': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785192040747009': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785191663251459': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference featured clinical data about CALQUENCE—a treatment option for adults with CLL.'},\n",
              " '1336785191654871041': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785191554097152': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785191163973632': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190929264644': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190753095682': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190753079296': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190719393793': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785190631436288': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190404956160': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785190316699649': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336785190211895297': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Don’t miss Dr Michael Wang present AstraZeneca’s clinical data from CALQUENCE at this year’s virtual conference!'},\n",
              " '1336785190174199815': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual conference!'},\n",
              " '1336785189964455936': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqqbUX8 Learn more about the demonstrated safety and tolerability profile of CALQUENCE.'},\n",
              " '1336749685801775106': {'tweet_author': 'Coralie Seright (Lovebugs and Postcards)',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/T31Tzi5GEc #bloodcancerawareness #ad https://t.co/koo80IGjvP https://t.co/vKF60hrjUH'},\n",
              " '1336740572594376704': {'tweet_author': 'Elizabeth hurt',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. Calquence is a prescription treatment option for adult patients with CLL. https://t.co/bcU1EB38YM #bloodcancerawareness #ad https://t.co/cMWmUTldVy https://t.co/FIz6xlQ8Fg'},\n",
              " '1336729956869615616': {'tweet_author': 'EmatoInfo',\n",
              "  'tweet_text': \"#ASH20 | Leucemia linfatica cronica: il trattamento con acalabrutinib in monoterapia si caratterizza per l’ottimo profilo di safety, elemento assolutamente decisivo nell'ambito di questa patologia. L'intervista a Paolo Ghia [@SanRaffaeleMI]. \\nhttps://t.co/dTzv6l09cP\"},\n",
              " '1336713314227851264': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Acalabrutinib+R-CHOP in ND #DLBCL #ASH20 https://t.co/hReK2IngxX'},\n",
              " '1336711180967178243': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Acalabrutinib in R/R MCL #ASH20 https://t.co/jwz3TLIwxs'},\n",
              " '1336710567118184449': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Acalabrutinib cost effectiveness #ASH20 https://t.co/IF9eYVa8in'},\n",
              " '1336709163326574596': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Acalabrutinib cardiovascular events #ASH20 https://t.co/ilBGhugwz7'},\n",
              " '1336705401933492226': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'AVO (Acalabrutinib, Venettoclax + R/O in R/R #CLL #ASH20 https://t.co/MgetA1UgG3'},\n",
              " '1336666415848333313': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Early Intervention With Acalabrutinib in Patients With High Risk CLL https://t.co/nH9vPENaFS #CLL #leusm #hematology'},\n",
              " '1336658622110027776': {'tweet_author': 'Pepvax Inc',\n",
              "  'tweet_text': 'Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia - Targeted Oncology https://t.co/ICvz09sP1F https://t.co/s5EOD1ivwm'},\n",
              " '1336641406111191042': {'tweet_author': 'pharmaphorum',\n",
              "  'tweet_text': 'NHS England is to grant immediate access to cancer drug Calquence from @AstraZeneca for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it in first draft recommendations https://t.co/TDeYEDncwj #cancer #pharma'},\n",
              " '1336596452152385536': {'tweet_author': 'NICE',\n",
              "  'tweet_text': 'NICE has recommended the use of acalabrutinib for certain adults with untreated and treated chronic lymphocytic leukaemia. Read the draft guidance and take part in the consultation until Monday 11 January 2021, at: https://t.co/QRGsgACUdd https://t.co/IDZTWq5Bhk'},\n",
              " '1336546474042200065': {'tweet_author': 'mednetnews',\n",
              "  'tweet_text': 'Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia | Targeted\\xa0Oncology https://t.co/xwPSwP0ij8'},\n",
              " '1336503842259800064': {'tweet_author': 'Bionest Partners',\n",
              "  'tweet_text': \"AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice. After demonstrating positive long-term efficacy and tolerability in #MCL, does this open the door for Calquence in #CLL? https://t.co/tXiWpyegNP https://t.co/8GvCMTXMRB\"},\n",
              " '1336439052833337347': {'tweet_author': \"Lisa O'Driscoll\",\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/v46unah7p2 #bloodcancerawareness #ad https://t.co/DljdCKTD7E https://t.co/aQD1ULX1AC'},\n",
              " '1336412717322825728': {'tweet_author': 'Tamara Bowman',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/ejeIHp0kp4. #bloodcancerawareness #ad https://t.co/dYU8rG364A https://t.co/Yr152q3fYx'},\n",
              " '1336400417656164352': {'tweet_author': 'David Ledger',\n",
              "  'tweet_text': \"NICE backs AZ' Calquence for chronic lymphocytic leukaemia https://t.co/lMXJbU0JHb https://t.co/77CPBuyHR5\"},\n",
              " '1336398436179054594': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Management of Waldenström Macroglobulinemia in 2020: Acalabrutinib and Zanubrutinib #ASH20 https://t.co/ApLKP8w2tt'},\n",
              " '1336359899522080768': {'tweet_author': 'Plexus Ventures',\n",
              "  'tweet_text': 'NICE backs #AstraZeneca #Calquence for chronic lymphocytic #leukaemia https://t.co/Js1rSgNnsG @PharmaTimes @AstraZeneca #CLL'},\n",
              " '1336346700202594304': {'tweet_author': 'Pharmafocus',\n",
              "  'tweet_text': \"NICE recommendation for AstraZeneca's Calquence in chronic lymphocytic leukaemia populations https://t.co/N5hbZ20fjN https://t.co/G72Vaz3HQ2\"},\n",
              " '1336340134833180677': {'tweet_author': 'Cpl Life Sciences',\n",
              "  'tweet_text': '.@NICEComms backs @AstraZeneca Calquence for chronic lymphocytic #leukaemia https://t.co/5Ex1ktIoN2 #regulatory'},\n",
              " '1336325313760903174': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Dr. Brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.\\nhttps://t.co/43pVoOkpdi #leusm #ASH20'},\n",
              " '1336321127652605954': {'tweet_author': 'Pharma News',\n",
              "  'tweet_text': 'Eligible patients in England with Chronic Lymphocytic Leukaemia (CLL) granted immediate access to Calquence▼ (acalabrutinib) following positive NICE recommendation\\nhttps://t.co/zZJpwgS0in\\n#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/UcoVLdYEHl'},\n",
              " '1336321119490617345': {'tweet_author': 'Pharma News',\n",
              "  'tweet_text': 'Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia\\nhttps://t.co/girQo6U81g\\n#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/GLZtdpTDa1'},\n",
              " '1336316195147034624': {'tweet_author': 'Jon Angelo',\n",
              "  'tweet_text': \"NICE recommendation for AstraZeneca's Calquence in chronic lymphocytic leukaemia populations : https://t.co/bJq1uJ8HW5 #pharmaceutical\"},\n",
              " '1336306905598332930': {'tweet_author': 'NwokeAgulu',\n",
              "  'tweet_text': 'Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in\\xa0CLL https://t.co/vpFSnR8Hv9'},\n",
              " '1336305870800642050': {'tweet_author': 'Prescient Healthcare Group',\n",
              "  'tweet_text': 'Prescient coverage of #ASH2020, Day 3: Chronic Lymphocytic Leukemia (#CLL) – #ROR1inhibitor #MDM2inhibitor #ibrutinib #acalabrutinib #zanubritinib #ublituximab #LOXO305 https://t.co/LA8DLPmHMq https://t.co/UKc4Q5EVMI'},\n",
              " '1336300128064430082': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in CLL @DanaFarber @ASH_hematology #ASH20 #leusm https://t.co/qIUwM0DrlB'},\n",
              " '1336297360167641088': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia https://t.co/5eCCEez64l #CLL #leusm #hematology'},\n",
              " '1336281796418416642': {'tweet_author': 'Smart Clinical Pharmacology',\n",
              "  'tweet_text': 'Aprobación de acalabrutinib contra leucemia linfocítica crónica\\xa0en la Unión Europea https://t.co/mmuj7l3Xgj via @medscape'},\n",
              " '1336254493747507200': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'NICE backs AZ’ Calquence for chronic lymphocytic leukaemia https://t.co/dmm83g8Osj'},\n",
              " '1336251799028817920': {'tweet_author': 'PharmaTimes',\n",
              "  'tweet_text': \"NICE backs AZ' Calquence for chronic lymphocytic leukaemia https://t.co/QseroJzMbw #pharmanews #pharma\"},\n",
              " '1336246591573741568': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #Calquence data across four trials reinforces #Cardiovascular safety profile in patients with #ChronicLymphocyticLeukaemia https://t.co/4HC742Om8M'},\n",
              " '1336246534740930560': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #Calquence data across four trials reinforces #cardiovascular safety profile in patients with #ChronicLymphocyticLeukaemia https://t.co/4HC742Om8M'},\n",
              " '1336173663893266432': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH.'},\n",
              " '1336173663691956227': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH.'},\n",
              " '1336173663423524864': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH.'},\n",
              " '1336173662106423296': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data were released at ASH.'},\n",
              " '1336173660336390145': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference featured clinical data about CALQUENCE—a treatment option for adults with CLL. #ASH20'},\n",
              " '1336139674578870272': {'tweet_author': 'vshariharakrishnan',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/zwG2Vq7Riu\"},\n",
              " '1336122854279143425': {'tweet_author': 'Joseph Cioccio, DO',\n",
              "  'tweet_text': 'The only pts to still benefit from chemo in #cll are young with unmutated IGHV and no TP53 or 17pdel otherwise front line tx is chemo free! \\n\\nPreferred tx either venetoclax+obinatuzumab or acalabrutinib w/ or w/o CD20 moab #ASH2020 https://t.co/zpspQNy8y1'},\n",
              " '1336062988978151425': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL https://t.co/JODdUoN3UF'},\n",
              " '1336052359223447552': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'Pleased to be leading UK @NCRI_partners CARAMEL pilot trial in older pts with 1L #acalabrutinib #rituximab in elderly pts unfit for standard immunochemotherapy in #MCL \\n\\nHopefully opening Q1-2 2021. How will it compare to #ibrutinib-R phase II data? https://t.co/5LMHoxGK6y'},\n",
              " '1336050170816040964': {'tweet_author': '****',\n",
              "  'tweet_text': \"AwesomeCapital: ASH: AstraZeneca's Calquence, BeiGene's Brukinsa t... https://t.co/8Ro1SCDvhe\"},\n",
              " '1336036395903815691': {'tweet_author': 'Investor News',\n",
              "  'tweet_text': 'CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia $AZN https://t.co/oGzpJRnaOf'},\n",
              " '1336031533103198211': {'tweet_author': 'BrainSights iOS App',\n",
              "  'tweet_text': 'CORRECTING and REPLACING\\xa0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma - Neuro Central via BrainSights for iOS https://t.co/SZ6IN4MAJt'},\n",
              " '1336023653239181314': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Dr. Brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.\\nhttps://t.co/43pVoOC0BS #ASH20 #leusm'},\n",
              " '1336005330564747265': {'tweet_author': 'Pharma Top News',\n",
              "  'tweet_text': \"ASH 2020: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice | FiercePharma #pharmatopnews #oncology #oncologytopnews https://t.co/gBB1X0TTK1\"},\n",
              " '1335992731844296706': {'tweet_author': 'David Ledger',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability in MCL https://t.co/xuH2beSMTw https://t.co/ogGl49uKl6'},\n",
              " '1335992597005873154': {'tweet_author': 'SeattleCancerCareAlliance',\n",
              "  'tweet_text': 'Today at #ASH20: Poster session with @MShadman, MD, MPH - \"2947 Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib\" https://t.co/d0HTtQeUKo #Hematology https://t.co/gzja1GKcQZ'},\n",
              " '1335991432436322310': {'tweet_author': 'IMPharma News',\n",
              "  'tweet_text': 'CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia \\nhttps://t.co/oF55LNXw5K'},\n",
              " '1335981212104445953': {'tweet_author': 'Biotech & Tech Stock Focus',\n",
              "  'tweet_text': '$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia  | Business Wire https://t.co/liPcF2DFs7'},\n",
              " '1335980641062592517': {'tweet_author': 'Crwe World',\n",
              "  'tweet_text': 'CORRECTING and REPLACING&amp;nbsp;CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With R https://t.co/cJ8P1WttRC'},\n",
              " '1335977403903045641': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic https://t.co/1NVeuD39Ja'},\n",
              " '1335976287664545796': {'tweet_author': 'Anne Sweden',\n",
              "  'tweet_text': 'Consider @CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL). It’s a convenient oral 2x a day capsule. Learn more: #bloodcancerawareness https://t.co/3UMq906vmi #ad https://t.co/kpqsMVmGLQ'},\n",
              " '1335975588473884674': {'tweet_author': 'LifeProNow-Pharma-Research and News',\n",
              "  'tweet_text': 'AZ’s Calquence shows long-term efficacy and tolerability in MCL\\nhttps://t.co/HAuiZ3uWDS https://t.co/XaryjEn1k0'},\n",
              " '1335972953180221443': {'tweet_author': 'Pharmacutical Daily',\n",
              "  'tweet_text': 'CORRECTING and REPLACING\\xa0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell\\xa0Lymphoma https://t.co/TLyHApsVh2'},\n",
              " '1335972786842578944': {'tweet_author': 'The British Journal of Cardiology',\n",
              "  'tweet_text': 'Pooled analysis @ASH_hematology of cardiovascular safety data in 762 patients treated with Calquence (acalabrutinib) monotherapy for chronic lymphocytic leukaemia (CLL), the most common adult leukaemia, showed a low incidence of cardiac adverse events. @AstraZeneca @BCOSCardioOnc'},\n",
              " '1335969803404775429': {'tweet_author': 'Devdiscourse',\n",
              "  'tweet_text': 'BRIEF-AstraZeneca Says Less Than 1% Of Patients Treated With Calquence Discontinued Treatment Due To Cardiac Adverse Events In Pooled Analysis https://t.co/gF1PgElQWf'},\n",
              " '1335967327200874496': {'tweet_author': 'OTC Dynamics, Inc.',\n",
              "  'tweet_text': '$AZN CORRECTING and REPLACING\\xa0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/9bOBPbYxpl'},\n",
              " '1335967035210153989': {'tweet_author': 'Stock Titan',\n",
              "  'tweet_text': '$AZN CORRECTING and REPLACING\\xa0CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma\\nhttps://t.co/bDMcZaWJHo'},\n",
              " '1335966935134195717': {'tweet_author': 'Investor News',\n",
              "  'tweet_text': 'CORRECTING and REPLACING CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle .. $AZN https://t.co/MdCwShoaPB'},\n",
              " '1335966873796685824': {'tweet_author': 'Keeping Life Sane',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/HoUcLnvD1x #bloodcancerawareness #ad https://t.co/ozEJghGHae https://t.co/2Mgh0iUKcD'},\n",
              " '1335965217101111296': {'tweet_author': 'OTC Dynamics, Inc.',\n",
              "  'tweet_text': '$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia https://t.co/CI7lKInfd7'},\n",
              " '1335964129224495104': {'tweet_author': 'Shifting Wealth',\n",
              "  'tweet_text': 'AstraZeneca says data from four Calquence trials reinforces CV safety in CLL\\n$AZN'},\n",
              " '1335964040816836610': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia https://t.co/fpte97uDSd'},\n",
              " '1335963626889416704': {'tweet_author': 'AstraZenecaUS',\n",
              "  'tweet_text': 'Cardiovascular (CV) adverse events may be a key consideration in chronic lymphocytic #leukemia (CLL) treatment decisions. Today at #ASH20 we’re presenting results of an analysis of pooled CV safety data across four trials in CLL. Learn more: https://t.co/4Gi0xwEVVo https://t.co/JyV0NGFlmC'},\n",
              " '1335963556852875264': {'tweet_author': 'Stock Titan',\n",
              "  'tweet_text': '$AZN CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia\\nhttps://t.co/s7AmAnUU6Z'},\n",
              " '1335958846553001986': {'tweet_author': 'Biotech & Tech Stock Focus',\n",
              "  'tweet_text': \"$AZN $BGNE ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/0jrHkdtOnR\"},\n",
              " '1335957750744903680': {'tweet_author': 'Dr. Carsten Wenzel',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability in MCL https://t.co/JvHjWIyvfe https://t.co/ksGNByhnKb'},\n",
              " '1335940206223106048': {'tweet_author': 'BiopharmaAsia',\n",
              "  'tweet_text': 'ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of Calquence - https://t.co/b8JIeZLF4S'},\n",
              " '1335933768528490496': {'tweet_author': 'Prescient Healthcare Group',\n",
              "  'tweet_text': 'Prescient coverage of #ASH2020, Day 2: Chronic Lymphocytic Leukemia (#CLL) – #acalabrutinib #venetoclax #obinutuzumab https://t.co/MRBDl9AdeQ https://t.co/WLy1gaofTm'},\n",
              " '1335917885143863298': {'tweet_author': 'CHItraders',\n",
              "  'tweet_text': \"$AZN AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/zBfxEhQ1au\"},\n",
              " '1335914582188187648': {'tweet_author': 'WICҚƸ︎Đ✧ȘPĿIҬŚ',\n",
              "  'tweet_text': \"▶︎ AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/FOL47mRFbO VIΛ WICҚƸ︎Đ✧ȘPĿIҬŚ FINΛNCIΛL REΛDS\"},\n",
              " '1335913278371926018': {'tweet_author': 'Gordon Gekko',\n",
              "  'tweet_text': \"AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/a7IfrxMoGZ\"},\n",
              " '1335913076416270336': {'tweet_author': 'Investor News',\n",
              "  'tweet_text': \"AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer $AZN https://t.co/8yWmcnr1VS\"},\n",
              " '1335912165979561991': {'tweet_author': 'Breaking News',\n",
              "  'tweet_text': \"$AZN - AstraZeneca's Calquence shows long-term efficacy and tolerability in patients with blood cancer https://t.co/IbDBcH5OeL\"},\n",
              " '1335904449622061056': {'tweet_author': 'PharmaTimes',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability in MCL https://t.co/4f3L0E9SVK #pharmanews #pharma'},\n",
              " '1335901590432215043': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability in MCL https://t.co/4DdzNkc7tO'},\n",
              " '1335894459070828544': {'tweet_author': 'PharmaShots - Incisive news in 3 shots',\n",
              "  'tweet_text': 'AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL @Pharmashot @AstraZeneca \\nhttps://t.co/SSI6xZmusR https://t.co/y57kfUqk3D'},\n",
              " '1335885262078025728': {'tweet_author': 'Medicircle.in',\n",
              "  'tweet_text': 'Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained\\n #LatestPharmaNewsDec7 #LatestAstrazenecaNewsDec7 \\nhttps://t.co/GQHZzUJ6BW'},\n",
              " '1335866653892960261': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Astrazeneca reported that #Calquence shows long-term efficacy and tolerability at three years  for patients with #relapsed or #refractory #mantlecelllymphoma $AZN https://t.co/iJGSKQcdkZ'},\n",
              " '1335811398467612672': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811276476387329': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811275561918464': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811274802929664': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811274429620224': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811274177794048': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811273045528576': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811272881758208': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811272479223808': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811272475111425': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335811272453935106': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about the demonstrated safety and tolerability profile of CALQUENCE. Join the virtual conversation to learn more! #ASH20'},\n",
              " '1335744469673525249': {'tweet_author': 'cafepharma',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/2Dd7CdJ1D8\"},\n",
              " '1335718758451646467': {'tweet_author': 'Shifting Wealth',\n",
              "  'tweet_text': 'CALQUENCE shows long-term efficacy, tolerability at 3 years in R/R MCL \\n$AZN'},\n",
              " '1335718044153257984': {'tweet_author': 'analyst land news',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/0NqwPRmrmn https://t.co/1fsa0r89Co\"},\n",
              " '1335705645006327815': {'tweet_author': 'Enosi Life Sciences',\n",
              "  'tweet_text': 'These “cytokine storms\" are created when there are high levels of pro-inflammatory TNF.\\n\\n\"...some COVID-19 patients suffer from \"cytokine storms,\" in which immune systems end up attacking the body after getting revving up to fight off the coronavirus. \" https://t.co/TSbSVAaRX6'},\n",
              " '1335701979318935552': {'tweet_author': 'ExBulletin',\n",
              "  'tweet_text': 'ASH: AstraZeneca’s Calquence and BeiGene’s Brukinsa are turning heads with new data, putting Imbruvica on high\\xa0alert https://t.co/MP6bBWr9E2'},\n",
              " '1335700302406664192': {'tweet_author': 'Dr Timos Papagatsias',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/nb6TYqWit2 #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #healthcare #biotech https://t.co/5Cn35fMGtb\"},\n",
              " '1335698575792148481': {'tweet_author': 'Wall St. Justin Bieber think.trade💭',\n",
              "  'tweet_text': '📰 NEWS ALERT: AstraZeneca Announced Calquence Shows Long-term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma in Presentation at ASH 2020\\n🕰 Time/Date: 2020-12-06T21:31:24.535000+00:00\\n-think.trade'},\n",
              " '1335692498002354178': {'tweet_author': 'PharmaCrowd',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/02Gy4NpuLI https://t.co/Yz6EF7oAh2\"},\n",
              " '1335692400354877440': {'tweet_author': 'FintechZoom',\n",
              "  'tweet_text': 'New article: \"Johnson &amp; Johnson - ASH: AstraZeneca\\'s Calquence, BeiGene\\'s Brukinsa turn heads with new data, putting Imbruvica on notice\" has been published on Fintech Zoom - https://t.co/adPNJ6RbBF @FintechZoom #Fintech #Blockchain #Crypto #Cryptocurrency #ICO'},\n",
              " '1335688725980979204': {'tweet_author': 'Continental Clinical',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/S54IU6veT0\"},\n",
              " '1335681794402881537': {'tweet_author': 'NewExpressNews',\n",
              "  'tweet_text': 'ASH: AstraZeneca’s Calquence, BeiGene’s Brukinsa turn heads with new data, putting Imbruvica on\\xa0notice https://t.co/w4Z9ZSGPPo'},\n",
              " '1335679918525526018': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'ASH: AstraZeneca’s Calquence, BeiGene’s Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/xgInJQBg6s'},\n",
              " '1335679662958071809': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': \"ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice https://t.co/5oYzzhKiLA\"},\n",
              " '1335674215983407104': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle https://t.co/GQ0bdnvfBD'},\n",
              " '1335669146030313473': {'tweet_author': 'BrainSights iOS App',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma - Neuro Central via BrainSights for iOS https://t.co/ni7XTtquFd'},\n",
              " '1335657756842467329': {'tweet_author': 'Anthony Mato',\n",
              "  'tweet_text': 'Very thoughtful answer. Thanks for taking my question. Clive Zent discussing which may be best the anti CD antibody to pair with the BTK inhibitor acalabrutinib. https://t.co/dnhMDywRce'},\n",
              " '1335628087342600193': {'tweet_author': 'Pharmacutical Daily',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell\\xa0Lymphoma https://t.co/lyPJvlt8Pj'},\n",
              " '1335615746278232068': {'tweet_author': 'Stock Market News',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/ejOAcuqoXi #StockMarket'},\n",
              " '1335606574849482754': {'tweet_author': 'Hottest Stocks Now',\n",
              "  'tweet_text': '$AZN Reveals findings from mid-stage trial evaluating CALQUENCE in patients with relapsed or refractory mantle cell lymphoma      #Astrazeneca       #MCL       #mantlecelllymphoma     #lymphoma      https://t.co/mNw8szIDyN'},\n",
              " '1335606445920972800': {'tweet_author': 'OTC Dynamics, Inc.',\n",
              "  'tweet_text': '$AZN CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/py9vCpQGfd'},\n",
              " '1335604254136913921': {'tweet_author': 'Corporate News',\n",
              "  'tweet_text': '$AZN CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/LNACBNGPHa'},\n",
              " '1335603847465603074': {'tweet_author': 'IMPharma News',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma \\nhttps://t.co/RfVqm1ITyJ'},\n",
              " '1335602524351508481': {'tweet_author': 'Investor News',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma $AZN https://t.co/eRVMJfkQlL'},\n",
              " '1335601900037709831': {'tweet_author': 'Crwe World',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle C https://t.co/y3FjZiBpqG'},\n",
              " '1335601278748004352': {'tweet_author': 'Latest News from Business Wire',\n",
              "  'tweet_text': 'CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma https://t.co/Vf692VoBYt https://t.co/Th59UhyUxL'},\n",
              " '1335600906985992193': {'tweet_author': 'AstraZenecaUS',\n",
              "  'tweet_text': 'Today we announced long-term follow-up results of the ACE-LY-004 trial in relapsed or refractory mantle cell #lymphoma (MCL) at #ASH20. Learn more about this latest development for people living with MCL: https://t.co/elpwOKu66y https://t.co/QJrSITwFNa'},\n",
              " '1335600771358806017': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https://t.co/RMh52fkmXG'},\n",
              " '1335600347063046146': {'tweet_author': 'Stock Titan',\n",
              "  'tweet_text': '$AZN CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma\\nhttps://t.co/BbUJycz0KQ'},\n",
              " '1335537348180930560': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) - chronic lymphocytic leukaemia (CLL) https://t.co/u3lRYIvDfK'},\n",
              " '1335448884911484930': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss Dr Michael Wang present AstraZeneca’s clinical data from CALQUENCE at this year’s virtual #ASH20 conference!'},\n",
              " '1335279810768216064': {'tweet_author': 'Ingrid Glimelius',\n",
              "  'tweet_text': 'Loxo-305 in mantle cell #lymphoma, very beneficial toxicity profile and ORR of 52% in previously treated. #ASH20 will it kill Ibrutinib and Acalabrutinib https://t.co/kHtXbDYhlT'},\n",
              " '1335253934399754240': {'tweet_author': 'Maria Badillo, MSN RN OCN CCRP',\n",
              "  'tweet_text': 'Not able to join #ASH2020 this year as I let my other team member register for this year’s conference. Excited to hear the results of our trials we run for #MCL such as Loxo305, VLS101,Ibrutinib, Acalabrutinib,Zuma 2 Car T. @michaelwangmd @MDAndersonNews #ASHFromHome'},\n",
              " '1335226436974735362': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'Thorough overview on safety data with BTKis by Nicola Lamanna. \\n\\nhttps://t.co/fNEYyoTxW3\\n\\nRCT of #acalabrutinib vs #ibrutinib monotherapy in high risk R/R #CLL awaited with great interest #CLL #ASH20 https://t.co/fzNKIL4taZ'},\n",
              " '1335217837997219840': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data will be released at #ASH20 that oncologists/hematologists won’t want to miss.'},\n",
              " '1335179944679403521': {'tweet_author': 'Мэрсэдэ́с Bouter LL.M.',\n",
              "  'tweet_text': 'Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors (inc. the off-label administration of acalabrutinib).\\n\\nhttps://t.co/AcI98PsAdX'},\n",
              " '1335086499365179393': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data will be released at #ASH20 that oncologists/hematologists won’t want to miss.'},\n",
              " '1335086498647998464': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data will be released at #ASH20 that oncologists/hematologists won’t want to miss.'},\n",
              " '1335086498454986752': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data will be released at #ASH20 that oncologists/hematologists won’t want to miss.'},\n",
              " '1335086497226252293': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A New CALQUENCE clinical data will be released at #ASH20 that oncologists/hematologists won’t want to miss.'},\n",
              " '1335080025473740801': {'tweet_author': 'Mostly Harmless',\n",
              "  'tweet_text': \"OMG now I am getting ads for super-specialized cancer immunotherapy drugs, like they were new cars or something. Just in time for Christmas, it's Calquence!\"},\n",
              " '1335037794276823041': {'tweet_author': 'BIOCIENCIA',\n",
              "  'tweet_text': 'Aprobación de acalabrutinib contra leucemia linfocítica crónica\\xa0en la Unión Europea https://t.co/yZWTQpojk0 a través de @medscape'},\n",
              " '1335026099735191558': {'tweet_author': 'Medscape ES',\n",
              "  'tweet_text': 'La Agencia Europea de Medicamentos (EMA) acaba de aprobar acalabrutinib para el tratamiento de leucemia linfocítica crónica, una de las leucemias más comunes en adultos. La terapia deberá ser aplicada por un especialista en fármacos neoplásicos. https://t.co/5V8y1MAEtE'},\n",
              " '1334943309266038787': {'tweet_author': 'Brand Institute, Inc',\n",
              "  'tweet_text': 'Congratulations to AstraZeneca on the EMA approval of CALQUENCE! #BIBrands\\n\\nCALQUENCE is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).\\n\\n#EMAapproval #DrugNaming #CLL #SLL https://t.co/qGNdErdrKT'},\n",
              " '1334935950246502400': {'tweet_author': 'Dr Pablo Marcelo Lombardo',\n",
              "  'tweet_text': 'Aprobación de acalabrutinib contra leucemia linfocítica crónica\\xa0en la Unión Europea https://t.co/NmRvbg7nMi via @medscape'},\n",
              " '1334878110622343172': {'tweet_author': 'Rebecca Miller',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/PUx1hd6vQP #bloodcancerawareness #ad https://t.co/2RBCWL3esZ https://t.co/vzIq0g7ih1'},\n",
              " '1334669772244447233': {'tweet_author': 'LaVonne Cladoosby Long',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/obEDJId2i5 #bloodcancerawareness #ad https://t.co/urxC89DmbN https://t.co/RyxzgbiqmP'},\n",
              " '1334613688595206148': {'tweet_author': 'Kelly Tomlinson',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/BDfy3CJRvS #bloodcancerawareness #ad https://t.co/cbq3wFcICj https://t.co/yjrLEC51OO'},\n",
              " '1334512725419053058': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference will feature clinical data about CALQUENCE—a treatment option for adults with CLL. #ASH20'},\n",
              " '1334512724210958336': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference will feature clinical data about CALQUENCE—a treatment option for adults with CLL. #ASH20'},\n",
              " '1334512721723736064': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Attention #ASH20 attendees: Tune in on Dec 7 to watch Dr Paolo Ghia present on the final analysis of the pivotal CALQUENCE trial in patients with relapsed/refractory CLL.'},\n",
              " '1334512721685929984': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference will feature clinical data about CALQUENCE—a treatment option for adults with CLL. #ASH20'},\n",
              " '1334512720750796802': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Attention #ASH20 attendees: Tune in on Dec 7 to watch Dr Paolo Ghia present on the final analysis of the pivotal CALQUENCE trial in patients with relapsed/refractory CLL.'},\n",
              " '1334512719311953920': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Attention #ASH20 attendees: Tune in on Dec 7 to watch Dr Paolo Ghia present on the final analysis of the pivotal CALQUENCE trial in patients with relapsed/refractory CLL.'},\n",
              " '1334512717646839808': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Attention #ASH20 attendees: Tune in on Dec 7 to watch Dr Paolo Ghia present on the final analysis of the pivotal CALQUENCE trial in patients with relapsed/refractory CLL.'},\n",
              " '1334512716258676742': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A This year’s all-virtual ASH 2020 conference will feature clinical data about CALQUENCE—a treatment option for adults with CLL. #ASH20'},\n",
              " '1334379212292169728': {'tweet_author': \"Mommy's Playbook\",\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/mUUsCdsy8z #bloodcancerawareness #ad https://t.co/jPQIHPtq14 https://t.co/Pk978NekcO'},\n",
              " '1334290404615839746': {'tweet_author': 'knowmedge',\n",
              "  'tweet_text': 'Q1: Acalabrutinib is used to manage what condition? #ABIM #MedEd'},\n",
              " '1334269937716666368': {'tweet_author': 'IceCreamStickyFinger',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/Xbm1MDi8nb #bloodcancerawareness #ad https://t.co/cjhLoGYkP0 https://t.co/Q8tBJWRh5Z'},\n",
              " '1334265275949072386': {'tweet_author': 'Brittany',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/b3IjDBRMXt #bloodcancerawareness #ad https://t.co/rkSdwQR3CJ https://t.co/x2KyjOQZlA'},\n",
              " '1334165581549985792': {'tweet_author': 'Carrie',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/LAJJr1sdOP #bloodcancerawareness #ad https://t.co/oWkwowJo7V https://t.co/17s9RWLeha'},\n",
              " '1334031007691931648': {'tweet_author': 'Christian Yosores',\n",
              "  'tweet_text': 'DOH said the \"Acalabrutinib\" arm of WHO\\'s Solidarity Trial will no longer push through because evidence from AstraZeneca’s trial showed that there was \"no significant improvement\" in the treatment outcomes of patients. | @BomboRadyoNews'},\n",
              " '1334028814821720064': {'tweet_author': 'Inquirer',\n",
              "  'tweet_text': 'DOH said the acalabrutinib arm of the WHO-led Solidarity Therapeutics Trial will no longer push through after AstraZeneca’s study showed the anticancer drug did not help reduce deaths and the need for assisted ventilation among hospitalized COVID-19 patients. | @jovicyeeINQ'},\n",
              " '1334028554892312578': {'tweet_author': 'jovic yee',\n",
              "  'tweet_text': 'DOH said the acalabrutinib arm of the WHO-led Solidarity Therapeutics Trial will no longer push through after AstraZeneca’s study showed the anticancer drug did not help reduce deaths and the need for assisted ventilation among hospitalized COVID-19 patients @inquirerdotnet'},\n",
              " '1333971511137415169': {'tweet_author': 'Maria',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL.  https://t.co/LTUgBbUILm #bloodcancerawareness #ad https://t.co/miQQPzwY0d'},\n",
              " '1333833603294216192': {'tweet_author': 'Heidi Bee',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription @CalquenceHCP  for adult patients. https://t.co/OGel3fMZUP #bloodcancerawareness #ad https://t.co/wZvwaOc6pz https://t.co/0lNAr5r0IX'},\n",
              " '1333814208744460291': {'tweet_author': 'Catherine Lewis',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more:\\xa0https://t.co/WevhiBxQfI #bloodcancerawareness #ad https://t.co/3YUQyCoLcL https://t.co/eqpzOmQe0P'},\n",
              " '1333744538960084994': {'tweet_author': '@COVID_Evidence',\n",
              "  'tweet_text': 'https://t.co/k5GfHG63vK:  WHO COVID-19 Solidarity Trial for COVID-19 Treatments: Condition: \\xa0 Covid19 Interventions: \\xa0 Drug:\\xa0Remdesivir; \\xa0 Drug:\\xa0Acalabrutinib; \\xa0 Drug:\\xa0Interferon\\xa0beta-1a; \\xa0 Other:\\xa0Standard\\xa0of\\xa0Care Sponsor:… https://t.co/svBnaHlQ5H #covid19 #SARSCOV2 #coronavirus'},\n",
              " '1333715269156483073': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'New by @Medivizor: Comparing acalabrutinib to standard treatments in patients with chronic lymphocyt... https://t.co/tLXIunsT1a #Leukemia'},\n",
              " '1333609405326176257': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Comparing acalabrutinib to standard treatments in patients with chronic lymphocytic... (via @medivizor) https://t.co/tLXIunsT1a #Leukemia'},\n",
              " '1333533109212618754': {'tweet_author': 'Kathy Hodson',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/Bn3QVszI9w #bloodcancerawareness #ad https://t.co/0Qz7GgN0Vh https://t.co/FJeAoLmTmz'},\n",
              " '1333520512853700609': {'tweet_author': 'Home Jobs by MOM',\n",
              "  'tweet_text': 'With CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients with CLL or SLL. Learn more at https://t.co/PH7CfydjBT #bloodcancerawareness #ad https://t.co/LnzxMpDung https://t.co/7g0xH0DrP6'},\n",
              " '1333511555409797120': {'tweet_author': 'Angie Agerter',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/2VET773saj #bloodcancerawareness #ad https://t.co/pcdnz5RbwV https://t.co/GLvEHvRJgk'},\n",
              " '1333497315764678656': {'tweet_author': 'Ana',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule.\\xa0If you or someone you love has CLL, you may have options with\\xa0prescription\\xa0CALQUENCE for adult patients.\\xa0https://t.co/q96D7TjXSI\\xa0#bloodcancerawareness #ad\\xa0https://t.co/scCbjKEI6I https://t.co/A69aBMwQI8'},\n",
              " '1333440658137235456': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual #ASH20 conference!'},\n",
              " '1333440656010850305': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual #ASH20 conference!'},\n",
              " '1333440655159418881': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual #ASH20 conference!'},\n",
              " '1333440654777704448': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Don’t miss AstraZeneca’s big reveal of CALQUENCE patient data at this year’s virtual #ASH20 conference!'},\n",
              " '1333421840182751234': {'tweet_author': 'Lindsey G.',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/QQefuBeDeb #bloodcancerawareness #ad https://t.co/KaW6GaAICw https://t.co/cBv8eK4Wia'},\n",
              " '1333359343291535361': {'tweet_author': 'Gelbe Liste',\n",
              "  'tweet_text': 'Zum 1. Dezember 2020 kommt das Arzneimittel #Calquence (Acalabrutinib) auf den deutschen Markt. Es handelt sich um eine neue Behandlungsoption bei chronisch lymphatischer #Leukämie (CLL): https://t.co/iyUxxIlE7f https://t.co/tmmuY01PT6'},\n",
              " '1333233071101865988': {'tweet_author': 'icefairy',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/HOEi3Qx9X2 #bloodcancerawareness #ad https://t.co/3pC3rEhyOP https://t.co/ZHMHd0IbbX'},\n",
              " '1333177579314896896': {'tweet_author': 'Imperfect Women',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients with CLL. https://t.co/87tinmMKC9 #bloodcancerawareness #ad https://t.co/3dVKeFaTdr https://t.co/Loqjpg50C6'},\n",
              " '1332786101409505280': {'tweet_author': 'Candy Washington',\n",
              "  'tweet_text': 'With CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients with CLL or SLL. Learn more at https://t.co/unujqqXdgF #bloodcancerawareness #ad https://t.co/En0t6IDTXO https://t.co/B8Rqzgn30V'},\n",
              " '1332723331825606661': {'tweet_author': 'Lauren Beth',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription  CALQUENCE for adult patients. https://t.co/EySwYazd4Y #bloodcancerawareness #ad https://t.co/eL84PgNO3a https://t.co/TVWXaBpCPV'},\n",
              " '1332323142417702913': {'tweet_author': 'Lynne Mac Lean',\n",
              "  'tweet_text': 'Top story: Acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia - Medivizor https://t.co/GwX6RoRGD0, see more https://t.co/JwIx5tG5Ze'},\n",
              " '1332288686277468167': {'tweet_author': 'Paul Wright',\n",
              "  'tweet_text': 'Top story: Acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia - Medivizor https://t.co/UpzRFTnS1U, see more https://t.co/vXnuH4zY0L'},\n",
              " '1332259013472497665': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https://t.co/gL8tkhWkIC via @medivizor #Leukemia'},\n",
              " '1332037025583820801': {'tweet_author': 'TF 2',\n",
              "  'tweet_text': '$AZN - “AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.” Now COVID vaccine : https://t.co/cNtFh0d88S'},\n",
              " '1331792396162621441': {'tweet_author': 'Leave The Cannoli',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/xDWay9czSg #bloodcancerawareness #ad https://t.co/1tKQmxDMwR https://t.co/llEXbMheia'},\n",
              " '1331751113033478144': {'tweet_author': 'Mafiusa',\n",
              "  'tweet_text': \"Headline News - Steals &amp; Deals @EmilyReviewsCom: 'With CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients wit… https://t.co/FPRP2XavpM, see more https://t.co/FuPeDpBSxB\"},\n",
              " '1331676594679779335': {'tweet_author': 'Emily Reviews',\n",
              "  'tweet_text': 'With CALQUENCE, feel supported all day and night with patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication to treat adult patients with CLL or SLL. Learn more at https://t.co/wkoEYhuMED #bloodcancerawareness #ad https://t.co/5dB9qfx9bf https://t.co/77RNxFjsNr'},\n",
              " '1331631905935142914': {'tweet_author': 'Kelly & Alex',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/TXh0hAdz2e #bloodcancerawareness #ad https://t.co/Yi2XxGkaJ8'},\n",
              " '1331600402513588225': {'tweet_author': 'Deliciously Savvy',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. 👉🏼https://t.co/Zl0uXxvp4o👈🏼\\n #bloodcancerawareness #ad https://t.co/XkhD9iA4UP https://t.co/7y060bu9UO'},\n",
              " '1331599941429506050': {'tweet_author': 'Deliciously Savvy',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. 👉🏼https://t.co/2RKhq2kkb0👈🏼\\n #bloodcancerawareness #ad https://t.co/XkhD9iA4UP https://t.co/S2SmE1Pygl'},\n",
              " '1331521877391523842': {'tweet_author': 'ティーズ',\n",
              "  'tweet_text': '★アストラゼネカ、「CALAVI試験は残念な結果に……」★\\n\\n#アストラゼネカ は、#新型コロナウイルス性呼吸器症状 を有する入院患者さんを対象とする #Calquence®（以下、アカラブルチニブ）のCALAVI第Ⅱ相試験において、主要評価項目を達成しなかったことを発表しました。\\nhttps://t.co/Iz9Ybcr0yt'},\n",
              " '1331515468461576193': {'tweet_author': 'Haute Autorité de santé',\n",
              "  'tweet_text': '✏Contribuez | Nous évaluons le nouveau #médicament CALQUENCE (acalabrutinib) dans le traitement des patients atteints de #leucémie lymphoïde chronique (LLC) non précédemment traitée\\n👉 https://t.co/wTNjnRgZ7R'},\n",
              " '1331397095962578944': {'tweet_author': 'Cleverly Changing (She/her)',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/uRiuJOnusS #bloodcancerawareness #ad https://t.co/DeHY0fK2PY https://t.co/jxSUSEqCdf'},\n",
              " '1331352643202134020': {'tweet_author': 'ELMENS',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/AK5C2fLTfh \\n\\n#bloodcancerawareness #ad https://t.co/UnTvKFioCa https://t.co/FfTiGaJQBZ'},\n",
              " '1331314457721626625': {'tweet_author': 'Alexandria',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/OEj2xppLui #bloodcancerawareness #ad https://t.co/n7pmoGG8yd https://t.co/RYmMOWARRC'},\n",
              " '1331308051060625410': {'tweet_author': 'Jaclyn',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/Cph1DlgT2z #bloodcancerawareness #ad https://t.co/KtiKltoyCD https://t.co/3BUeQIoR3J'},\n",
              " '1331306983312420865': {'tweet_author': 'Stephanie BeautyBrite Ⓥ',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/tBYtAWeA7Q #bloodcancerawareness #ad https://t.co/odXrud3vnT https://t.co/GZh95orRUb'},\n",
              " '1331305601104629761': {'tweet_author': 'Stephanie BeautyBrite Ⓥ',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/tBYtAWeA7Q #bloodcancerawareness #ad https://t.co/odXrud3vnT https://t.co/NEEK6PStSX'},\n",
              " '1331301655015526400': {'tweet_author': 'Jennifer Soltys',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/WKSExhUDUz #bloodcancerawareness #ad https://t.co/qx9efpN5cp https://t.co/XnVrEkV7eG'},\n",
              " '1331301556369588225': {'tweet_author': 'Vanessa Diaz',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/PlsWJTJ5WF #bloodcancerawareness #ad https://t.co/MNuMX5b5da https://t.co/B8fCAZP7xQ'},\n",
              " '1331301265968685065': {'tweet_author': 'Colleen Padilla',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/lEqnL1Ojxb #bloodcancerawareness #ad https://t.co/IwOx3aaTeY https://t.co/dVvKNDaQwN'},\n",
              " '1331300361701822466': {'tweet_author': 'Jenn p',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/LhC0IinxYC #bloodcancerawareness #ad https://t.co/IkAKhZTSpp https://t.co/Z424LjRId6'},\n",
              " '1331300339920883716': {'tweet_author': 'Jays SweetNSour Life',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, twice a day capsule. If you or someone you love has CLL, you may have options with prescription CALQUENCE for adult patients. https://t.co/PNKGq59aCR #bloodcancerawareness #ad https://t.co/G2Fg3POnie https://t.co/7CfDZrgJF6'},\n",
              " '1331236402537914368': {'tweet_author': 'FancyFinancy',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating COVID-19 https://t.co/DHkyNNrzmG'},\n",
              " '1331228704538849282': {'tweet_author': 'FancyFinancy',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/8dDVZEF6hc https://t.co/6GuNjqcsvx\"},\n",
              " '1331104513638490113': {'tweet_author': 'Zazoom Social News',\n",
              "  'tweet_text': 'Leucemia linfocitica: acalabrutinib approvato in UE -  #Leucemia #linfocitica: #acalabrutinib  https://t.co/Z2L8OV1WL7'},\n",
              " '1331037100809064448': {'tweet_author': 'Kimberly Kong',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/dfXwwKX4Oz. #bloodcancerawareness #ad https://t.co/LyfGo77dcU https://t.co/LiwdTFqO56'},\n",
              " '1331019187238576129': {'tweet_author': 'a watcher',\n",
              "  'tweet_text': '2020年11月20日【アストラゼネカ｜日】『新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とする、アカラブルチニブ（Calquence®）CALAVI第Ⅱ相試験の最新情報』が公開\\n\\n英本社発表抄訳\\n\\n呼吸不全未発症の生存患者の割合増加という主要評価項目を達成せず\\n\\nhttps://t.co/X1PEde9Spp'},\n",
              " '1330979862153203718': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'V comprehensive rw by Danilov &amp; @DrDanPersky \\nacalabrutinib in #MCL #CLL &amp; #WM. Recommended reading! #lymsm \\n\\nIncorporating acalabrutinib, a selective next‐generation BTK inhibitor, into clinical practice for the treatment of haematological malignancies https://t.co/WrnGL0Z6jl'},\n",
              " '1330975416396427267': {'tweet_author': 'Amber Koehler, PA-C',\n",
              "  'tweet_text': 'Great news for patients with #CLL in the EU! https://t.co/ZfRmfV1CaW'},\n",
              " '1330876630684880903': {'tweet_author': 'Mariah Moon',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/CAv3wt52fb #bloodcancerawareness #ad https://t.co/K5OKNKqGo1 https://t.co/3QBnlKibus'},\n",
              " '1330737910111481858': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Results showed that the majority of patients who received a 10- to 14-day course of acalabrutinib experienced improvement in oxygenation that was found to occur within 1 to 3 days of treatment. #COVID-19 https://t.co/NssVAZ1vEt'},\n",
              " '1330492185842769920': {'tweet_author': 'Erica Valentin',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/5spf24Oa3A #bloodcancerawareness #ad https://t.co/sb2Xa3ayEP https://t.co/mUPuCji8bG'},\n",
              " '1330425900664549377': {'tweet_author': 'Lymphoma Papers',\n",
              "  'tweet_text': 'Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. #lymphoma #lymsm https://t.co/p0iF4DQKzn'},\n",
              " '1330411067680419840': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) - chronic lymphocytic leukaemia (CLL) https://t.co/u3lRYIvDfK'},\n",
              " '1330345299936751617': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'The approvals of ibrutinib and acalabrutinib have been transformative to the CLL treatment paradigm, but could have even more power in combination. @ASkarbnik @NovantHealth #leusm https://t.co/sINvk3S9sW'},\n",
              " '1330282349779705862': {'tweet_author': 'PracticeUpdate',\n",
              "  'tweet_text': 'Pembrolizumab Plus Acalabrutinib for Platinum-Resistant Metastatic #Urothelial Carcinoma.\\n\\n📽️ #ESMO20 interview with @sonpavde  🔽 #blcsm @myESMO \\nhttps://t.co/Z41GBayMa9'},\n",
              " '1330224551268134912': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'The addition of acalabrutinib to best supportive care in patients with respiratory symptoms from #COVID-19 failed to increase the proportion of patients who remained alive and free of respiratory failure. https://t.co/MUsCSBQ2xR'},\n",
              " '1330153398340087808': {'tweet_author': 'Amy Smith',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/ai5FkMGUan #bloodcancerawareness #ad https://t.co/6bmCbv2QBe https://t.co/EUebm9Vlqc'},\n",
              " '1330104700537024513': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. https://t.co/OPcVZAmkG5 #MCL #lymsm #hematology https://t.co/aUitt2hE6M'},\n",
              " '1329974037821308928': {'tweet_author': 'MomGlenz',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/UthOFGLLbr #bloodcancerawareness #ad https://t.co/ErXHERMwX0 https://t.co/AytLnPBBPz'},\n",
              " '1329862080653094913': {'tweet_author': 'Da Vinci - Also follow @OutdoorsyBW',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. @CalquenceHC is a prescription treatment option for adult patients with CLL. https://t.co/UUQC7sVYm0 #bloodcancerawareness #ad https://t.co/mNLjX9R7Ze https://t.co/hX0lvkywy5'},\n",
              " '1329757371674013696': {'tweet_author': 'Gelbe Liste',\n",
              "  'tweet_text': 'Die Europäische Kommission hat #Calquence mit dem Wirkstoff #Acalabrutinib die Zulassung für die Behandlung von chronisch lymphatischer #Leukämie (CLL) erteilt: https://t.co/OpBRvSmVBf https://t.co/sFV21fdpr5'},\n",
              " '1329738783898537985': {'tweet_author': 'JPubb 日本企業 リリース 医薬品',\n",
              "  'tweet_text': '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とする、アカラブルチニブ（Calquence®）CALAVI第Ⅱ相試験の最... 〔11/20 アストラゼネカ〕 https://t.co/oSFvR0eZRl'},\n",
              " '1329710517728862208': {'tweet_author': 'NEWSRELEA.SE',\n",
              "  'tweet_text': 'アストラゼネカ株式会社、新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験の最新情報 https://t.co/w2QitdMJ3m'},\n",
              " '1329645262969606146': {'tweet_author': 'PR TIMESビジネス',\n",
              "  'tweet_text': '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験... https://t.co/uNtxVmf86k'},\n",
              " '1329641266913669120': {'tweet_author': 'コロナ vs. AI 最新テクノロジーで感染症に挑む【書籍】',\n",
              "  'tweet_text': '\" 新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験の最新情報\" #創薬 #創薬AI #AI #機械学習 #コロナウイルス #Coronavirus https://t.co/H2OjFyzP5G'},\n",
              " '1329637376147111937': {'tweet_author': 'PR TIMESニュース',\n",
              "  'tweet_text': '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験... https://t.co/Ow7fO1u2g6'},\n",
              " '1329636038340390912': {'tweet_author': 'WMR Tokyo - スタートアップ',\n",
              "  'tweet_text': '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第II相試験の最新情報 https://t.co/rbKwKoPKxV'},\n",
              " '1329611461082144769': {'tweet_author': 'Colin Cesvette',\n",
              "  'tweet_text': 'Top story: Treatment for CLL/SLL and MCL | CALQUENCE® (acalabrutinib) https://t.co/BTaWyJmr4F, see more https://t.co/0KRQOKlmtG'},\n",
              " '1329564625549938689': {'tweet_author': \"What's up dearie?\",\n",
              "  'tweet_text': 'With CALQUENCE, feel supported day and night with their patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication used to treat adult patients with CLL. Learn more at https://t.co/r0X9hV6lu8. #bloodcancerawareness #ad https://t.co/u5RPyBDiXu https://t.co/lIjfV8mulj'},\n",
              " '1329557569321492480': {'tweet_author': 'BiotechBioPharma',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating COVID-19 https://t.co/o59KhfbzC0'},\n",
              " '1329545054101364737': {'tweet_author': 'CADTH',\n",
              "  'tweet_text': 'CADTH has issued a recommendation for #Acalabrutinib (#Calquence) to be reimbursed with clinical criteria and/or conditions for the treatment of chronic lymphocytic #leukemia.\\n\\nSee the full recommendation 👉 https://t.co/GuoOZZsthw https://t.co/1ahCvLyVMr'},\n",
              " '1329537486704566274': {'tweet_author': 'BiotechBioPharma',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/JXQcmsYL3W https://t.co/KNfLRjDdZm\"},\n",
              " '1329536787233071105': {'tweet_author': 'melissa weintraub',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/R4DNlk30vf. #bloodcancerawareness #ad https://t.co/KmZVQ13uzc https://t.co/va6aZiqr6u'},\n",
              " '1329530040233684992': {'tweet_author': 'HEATHER | Pink Ninja Blogger',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/OXSb1lnYt5. #bloodcancerawareness #ad https://t.co/nzboNF8seu https://t.co/Vw9XOhQcmK'},\n",
              " '1329502984095420416': {'tweet_author': 'Garf',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/33v99iO1du. #bloodcancerawareness #ad https://t.co/RWXmoQ00a9 https://t.co/KqyCP62fQs'},\n",
              " '1329486917130448898': {'tweet_author': 'Your Helpful Wendy',\n",
              "  'tweet_text': 'If you or someone you love has blood cancer (CLL, SLL or MCL), you have treatment options with @CALQUENCE It’s a convenient oral, 2x a day capsule, so you can focus on the lifestyle you want! #bloodcancerawareness https://t.co/08Ykw4xnCi #ad https://t.co/xcE7dYS90T'},\n",
              " '1329456913034178562': {'tweet_author': 'Financial Carnivores',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating COVID-19 https://t.co/UmzllPdq6e'},\n",
              " '1329451877344403468': {'tweet_author': 'Financial Carnivores',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/eZxaeUK5Ym https://t.co/XlX0OLP9yU\"},\n",
              " '1329438717929467907': {'tweet_author': 'My Life is a Journey🇨🇴😷',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/kRN5kp5QkI #bloodcancerawareness #ad https://t.co/zk4pqEdZaw https://t.co/qsg5f8REc5'},\n",
              " '1329370635064238080': {'tweet_author': 'Quant Data',\n",
              "  'tweet_text': 'AstraZeneca Says Presentations Support Calquence Efficacy and Tolerability With Long-term Follow-up In Mantle Cell Lymphoma and Pooled Safety Data in Chronic Lymphocytic Leukaemia\\n\\nRelated Tickers: $AZN\\nRead more at: https://t.co/KOFeTLi4vu'},\n",
              " '1329321009493778437': {'tweet_author': 'Swedish Biotech',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating COVID-19 https://t.co/QzSWlwdd6W'},\n",
              " '1329320381207887873': {'tweet_author': 'いつも悩んでる人',\n",
              "  'tweet_text': 'アステラゼネカ\\u3000オックスフォードの第2層の有効性確認\\n数週間以内に第3層へ\\n\\nUpdate on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19\\nhttps://t.co/zf2pSLC8x4 https://t.co/tpWSvtwgC2'},\n",
              " '1329310955877101568': {'tweet_author': 'Swedish Biotech',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/5g6XhXdxB9 https://t.co/Nn7KJnEtvf\"},\n",
              " '1329229171818696710': {'tweet_author': 'CURE Magazine',\n",
              "  'tweet_text': 'CURE &amp; AstraZeneca are proud to present the first CALQUENCE Connections on November 21 at 2PM ET! Join us as a doctor, patient, and care team discusses their experiences with chronic lymphocytic leukemia and answers audience questions. Learn more: https://t.co/QpxnZ2ovIi https://t.co/fUuowHrI6C'},\n",
              " '1329217531958202370': {'tweet_author': 'Wrapped Up N U',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/6thbETrrXi #bloodcancerawareness #ad https://t.co/QHd9kft68l https://t.co/S97TcXxd0n'},\n",
              " '1329147290561474560': {'tweet_author': 'pamelamaynard',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/avT0IQnVP7 #bloodcancerawareness #ad https://t.co/pkTV138kA1 https://t.co/OiiAxQDj9A'},\n",
              " '1329141382875934726': {'tweet_author': 'SensiblySara',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/XSTVkYN3Sq #bloodcancerawareness #ad https://t.co/cWBf0TaupW https://t.co/OVbuUHCaKB'},\n",
              " '1329095631638470656': {'tweet_author': 'The Frugal Navy Wife',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. @CalquenceHCP is a prescription treatment option for adult patients with CLL. https://t.co/3maTlnPaCn #bloodcancerawareness #ad https://t.co/AwWPF5P1Uw https://t.co/5BsvJUAHPP'},\n",
              " '1329093771456376833': {'tweet_author': 'Christine | The Growing Creatives',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/LUQkyCKbpS #bloodcancerawareness #ad https://t.co/d7p49HxVT0 https://t.co/crTzQEDWyy'},\n",
              " '1329092456315576320': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib Misses the Mark in Patients Hospitalized With #COVID-19–Related Respiratory Symptoms https://t.co/ylodsq4T0Y'},\n",
              " '1329081154863960069': {'tweet_author': 'DCapdepon',\n",
              "  'tweet_text': 'https://t.co/Z8ot6mNDTF https://t.co/D56DnZH8n9'},\n",
              " '1328956741019701250': {'tweet_author': 'Medical Tribune《公式》',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinib、慢性リンパ性白血病を適応にEUで承認取得 https://t.co/HCShFs9PGh'},\n",
              " '1328859141402669058': {'tweet_author': 'The Zamp Camp',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/VyGvWsvgSb #bloodcancerawareness #ad https://t.co/vkysAdnZnj https://t.co/7e1xmiE0uN'},\n",
              " '1328843536935116801': {'tweet_author': 'Lori Felix',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/z7v1LBsqzA #bloodcancerawareness #ad https://t.co/Ed1Bfsuath https://t.co/aWoK0w4xCs'},\n",
              " '1328826492915228676': {'tweet_author': 'Michele Nadeem-Baker',\n",
              "  'tweet_text': 'CLL Treatment Research: Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL https://t.co/IlJKwhCBDK \\n#CLL #ChronicLymphocyticLeukemia #AscendStudy #Acalabrutinib #BTKInhibitor @MDedgeHemOnc @MicheleNadeemB'},\n",
              " '1328820468330221570': {'tweet_author': 'niecyisms by CLC Studios',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/fowtBGo9I7 #bloodcancerawareness #ad https://t.co/F5KkF6Gjc1 https://t.co/2USlBUWuYl'},\n",
              " '1328761967360749570': {'tweet_author': 'Liz Cleland',\n",
              "  'tweet_text': 'Consider @CalquenceHCP for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/BdMdw0az92. \\n\\n#bloodcancerawareness #ad \\nhttps://t.co/mHoYUVp33s https://t.co/KknSh910pK'},\n",
              " '1328760696100700160': {'tweet_author': 'TheYumYumFoodie',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/cPrVeO7bRe #bloodcancerawareness #ad https://t.co/wmJavEs8C2 https://t.co/PFF4wchuFG'},\n",
              " '1328733949548396546': {'tweet_author': \"Susie's Reviews\",\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/fUJ31EJWM7. #bloodcancerawareness #ad https://t.co/3TImAQ15rw https://t.co/Ee4bHD0BWE'},\n",
              " '1328712966829641733': {'tweet_author': 'Amanda Taylor',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/fCHuJzmAnn #bloodcancerawareness #ad https://t.co/8xmle91N9k https://t.co/HTydQ0Zwiz'},\n",
              " '1328706715815178240': {'tweet_author': 'Anne-Marie @ This Mama Cooks! On a Diet',\n",
              "  'tweet_text': 'With CALQUENCE, feel supported day and night with their patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication used to treat adult patients with CLL. Learn more at https://t.co/fdHqNuMcQa. #bloodcancerawareness #ad https://t.co/DOTCyuzt9m https://t.co/n61Fijkpfx'},\n",
              " '1328682864066646016': {'tweet_author': 'Shelly Belly',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/AGNCci4ppz #bloodcancerawareness #ad https://t.co/YeEPWJi7Zo https://t.co/QEiTTEoBZc'},\n",
              " '1328675636471353344': {'tweet_author': 'MissingLynxx',\n",
              "  'tweet_text': 'With CALQUENCE, feel supported day and night with their patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication used to treat adult patients with CLL. Learn more at https://t.co/QpX0aHM2Jw. #bloodcancerawareness #ad https://t.co/FaEXnryeHO https://t.co/0gtQ5zk3CO'},\n",
              " '1328656271017455619': {'tweet_author': 'CISMeF Quoi de neuf',\n",
              "  'tweet_text': 'Calquence - acalabrutinib https://t.co/MEUHtZquhl'},\n",
              " '1328641633668239360': {'tweet_author': 'Krystal 👩🏻\\u200d💻',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/adJBSj8xr4 #bloodcancerawareness #ad https://t.co/qmsGJjYjxw https://t.co/C9fS13op8b'},\n",
              " '1328633229352562689': {'tweet_author': 'BiopharmaAsia',\n",
              "  'tweet_text': 'Updated CALAVI Phase II trials Results for Calquence in patients hospitalised with symptoms of COVID-19 - https://t.co/WDMTr7U2E4'},\n",
              " '1328620150925316098': {'tweet_author': '薬剤師ニュース配信くん',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence(R)）EUにおいて、慢性リンパ性白血病の治療薬として承認取得 - PR TIMES\\nhttps://t.co/XttYMFNT3T'},\n",
              " '1328581329395519488': {'tweet_author': 'Oncology News Australia',\n",
              "  'tweet_text': \"Oncology News Update: 'Acalabrutinib demonstrated superior progression-free survival for r/r chronic lymphocytic leukaemia patients' has been published on Oncology News Australia - https://t.co/fNAwjKBpK7 #oncnews https://t.co/LFwoRUAzFn\"},\n",
              " '1328568561942597636': {'tweet_author': 'NEWSRELEA.SE',\n",
              "  'tweet_text': 'アストラゼネカ株式会社、アストラゼネカのアカラブルチニブ（Calquence®）EUにおいて、慢性リンパ性白血病の治療薬として承認取得 https://t.co/1y2HZmf0CP'},\n",
              " '1328561017438097409': {'tweet_author': 'JPubb 日本企業 リリース 医薬品',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）、EUにおいて慢性リンパ性白血病の治療薬として承認取得 〔11/17 アストラゼネカ〕 https://t.co/9CGRkHwoT7'},\n",
              " '1328546057156919298': {'tweet_author': 'a watcher',\n",
              "  'tweet_text': '2020年11月17日【アストラゼネカ｜日】『アカラブルチニブ（Calquence®）、EUにおいて慢性リンパ性白血病の治療薬として承認取得』が公開されています\\n\\n英本社発表抄訳\\n\\n未治療、または再発／難治性患者さんのいずれにおいても大幅な無増悪生存期間の延長と良好な忍容性\\n\\nhttps://t.co/2YONzetwqT'},\n",
              " '1328527927848275970': {'tweet_author': 'PR TIMESビジネス',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）EUにおいて、慢性リンパ性白血病の治療薬として承認取得 https://t.co/Vh1Mjj2zBR'},\n",
              " '1328520513149313025': {'tweet_author': 'Kaila Yu',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/eY8F2fVMHM #bloodcancerawareness #ad https://t.co/8MVKMMPJj1 https://t.co/Btq3EhVMhO'},\n",
              " '1328520032691781632': {'tweet_author': 'PR TIMESニュース',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence®）EUにおいて、慢性リンパ性白血病の治療薬として承認取得 https://t.co/FqxIkGA9LG'},\n",
              " '1328519661407899650': {'tweet_author': 'WMR Tokyo - スタートアップ',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence(R)）EUにおいて、慢性リンパ性白血病の治療薬として承認取得 https://t.co/ucdmgUqyxu'},\n",
              " '1328513364499296258': {'tweet_author': 'Olivia Douglass',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/3NpHQ4KRvi #bloodcancerawareness #ad https://t.co/3cwA10K84Q https://t.co/tTU26CFciR'},\n",
              " '1328504026426613762': {'tweet_author': \"Susie's Reviews\",\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/fUJ31EJWM7. #bloodcancerawareness #ad https://t.co/3TImAQ15rw https://t.co/UoyyRbMNmp'},\n",
              " '1328498589941846016': {'tweet_author': 'Trendy Cyndie Reviewz & Newz',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/ugOJpW32Rp. #bloodcancerawareness #ad https://t.co/wPbLwdjus2 https://t.co/fFwuKoUeqM'},\n",
              " '1328497112179478528': {'tweet_author': 'Momma Lew - Food and Fun by Reesa Lewandowski',\n",
              "  'tweet_text': 'Taking CLL medication should be as convenient as an oral, 2x a day capsule, allowing you to focus on the lifestyle you want. CALQUENCE is a prescription treatment option for adult patients with CLL. https://t.co/2A1p0iHcfo #bloodcancerawareness #ad https://t.co/GeBizRbvSc https://t.co/SQLorM6CyJ'},\n",
              " '1328497069452124163': {'tweet_author': 'Jessica',\n",
              "  'tweet_text': 'With @CalquenceHCP, feel supported day and night with their patient and caregiver resources. CALQUENCE is an oral, 2x a day prescription medication used to treat adult patients with CLL. Learn more at https://t.co/XOtVZGTjEK. #bloodcancerawareness #ad https://t.co/cHby4Ro413 https://t.co/hv4UXgCKGT'},\n",
              " '1328495529139994624': {'tweet_author': 'Tara Pittman',\n",
              "  'tweet_text': 'Consider CALQUENCE for any adult you may know living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It’s a prescription oral 2x a day capsule. Learn more: https://t.co/pzi1Z4mXgY. #bloodcancerawareness #ad https://t.co/3f5M3tfTcK https://t.co/4FEMFscdIT'},\n",
              " '1328493448312320007': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: 17p deletion testing for access to acalabrutinib in patients w/ relapsed or refractory chronic lymphocytic leukaemia https://t.co/3vVU2IFbFi'},\n",
              " '1328276030021382144': {'tweet_author': 'Vikesh Gudka',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials | BioSpace https://t.co/Q75SU9gNOC #jobs\"},\n",
              " '1328099205748035590': {'tweet_author': 'Evaluate Japan',\n",
              "  'tweet_text': 'AZ社BTK阻害剤Calquenceは、入院患者に効果が認められず、コロナウイルスが引き起こす重篤な炎症応答へのBTK阻害剤の効果に疑問が持たれている。IL-6遮断薬の中止もあり、Eli Lilly社、Regeneron社、AZ社の抗体薬への期待が相対的に高まっている。\\nhttps://t.co/eNkelaGsec\\n#エバリュエート #Covid19'},\n",
              " '1328022452287496194': {'tweet_author': 'CarnivoresHealth',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating COVID-19 https://t.co/AIlwVnmoRu'},\n",
              " '1328007363870281729': {'tweet_author': 'CarnivoresHealth',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/VQxSOTahdA https://t.co/TNjSHnR92l\"},\n",
              " '1327778426674176000': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'The regulatory decision was based on data from two phase 3 clinical chronic lymphocytic leukemia trials: ELEVATE-TN and ASCEND @MyUniSR @EMA_News #leusc https://t.co/c2QKcbuhOz'},\n",
              " '1327764702043262978': {'tweet_author': 'ECAM Norway',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short https://t.co/MiX4uz19xv\"},\n",
              " '1327735262055706627': {'tweet_author': 'Carlo Franzini',\n",
              "  'tweet_text': \"NOVITA' NEL TRATTAMENTO DELLA LEUCEMIA LINFATICA CRONICA - Approvato #Calquence ( #Acalabrutinib ) di #AstraZeneca\\n\\nIscrizione gratuita alle Newsletter Xagena di Medicina: https://t.co/aBt8A4PSFd\\n\\n#Ematologia #Medicina #OncoEmatologia #Xagena #Farmacia https://t.co/BqiB19jvtK\"},\n",
              " '1327689037033910274': {'tweet_author': 'CURE Magazine',\n",
              "  'tweet_text': 'Join CURE &amp; AstraZeneca on November 21 at 2PM ET for CALQUENCE Connections! Dr. Jeff Sharman joins Jim, a patient with chronic lymphocytic leukemia, Jim’s wife, Becky, and a nurse, to discuss their experiences with this disease. Learn more &amp; register: https://t.co/QpxnZ2ovIi https://t.co/UTBtfKflU1'},\n",
              " '1327522521567006723': {'tweet_author': 'Kaushik A.Sejpal',\n",
              "  'tweet_text': 'https://t.co/ZBytmWM61L'},\n",
              " '1327511022899486722': {'tweet_author': 'Official Page of MonkeyViral.com',\n",
              "  'tweet_text': '#Calquence fails to prevent respiratory failure in COVID-19 patients – MedLancr is now trending on https://t.co/FARU3CLtSB...\\nhttps://t.co/RsypfZotYu'},\n",
              " '1327397089345724417': {'tweet_author': 'PILOTforPULMONARY',\n",
              "  'tweet_text': 'In CALAVI Phase II Trials, Calquence (acalabrutinib) Fails to Reduce Mortality or Respiratory Failure in Patients Hospitalized with COVID-19\\nhttps://t.co/kCd7ctEeJO'},\n",
              " '1327340460914905088': {'tweet_author': 'EL GLOBAL',\n",
              "  'tweet_text': 'Tras la recomendación de la EMA, la Comisión Europea ha aprobado también este tratamiento, un inhibidor selectivo de la tirosina kinasa de Bruton @AstraZenecaES\\n\\nhttps://t.co/AhdX702yPl'},\n",
              " '1327333506389864450': {'tweet_author': 'Kari Tikkinen',\n",
              "  'tweet_text': 'AstraZeneca press release on #acalabrutinib phase 2 trials: unfortunately no help. More #COVID research from high quality trials needed\\n\\nPress release: https://t.co/kqfzqIs6Xu\\n\\nRegistrations:\\nhttps://t.co/HSE71hUqpQ\\nhttps://t.co/vNjm3pBZzO\\n\\n@EricTopol @MartinLandray @GermHunterMD https://t.co/tldCWnpIYq'},\n",
              " '1327314024292298752': {'tweet_author': 'Pharma Top News',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for COVID-19 | BioPharma Dive #pharmatopnews  https://t.co/vMgnbyaU5a'},\n",
              " '1327272979701649409': {'tweet_author': 'FintechZoom',\n",
              "  'tweet_text': 'New article: \"Costco - AstraZeneca\\'s (AZN) Calquence Fails in Coronavirus Study\" has been published on Fintech Zoom - https://t.co/4Vh6i9S9UF @FintechZoom #Fintech #Blockchain #Crypto #Cryptocurrency #ICO https://t.co/xBjEfYwqZS'},\n",
              " '1327271926197325824': {'tweet_author': 'Ester Hernández',\n",
              "  'tweet_text': 'No solo hay avances con la vacuna de la COVID-19...\\nAprobado el tratamiento contra la Leucemia linfocítica crónica, la leucemia más común en pacientes adultos\\nhttps://t.co/6vWjMDoO6c'},\n",
              " '1327271681967198209': {'tweet_author': 'ecancer en español',\n",
              "  'tweet_text': '#Acalabrutinib demostró una #supervivencia sin progresión superior para los pacientes con leucemia linfocítica crónica r/r\\n@AstraZeneca \\n#ecancer #OncoReporte\\nhttps://t.co/QLfq9n6xHt'},\n",
              " '1327232505011986435': {'tweet_author': 'Journal of the @NCCN',\n",
              "  'tweet_text': 'Comparing front-line treatments in #CLL with a focus on #acalabrutinib: https://t.co/WWAyD5F02a #leusm #JNCCN360 https://t.co/ZwCoHJ5Kfg'},\n",
              " '1327227288916811779': {'tweet_author': 'European Pharmaceutical Review',\n",
              "  'tweet_text': 'AstraZenaca reveals #Calquence (acalabrutinib) did not increase the proportion of hospitalised #Covid19 patients who remained alive and free of respiratory failure.\\n#clinicaltrials #pharma #therapeutics #drugrepurposing\\nRead the news: https://t.co/78dmeJIGHV https://t.co/OYyKQz5CZA'},\n",
              " '1327224011676405762': {'tweet_author': 'Carlo Centemeri',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails to help patients hospitalised with COVID-19 respiratory symptoms https://t.co/oatqNMeiOm via @fwpharma\"},\n",
              " '1327216274712133632': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma https://t.co/WmKvRLuZ4T #MCL #lymsm #hematology'},\n",
              " '1327213408538800129': {'tweet_author': 'Salvador S',\n",
              "  'tweet_text': 'La UE aprueba Calquence (AstraZeneca) para leucemia linfocítica crónica https://t.co/EEOOVGA7Uh'},\n",
              " '1327210359313231872': {'tweet_author': 'Sortiraparis',\n",
              "  'tweet_text': 'Covid-19 : le Calquence, un traitement efficace contre les chocs cytokiniques ? https://t.co/dEaTqirRJm'},\n",
              " '1327209741563682824': {'tweet_author': 'Laurent Pradal',\n",
              "  'tweet_text': 'Covid-19 : le Calquence, un traitement efficace contre les chocs cytokiniques ? https://t.co/jGri5pbZDh'},\n",
              " '1327209479855689731': {'tweet_author': 'cafepharma',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for COVID-19 https://t.co/tR4HCzw6p9'},\n",
              " '1327199285780201473': {'tweet_author': 'Pharmaceutical',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/o63qdWbTVh https://t.co/WdKHm3q2TC\"},\n",
              " '1327198780089839616': {'tweet_author': 'Serena Tinari',\n",
              "  'tweet_text': 'One more #COVID19 \"promising drug\" down. \\nThis time is @AstraZeneca Calquence (acalabrutinib) \\ncc @RecheckHealth  \\nhttps://t.co/RY7vDLYvKw'},\n",
              " '1327192023581945856': {'tweet_author': 'Pharma Prime Time',\n",
              "  'tweet_text': '#AstraZeneca cancer drug found ineffective for #COVID19\\n#pharmanews #ElonMusk \\n#healthcare\\nhttps://t.co/1uvuaaHx1l'},\n",
              " '1327183177518092294': {'tweet_author': 'Miguel Angel Grullon C.',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails to help patients hospitalised with COVID-19 respiratory symptoms.\\n\\nAcalabrutinib está aprobado para el tratamiento de adultos con leucemia linfocítica crónica y adultos con linfoma de células del manto. https://t.co/1kmeBV7xNK\"},\n",
              " '1327171180466372609': {'tweet_author': 'Sosyal Medya',\n",
              "  'tweet_text': \"AstraZeneca'nın umut olan ilacı koronavirüs tedavisinde etkisiz kaldı\\n\\nReuters'ın haberine göre koronavirüs hastalarının bağışıklık sisteminde oluşan sorunları baskılaması amaçlanan kan kanseri ilacı Calquence'in sonuçları başarısız oldu.\\n\\nhttps://t.co/r6R1oDaNsE\"},\n",
              " '1327167956950933510': {'tweet_author': '@investigando',\n",
              "  'tweet_text': 'La adición del inhibidor BTK acalabrutinib al tratamiento en pacientes hospitalizados con síntomas respiratorios de la COVID no aumentaría la proporción de pacientes vivos sin insuficiencia respiratoria\\nhttps://t.co/RTqFo4g0S3'},\n",
              " '1327144384689811460': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@SeemaAliBhat1, of @OSUCCC_James, discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL\\nhttps://t.co/rTGycOO6dq https://t.co/wEt4geb7DN'},\n",
              " '1327126811302629382': {'tweet_author': 'BioCalifornia',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials https://t.co/IHfebObtNz https://t.co/x5XoHusvTB\"},\n",
              " '1327109287756361730': {'tweet_author': 'Helen Ong',\n",
              "  'tweet_text': '$AZN ‘s #Calquence fails #COVID_19 study, joining the list of #repurposed_meds that have fallen short \\n\\n$AGNPF ‘s repurposed #ifenprodil for #ARD in #Covid patients remains highly promising. Company expected to report Ph2b/3 interim results shortly, NP https://t.co/ZOc5fhNiXa'},\n",
              " '1327104925633921024': {'tweet_author': 'Lyke Lyfe',\n",
              "  'tweet_text': 'Update on CALAVI Phase II Trials for Calquence in Patients Hospitalised with Respiratory Symptoms of COVID-19 – https://t.co/asLYGsWgL3\\xa0MedNews https://t.co/3RkjLnKCS1'},\n",
              " '1327083120584081408': {'tweet_author': 'Takehiko Yoshino',\n",
              "  'tweet_text': \"AstraZeneca's (AZN) Calquence Fails in Coronavirus Study https://t.co/Qb3UAH26Wo via @Yahoo\"},\n",
              " '1327078369196969984': {'tweet_author': 'Brainstormer 🇳🇱🇳🇱',\n",
              "  'tweet_text': 'https://t.co/suakSAViL0'},\n",
              " '1327077126072397824': {'tweet_author': 'Brainstormer 🇳🇱🇳🇱',\n",
              "  'tweet_text': 'https://t.co/k9meAQvYQs\\n\\nEen nieuw goed door EU gekeurd medicijn Calquence (Astrazenica) voor bloedkankersoorten is een trial geweest ook onder ziekenhuis opname patiënten covid. Zowel opname c19 zonder beademing en IC ventilatie patiënten... Hoe dan?\\n\\nhttps://t.co/Y7QNmOM5PD'},\n",
              " '1327068717356900357': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'The European Union has approved the next-generation BTK inhibitor acalabrutinib for use in adult patients with chronic lymphocytic leukemia. @MyUniSR @EMA_News https://t.co/bDkVq0albN'},\n",
              " '1327063393833013249': {'tweet_author': 'Pharmaceutical Market Europe',\n",
              "  'tweet_text': 'AZ’s BTK inhibitor Calquence fails in COVID-19 study\\nhttps://t.co/hb4lDMmpAl'},\n",
              " '1327061110936186882': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'AstraZenca’s Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19 https://t.co/GLUexnP1bx'},\n",
              " '1327044659558961152': {'tweet_author': 'Christina H',\n",
              "  'tweet_text': 'https://t.co/7RltuixF6f'},\n",
              " '1327004492928348165': {'tweet_author': 'FiercePharma',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short  https://t.co/4SwJZEsdoE\"},\n",
              " '1326999921824845825': {'tweet_author': 'Nikita',\n",
              "  'tweet_text': \"AstraZeneca's (AZN) Calquence Fails in Coronavirus Study https://t.co/Yr81FkRG6U via @Yahoo\"},\n",
              " '1326993391544979456': {'tweet_author': 'Biotech & Tech Stock Focus',\n",
              "  'tweet_text': \"$AZN AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials | BioSpace https://t.co/RgJT2VMcwu #jobs\"},\n",
              " '1326992961947758616': {'tweet_author': 'MAISA',\n",
              "  'tweet_text': \"$AZN saying its mid-stage trial of Calquence (acalabrutinib) as an addition to the best supportive care for patients hospitalized with respiratory symptoms of COVID-19 didn't meet the primary endpoint.\"},\n",
              " '1326989166954110980': {'tweet_author': 'R Mandy Alcuria',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short | FiercePharma https://t.co/AXvdewyjlq\"},\n",
              " '1326986574211346433': {'tweet_author': 'Ronald M. Chavin',\n",
              "  'tweet_text': '11-12-2020:  In a clinical trial just released today by AstraZeneca, bad news for their anti-leukemia &amp; anti-lymphoma drug, Calquence (acalabrutinib), for treating COVID-19. There was no benefit from the drug\\nhttps://t.co/8JwlIjSHTd\\nhttps://t.co/KtFR1wSQkF\\nhttps://t.co/HPp6mA5xFG'},\n",
              " '1326985634771251201': {'tweet_author': 'Continental Clinical',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short https://t.co/hSleHPJKUs\"},\n",
              " '1326985618216251392': {'tweet_author': 'Endpoints News',\n",
              "  'tweet_text': \"In today's #Covid19 roundup: Though the presidential election has come and gone, tensions between the White House and government health officials remain.\\n\\nhttps://t.co/VgnlrngxD7\"},\n",
              " '1326981850569453568': {'tweet_author': 'WebWire',\n",
              "  'tweet_text': 'Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 https://t.co/KMnCB0PKpq'},\n",
              " '1326980782007734273': {'tweet_author': 'Infectotuits',\n",
              "  'tweet_text': 'Otro anticuerpo monoclonal que NO funciona en evitar empeoramiento en pacientes con #COVID19\\n\\nacá el posicionamiento de #AstraZeneca sobre #Acalabrutinib https://t.co/Ma5HSAbNyr'},\n",
              " '1326980529825189888': {'tweet_author': 'ZdravMedInfo',\n",
              "  'tweet_text': 'Acalabrutinib оказался не эффективен в качестве потенциального метода лечения COVID-19 https://t.co/PDp6iecXs9'},\n",
              " '1326977785890562049': {'tweet_author': 'Koronavirüs Haber ☣️',\n",
              "  'tweet_text': 'İngiltere-İsveç ortaklığı olan ünlü ilaç şirketi AstraZeneca tarafından kan kanseri tedavisi için kullanılan Calquence ilacının korona virüs tedavisinde başarısız olduğu açıklandı.'},\n",
              " '1326974691660210176': {'tweet_author': 'maybeawriter',\n",
              "  'tweet_text': 'AstraZeneca says its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19 https://t.co/WNl3oitzvL via @business'},\n",
              " '1326968616156360706': {'tweet_author': 'Siber Gazete',\n",
              "  'tweet_text': \"AstraZeneca'nın umut olan ilacı koronavirüs tedavisinde etkisiz kaldı\\n\\nReuters'ın haberine göre koronavirüs hastalarının bağışıklık sisteminde oluşan sorunları baskılaması amaçlanan kan kanseri ilacı Calquence'in sonuçları başarısız oldu.\\n\\n#COVID\\n#haber\\n#SONDAKIKA https://t.co/oedRTJVlmH\"},\n",
              " '1326968182721089537': {'tweet_author': 'Kevin Paul Oge',\n",
              "  'tweet_text': \"AstraZeneca's Calquence Fails Pair of Phase II COVID-19 Trials | BioSpace https://t.co/q38xyvY6wD #jobs\"},\n",
              " '1326950799587487744': {'tweet_author': 'Dr Timos Papagatsias',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short https://t.co/MhcieDu38j  &gt;&gt;&gt; https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharma #pharmaceutical https://t.co/XJcjaceOdL\"},\n",
              " '1326949734599315457': {'tweet_author': 'NewExpressNews',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen\\xa0short https://t.co/FrVB4iWHvY'},\n",
              " '1326945265434046465': {'tweet_author': 'Briefing.com',\n",
              "  'tweet_text': '$AZN: AstraZeneca reports CALAVI Phase II trials for Calquence in patients hospitalized with respiratory symptoms of... https://t.co/SrcSOm7lDb'},\n",
              " '1326943163018334210': {'tweet_author': 'Synergy Healthcare, LLC',\n",
              "  'tweet_text': 'COVID-19 tracker: Moderna hits phase 3 case count for vaccine review; AstraZeneca’s Calquence misses in COVID trial | FiercePharma https://t.co/gbTIba5WBy'},\n",
              " '1326941957172719617': {'tweet_author': 'Fuerza/Fuerza',\n",
              "  'tweet_text': 'La UE aprueba Calquence (AstraZeneca) para leucemia linfocítica crónica https://t.co/wfMiatHx6w'},\n",
              " '1326933235352350721': {'tweet_author': 'Redacción Médica',\n",
              "  'tweet_text': '#Industria| La UE aprueba Calquence (@AstraZeneca) para la leucemia linfocítica crónica  https://t.co/lSNumf738L'},\n",
              " '1326929655643901953': {'tweet_author': 'Ben Fidler',\n",
              "  'tweet_text': 'AstraZeneca cancer drug found ineffective for treating #COVID19 https://t.co/jCpWbagcNJ by Kristin Jensen $AZN $RHHBY $NVS $SNY $REGN'},\n",
              " '1326926445591973888': {'tweet_author': 'Lu Chen #nobias',\n",
              "  'tweet_text': 'https://t.co/UIFz5zeGUp acalabrutinib did not meet the primary endpoint to keep patient alive or free of ventilator. cytokine storm hypothesis is almost dead.'},\n",
              " '1326923472333836288': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short https://t.co/Z2F9c2bbTG'},\n",
              " '1326920700897099776': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short https://t.co/4QJwE0FUuq\"},\n",
              " '1326919870915751936': {'tweet_author': 'Nathan Vardi',\n",
              "  'tweet_text': 'Calquence misses in trial of later-stage Covid-19 patients. Disappointing result for those who thought a selective BTK inhibitor could make a difference in the pandemic. https://t.co/6wcHKRMF5S'},\n",
              " '1326910137228013568': {'tweet_author': 'HABER3.com 🇹🇷',\n",
              "  'tweet_text': \"Ünlü ilaç üreticisi AstraZeneca'nın kan kanseri ilacı Calquence'ın koronavirüs tedavisinde etkisiz olduğu belirlendi. https://t.co/6gGcZLhbnp https://t.co/4jQBXnk1Ct\"},\n",
              " '1326909996236484608': {'tweet_author': 'Endpoints News',\n",
              "  'tweet_text': 'Covid-19 roundup: Political pressures at FDA continue post-election; Medicago takes GSK adjuvant into its first PhII/III https://t.co/VgnlrmYWLz'},\n",
              " '1326906969182121990': {'tweet_author': '****',\n",
              "  'tweet_text': \"AwesomeCapital: AstraZeneca's Calquence flunks mid-stage COVID-19 ... https://t.co/Qfi1j64IVG\"},\n",
              " '1326904868821491717': {'tweet_author': 'ABC Gazetesi',\n",
              "  'tweet_text': \"Kanser ilacı Calquence'ın koronavirüs tedavisinde etkisiz olduğu ortaya çıktı\\nhttps://t.co/vLlIRsRpEn\\n#Kovid19\"},\n",
              " '1326899568013873153': {'tweet_author': 'Dr Timos Papagatsias',\n",
              "  'tweet_text': \"Covid-19 roundup: Political pressures at FDA continue post-election; AstraZeneca's attempt to repurpose Calquence… https://t.co/8EF5p5y65L  &gt;&gt;&gt; https://t.co/HTA6IsGiV5 #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare https://t.co/hqbapkkGfZ\"},\n",
              " '1326895867530502150': {'tweet_author': 'Leonid Schneider',\n",
              "  'tweet_text': \".@AstraZeneca's repurposed leukaemia drug #Calquence surprisingly does not work at all against #COVID19. @tagesschau https://t.co/Z4nqRVwYSe\"},\n",
              " '1326892009848778753': {'tweet_author': 'Mr. Rama Vs. Comics',\n",
              "  'tweet_text': 'Yo, this ads are staring to scare the shit out of me.\\nWHAT DO TO KNOW CALQUENCE https://t.co/m4ErS3jyHj'},\n",
              " '1326890136987181059': {'tweet_author': 'Imran Iftikhar',\n",
              "  'tweet_text': \"No one can match my faith, I am truly the most beloved man of the Lord. :)\\n\\nNews: #AstraZeneca's blood cancer treatment, Calquence, failed to improve survival rates and prevent lung failure in patients hospitalised with symptoms of #COVID19. https://t.co/9jSZcmL7hJ\"},\n",
              " '1326887899028213760': {'tweet_author': 'Anand C. Patel',\n",
              "  'tweet_text': 'These failures (anti-IL-6, now BTKi) make me think patients need to be objectively identified as having CRS before entry into studies of immunomodulators for COVID, rather than a \"everyone who\\'s really sick\" approach. https://t.co/VAs7BWoEPi'},\n",
              " '1326887279999164416': {'tweet_author': 'Allison Gatlin',\n",
              "  'tweet_text': '#Biotech and #pharmaceuticals news: $FPRX is up again -- roughly 20% right -- on preclinical data in cancer treatment. $AZN sank after Calquence missed its key goal in Phase 2 study of hospitalized #Covid19 patients.'},\n",
              " '1326883404298784768': {'tweet_author': 'bioinvest.io',\n",
              "  'tweet_text': 'Надежда AstraZeneca на эффективность противоракового препарата Calquence в лечении  ковида не оправдалась. Во 2-ой фазе клин. испытаний Calquence не улучшил выживаемость тяжелых пациентов https://t.co/J09DJCWIcE'},\n",
              " '1326883096961093635': {'tweet_author': 'mednetnews',\n",
              "  'tweet_text': 'Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 | Small\\xa0Molecules https://t.co/MrdhwD6Ori'},\n",
              " '1326879085801467904': {'tweet_author': 'Jon Angelo',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients : https://t.co/OXdA2K2e5E #pharmaceutical'},\n",
              " '1326874161386549251': {'tweet_author': 'Briefing.com',\n",
              "  'tweet_text': '$AZN (-1.2%) reports CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of #COVID19 did not meet primary endpoint'},\n",
              " '1326869393905770497': {'tweet_author': 'Новости GMP',\n",
              "  'tweet_text': 'Acalabrutinib оказался не эффективен в качестве потенциального метода лечения COVID-19 - https://t.co/QALAuDCaMK https://t.co/2V4uqnPUe7'},\n",
              " '1326868851519332353': {'tweet_author': 'CDE News',\n",
              "  'tweet_text': \"#AstraZeneca's cancer drug #Calquence fails to meet main goal in #COVID-19 trials https://t.co/nd06LWEqk9\"},\n",
              " '1326867296892170240': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 https://t.co/aIDqP5ynUp'},\n",
              " '1326866471494983682': {'tweet_author': 'PharmaShots - Incisive news in 3 shots',\n",
              "  'tweet_text': 'AstraZenca’s Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19 @Pharmashot @AstraZeneca \\nhttps://t.co/6KhXxjiNHT https://t.co/eqIiafhMiw'},\n",
              " '1326864823682965504': {'tweet_author': 'Terra',\n",
              "  'tweet_text': \"#Coronavírus: Medicamento contra o câncer da AstraZeneca tem resultado 'decepcionante' no tratamento da covid-19 https://t.co/cwR38FQAcw\"},\n",
              " '1326864220286115840': {'tweet_author': 'Briefing.com',\n",
              "  'tweet_text': '$AZN: AstraZeneca reports CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of... https://t.co/SrcSOm7lDb'},\n",
              " '1326862983755145216': {'tweet_author': 'The Medical Ed Cons.',\n",
              "  'tweet_text': \"Pharmaceutical giant AstraZeneca rushes its blood cancer drug Calquence into coronavirus trials 'after it showed benefit for patients in intensive care'\\n\\nhttps://t.co/oJMQTDFcZ8\"},\n",
              " '1326860391935324165': {'tweet_author': 'Soumyajyoti Biswas',\n",
              "  'tweet_text': '$AZN\\nAstraZeneca (NASDAQ:AZN) reports Phase II results from The CALAVI trials investigating BTK inhibitor Calquence (acalabrutinib) plus best supportive care (BSC) versus BSC alone in hospitalised patients with COVID-19 disease.... https://t.co/dUaOgUSx20'},\n",
              " '1326858196879892482': {'tweet_author': 'San Francisco Biotechnology Network',\n",
              "  'tweet_text': \"SFBN Feed: Covid-19 roundup: AstraZeneca's attempt to repurpose Calquence flops: It may be time to cross off another repurposed drug from the list of potential Covid-19 treatments. AstraZeneca’s ... #BayArea #Biotech https://t.co/zq6ExzsFi4\"},\n",
              " '1326856875707654150': {'tweet_author': 'Daniel J Drucker',\n",
              "  'tweet_text': 'No role for targeting BTK #COVID19 Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 https://t.co/E1hk6OO6uH'},\n",
              " '1326856528419188736': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': \"Covid-19 roundup: AstraZeneca's attempt to repurpose Calquence flops https://t.co/7O3GACY9Ra\"},\n",
              " '1326855389506383873': {'tweet_author': 'Endpoints News',\n",
              "  'tweet_text': \"Covid-19 roundup: AstraZeneca's attempt to repurpose Calquence flops https://t.co/VgnlrmYWLz\"},\n",
              " '1326854151008038912': {'tweet_author': 'CHItraders',\n",
              "  'tweet_text': \"$AZN AstraZeneca's Calquence flunks mid-stage COVID-19 study https://t.co/bb8v28s70i\"},\n",
              " '1326849338585313285': {'tweet_author': 'PressReleasePoint',\n",
              "  'tweet_text': 'https://t.co/Md0aLh039H Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19'},\n",
              " '1326847719978176513': {'tweet_author': 'Gordon Gekko',\n",
              "  'tweet_text': \"AstraZeneca's Calquence flunks mid-stage COVID-19 study https://t.co/DC9zF468BR\"},\n",
              " '1326846551885426688': {'tweet_author': 'Breaking News',\n",
              "  'tweet_text': \"$AZN - AstraZeneca's Calquence flunks mid-stage COVID-19 study https://t.co/6AG4vdmRqf\"},\n",
              " '1326838691428528129': {'tweet_author': 'Market Intelligence: Healthcare',\n",
              "  'tweet_text': \"AstraZeneca's #cancer drug #Calquence disappoints in mid-stage COVID-19 trials $AZN #covid19 #clinicaltrials\\nhttps://t.co/QnHSZuIDUR https://t.co/RV0f0qCYiM\"},\n",
              " '1326834935165022210': {'tweet_author': 'Nicolas Viudez',\n",
              "  'tweet_text': \"Après Novartis et son canakinumab, la semaine dernière, c'est désormais acalabrutinib d'AstraZeneca qui échoue sur les formes sévères du #COVID19. https://t.co/p4Yr1jAdAk\"},\n",
              " '1326834169570336768': {'tweet_author': 'CHItraders',\n",
              "  'tweet_text': '$AZN Announced Calavi Phase Ii Trials for Calquence in Patients Hospitalised With Respiratory Symptoms of Covid-19 Did Not Meet Primary Endpoint\\nhttps://t.co/LF9ZH3R9NG'},\n",
              " '1326833348619235330': {'tweet_author': 'Quant Data',\n",
              "  'tweet_text': 'AstraZeneca Announced Calavi Phase Ii Trials for Calquence in Patients Hospitalised With Respiratory Symptoms of Covid-19 Did Not Meet Primary Endpoint\\n\\nRelated Tickers: $AZN'},\n",
              " '1326831764900376576': {'tweet_author': 'FirstWord Pharma',\n",
              "  'tweet_text': \"AstraZeneca's Calquence fails to help patients hospitalised with #COVID19 respiratory symptoms https://t.co/cjxCEVFtWE $AZN\"},\n",
              " '1326830554441019397': {'tweet_author': 'Al Arabiya English',\n",
              "  'tweet_text': '#AstraZeneca’s blood cancer treatment, Calquence, fails to improve survival rates and prevent lung failure in patients hospitalized with symptoms of #COVID19, the drugmaker says, citing results from mid-stage trials.\\n\\nhttps://t.co/LWM6B50qgK'},\n",
              " '1326824426021679105': {'tweet_author': 'Bloomberg Australia',\n",
              "  'tweet_text': 'AstraZeneca says its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19 https://t.co/5D9UnGgvsQ'},\n",
              " '1326812318202814465': {'tweet_author': 'Economía Digital',\n",
              "  'tweet_text': 'El fármaco contra la leucemia calquence, desarrollado por Astrazeneca, ha fracasado en los ensayos que estudiaban su eficacia en pacientes con coronavirus https://t.co/aTfcAv9tcm'},\n",
              " '1326809401014046722': {'tweet_author': 'Bloomberg',\n",
              "  'tweet_text': 'AstraZeneca says its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19 https://t.co/zEmWR9UgTa'},\n",
              " '1326808303389839360': {'tweet_author': 'Nel Sestayo',\n",
              "  'tweet_text': 'CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure https://t.co/HSiA3ga094 $AZN'},\n",
              " '1326806251133612033': {'tweet_author': 'Healthcare',\n",
              "  'tweet_text': '[BioToday][企業] AstraZenecaのBTK阻害剤CalquenceがCOVID-19入院患者に無効 https://t.co/y5mnlYxxDU'},\n",
              " '1326798157087297536': {'tweet_author': '@Easy_Branches #guestpostingservices',\n",
              "  'tweet_text': 'AstraZeneca’s cancer drug fails to meet main goal in COVID-19 trials: AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalized with… https://t.co/GSr59b4Dcg #FinancialPersonal'},\n",
              " '1326795614517080064': {'tweet_author': 'M',\n",
              "  'tweet_text': '$AZN acalabrutinib fails its Covid trial https://t.co/wBZJc9Xoji'},\n",
              " '1326793360586268673': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': '[企業] AstraZenecaのBTK阻害剤CalquenceがCOVID-19入院患者に無効 https://t.co/tRxN2WRvTX'},\n",
              " '1326782926948864000': {'tweet_author': 'Cision News',\n",
              "  'tweet_text': 'Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 https://t.co/oJIhIIKdFS'},\n",
              " '1326525838108585984': {'tweet_author': 'Ritrattodellasalute',\n",
              "  'tweet_text': '#leucemia linfatica cronica: #acalabrutinib approvato in EU. Ha dimostrato un beneficio significativo in termini di efficacia e tollerabilità a lungo termine.\\nhttps://t.co/TUUKhxibOj https://t.co/USmo7mbsgP'},\n",
              " '1326517732645408769': {'tweet_author': 'LARVOL',\n",
              "  'tweet_text': \"The European Commission has approved @AstraZeneca's #Calquence (acalabrutinib)for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).\\nFor full article visit: https://t.co/wEgFGEEhwu\\n#cancernews #cancerdata\"},\n",
              " '1326483658803449857': {'tweet_author': 'I Malati Invisibili',\n",
              "  'tweet_text': 'TUMORI RARI – LEUCEMIA LINFATICA CRONICA (LLC), LA COMMISSIONE EUROPEA HA APPROVATO ACALABRUTINIB.\\nhttps://t.co/tPMvNlXCJJ\\n#comitatoimalatiinvisibili #imalatiinvisibili #comitatoimi #comitatoimionlus #malattierare https://t.co/FrEckmurCm'},\n",
              " '1326435489763778561': {'tweet_author': '1stOncology',\n",
              "  'tweet_text': '#Calquence approved in the EU for the treatment of #ChronicLymphocyticLeukaemia $AZN https://t.co/b4jEjr7vuD'},\n",
              " '1326307537679863808': {'tweet_author': 'Chris Manfuso',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/lSxgVJV99E https://t.co/DCrXsIEM9i'},\n",
              " '1326269575302934529': {'tweet_author': '@investigando',\n",
              "  'tweet_text': 'LA CE aprobó el inhibidor selectivo BTK acalabrutinib para la leucemia linfocítica crónica, así como el linfoma linfocítico pequeño. Combinado con obinutuzumab y en monoterapia reduciría el riesgo de progresión de enfermedad o muerte https://t.co/RB6fYcIXD4'},\n",
              " '1326265003394134016': {'tweet_author': 'Benlazar S.M Aminé',\n",
              "  'tweet_text': 'Acalabrutinib receives approval in Europe for the treatment of #CLL #leusm\\nhttps://t.co/gegxG2eTdy'},\n",
              " '1326253433192501249': {'tweet_author': 'David Ledger',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/tgF5LDQABv https://t.co/sT6RLUGiOT'},\n",
              " '1326237439577513986': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib Approved in Europe for Chronic Lymphocytic Leukemia @MyUniSR #leusm  https://t.co/graUdKJHGz'},\n",
              " '1326236220570169344': {'tweet_author': 'Samir Sheth ☕',\n",
              "  'tweet_text': 'One tweet about pharma and already getting ads to join an event on BTK inhibitors, a treatment for CLL, courtesy of calquence acalabrutinib 😶 https://t.co/tCEgCDsN7T'},\n",
              " '1326226890089226241': {'tweet_author': 'Plexus Ventures',\n",
              "  'tweet_text': '#AstraZeneca: EU Approves #Calquence To Treat Chronic Lymphocytic #Leukaemia https://t.co/YmLSe7hExx @Nasdaq @AstraZeneca'},\n",
              " '1326223609258373121': {'tweet_author': 'Bls-D.Com',\n",
              "  'tweet_text': 'Leucemia linfatica cronica. Acalabrutinib ottiene l’approvazione in Europa https://t.co/cRBFtXG0es'},\n",
              " '1326220577476997121': {'tweet_author': 'José Viurquis',\n",
              "  'tweet_text': 'El medicamento acalabrutinib ha mejorado a pacientes en situación grave de COVID-19. Publicado en la sección #Salud de @Notimex  https://t.co/50siJTwS2x'},\n",
              " '1326193050272600065': {'tweet_author': 'UroToday.com',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab vs pembrolizumab &amp; acalabrutinib in patients with platinum-resistant #mUC. #BeyondTheAbstract on UroToday &gt; https://t.co/lp7h6gCqrl @AmericanCancer @TiansterZhang @MRHarrisonMD @AlvaAjjai @sonpavde @Daniel_J_George @LenAppleman https://t.co/piNvzp8K96'},\n",
              " '1326189124731203584': {'tweet_author': 'Blood Cancer Uncensored',\n",
              "  'tweet_text': 'Venetoclax and obinutuzumab funded in England by NICE, acalabrutinib licensed- the end of FCR chemotherapy for\\xa0CLL? https://t.co/wpIvzeffdG'},\n",
              " '1326176828306972678': {'tweet_author': 'Sporočila za javnost O-STA',\n",
              "  'tweet_text': 'Zdravilo Calquence je v EU odobreno za zdravljenje kronične limfocitne levkemije https://t.co/mtVdqAUajM @ASTRAZENECAUK'},\n",
              " '1326161961491566593': {'tweet_author': 'gRttwit',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of patients with chronic lymphocytic leukaemia https://t.co/3ZEUVEJti3'},\n",
              " '1326160692529917953': {'tweet_author': 'Repubblica Salute',\n",
              "  'tweet_text': 'Leucemia linfatica cronica, approvata in Europa una nuova terapia mirata: Via libera dalla Commissione europea per acalabrutinib: un farmaco target di nuova generazione, per il trattamento dei pazienti adulti, sia in prima linea sia dopo ricaduta, o per… https://t.co/qTFfRWY1jL'},\n",
              " '1326149790787379203': {'tweet_author': 'BiopharmaAsia',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of patients with chronic lymphocytic leukaemia - https://t.co/ATb7wmeD8f'},\n",
              " '1326137195326033921': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/KXxPfdvwh3'},\n",
              " '1326134519498334214': {'tweet_author': 'Pharma Trader',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/bDTcvECCIQ'},\n",
              " '1326134519376699392': {'tweet_author': 'Iceberg Vision',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/pz2cCPhLXf'},\n",
              " '1326134519112495104': {'tweet_author': 'Everything Pharma',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/by9jj0Bqug'},\n",
              " '1326130486729641984': {'tweet_author': 'Theriaque_officiel',\n",
              "  'tweet_text': '#AMM européenne pour #Calquence* #acalabrutinib dans la leucémie lymphoïde chronique #LLC\\nhttps://t.co/RhdGyiKwRQ'},\n",
              " '1326129244624220163': {'tweet_author': 'PharmaCrowd',\n",
              "  'tweet_text': 'EU OK for AZ’s Calquence in CLL https://t.co/XD5V9kxshM https://t.co/dHtjONbc87'},\n",
              " '1326120888849215488': {'tweet_author': 'Salutedomani',\n",
              "  'tweet_text': 'Terapia leucemia linfatica cronica, acalabrutinib approvato in Europa https://t.co/dQ2rtKSeXo'},\n",
              " '1326120888639475712': {'tweet_author': 'saluteH24.com',\n",
              "  'tweet_text': 'Terapia leucemia linfatica cronica, acalabrutinib approvato in Europa https://t.co/b5kQjV12F9'},\n",
              " '1326120887372820485': {'tweet_author': 'Antonio Caperna',\n",
              "  'tweet_text': 'Terapia leucemia linfatica cronica, acalabrutinib approvato in Europa https://t.co/TRqsGUerUm'},\n",
              " '1326120887133696004': {'tweet_author': 'Derma News OK',\n",
              "  'tweet_text': 'Terapia leucemia linfatica cronica, acalabrutinib approvato in Europa https://t.co/iOwm8427zK'},\n",
              " '1326105689337565184': {'tweet_author': 'Medinews',\n",
              "  'tweet_text': '#Leucemia linfatica cronica: #acalabrutinib approvato in Europa per #beneficio significativo in termini di efficacia e tollerabilità a lungo termine nel trattamento in prima linea e nella malattia recidivante o refrattaria.\\n\\nhttps://t.co/KiOjg4LE39 https://t.co/JEwfS9rAPH'},\n",
              " '1326103795496083457': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'Next generation BTKi, acalabrutinib, has been approved in Europe for the treatment of adult patients with CLL. Acalabrutinib demonstrated promising clinical efficacy and was well tolerated across the two clinical studies which led to its approval ➡️ https://t.co/MM7J2fnhdx https://t.co/7OOFQTrFbh'},\n",
              " '1326059300574408707': {'tweet_author': 'PHARMABOX.IN',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence (acalabrutinib) Receives EU’s Approval for Chronic Lymphocytic Leukaemia https://t.co/uyQyvyJ0Iv'},\n",
              " '1326051779113480192': {'tweet_author': 'PharmaShots - Incisive news in 3 shots',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence (acalabrutinib) Receives EU’s Approval for Chronic Lymphocytic Leukaemia @Pharmashot @AstraZeneca \\nhttps://t.co/F6aAGSBudX https://t.co/o6BcfZ8XyP'},\n",
              " '1325841091120099329': {'tweet_author': 'Prashant Mehta',\n",
              "  'tweet_text': 'Acalabrutinib launched at a whopping 1.4 L /month with PAP Support\\nWith the Ibrutinib generic available,I am not sure how much this will help \\n\\nI wish for a lower cost and better access'},\n",
              " '1325826908483809280': {'tweet_author': 'Medicircle.in',\n",
              "  'tweet_text': 'Calquence is approved for the treatment of CLL and small lymphocytic lymphoma in the US and is approved for CLL in several other countries worldwide.\\n#LatestPharmaNewsNov9 #LatestAstrazenecaNewsNov9 #TreatmentforChronicLymphocyticLeukaemia #TreatmentforCLL\\nhttps://t.co/WTCz8iGMdO'},\n",
              " '1325822587323052034': {'tweet_author': 'WebWire',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia https://t.co/avIAqF4wqr'},\n",
              " '1325798123109691395': {'tweet_author': 'Himani Chandna',\n",
              "  'tweet_text': '-Learnings from WHO’s Solidarity trial\\n-Covaxin by when?\\n-Why Acalabrutinib arm should be added?\\n-Why Remdesivir needs more testing before being junked? \\n\\nICMR-NARI chief Dr Samiran Panda tells @ThePrintIndia in a detailed interview. \\n\\nhttps://t.co/5h1sRlB4eJ'},\n",
              " '1325791068441341952': {'tweet_author': 'HealthcarePRwire',\n",
              "  'tweet_text': 'AstraZeneca’s Calquence (acalabrutinib) has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia #healthcare \\n\\n#leukaemia #bloodcancer #Cancer\\n\\nhttps://t.co/V7BvNX3wYe'},\n",
              " '1325790548968546304': {'tweet_author': 'IndustryPRwire',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia\\nhttps://t.co/gfFGz7BdVW'},\n",
              " '1325785748788957184': {'tweet_author': 'LARVOL',\n",
              "  'tweet_text': '#Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia. Explore more predictive biomarker data and news for FREE at: https://t.co/vjFQpNsgAk\\nFor full news article visit: https://t.co/LXHt29qlSP\\n#cancernews #cancerdata https://t.co/tMiquuhZvp'},\n",
              " '1325778917966295041': {'tweet_author': 'Briefing.com',\n",
              "  'tweet_text': '$AZN: AstraZeneca receives EU approval for Calquence https://t.co/gGhPz9jTzu'},\n",
              " '1325776033644122117': {'tweet_author': 'Stocks tweets',\n",
              "  'tweet_text': \"AstraZeneca's Calquence OK'd in Europe for CLL https://t.co/chppEKS7Wr\"},\n",
              " '1325771904549007361': {'tweet_author': 'FirstWord Pharma',\n",
              "  'tweet_text': \"AstraZeneca's BTK inhibitor Calquence approved in Europe for CLL https://t.co/Gfzw2xRAZl $AZN\"},\n",
              " '1325754940564926465': {'tweet_author': 'Company News HQ',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia https://t.co/oJYsT77oLy'},\n",
              " '1325749065200656386': {'tweet_author': 'The Pharma Letter',\n",
              "  'tweet_text': 'European approval for #Calquence in CLL @AstraZeneca https://t.co/BhUQbu9gjG https://t.co/jZnX5HHofn'},\n",
              " '1325744326907891712': {'tweet_author': 'NonSell.com',\n",
              "  'tweet_text': 'AstraZeneca: EU Approves Calquence To Treat Chronic Lymphocytic Leukaemia - [US Market News], Source: Nasdaq News - https://t.co/fWUdbvKdVL'},\n",
              " '1325743085356244993': {'tweet_author': 'Quant Data',\n",
              "  'tweet_text': 'AstraZeneca Announced Calquence Approved in the Eu for the Treatment of Chronic Lymphocytic Leukaemia\\n\\nRelated Tickers: $AZN'},\n",
              " '1325739460584120320': {'tweet_author': 'Inara Bright',\n",
              "  'tweet_text': 'AstraZeneca Announced Calquence Approved in the EU for the Treatment of Chronic Lymphocytic Leukaemia\\n$AZN'},\n",
              " '1325735967915978759': {'tweet_author': 'Mehrdad Yousefi',\n",
              "  'tweet_text': \"AstraZeneca's said its drug Calquence had received European Union approval for the treatment of adult patients with chronic lymphocytic leukaemia (CCL) adding to approvals already received in the US and several other countries worldwide.\"},\n",
              " '1325719765558697985': {'tweet_author': 'WheelieDealer',\n",
              "  'tweet_text': '#AZN Calquence Approved in EU for treating Chronic Lymphocytic Leukaemia.'},\n",
              " '1325718500871188480': {'tweet_author': 'GraniteShares Europe',\n",
              "  'tweet_text': \"#AstraZeneca's #Calquence (#acalabrutinib) has been approved in the EU for the treatment of adult patients with chronic lymphocytic #leukaemia (#CLL), the most common type of leukaemia in adults.\\n#oncology #haematology #pharma $AZN #singlestockETPs\\nhttps://t.co/66gsMtTizU\"},\n",
              " '1325709823862853632': {'tweet_author': 'EIN Presswire: EU Politics Newswire',\n",
              "  'tweet_text': 'BRIEF-AstraZeneca Says Calquence Approved In The EU For CLL https://t.co/5xfrLo8bfh'},\n",
              " '1325708383165485063': {'tweet_author': 'Golden Casino News',\n",
              "  'tweet_text': 'Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia - https://t.co/HDbtnCzdXF'},\n",
              " '1325432893951205376': {'tweet_author': 'Urology',\n",
              "  'tweet_text': 'Pembrolizumab vs Pembrolizumab and Acalabrutinib in Patients With Platinum-Resistant Metastatic Urothelial Cancer https://t.co/L0MgR9zqzr #bladdercancer #blcsm'},\n",
              " '1324935240180146177': {'tweet_author': 'Oncology',\n",
              "  'tweet_text': 'Pembrolizumab Plus Acalabrutinib for Platinum-Resistant Metastatic Urothelial Carcinoma https://t.co/SEcpeVmd2e #oncology'},\n",
              " '1324711997456482304': {'tweet_author': 'WCM Englander Institute for Precision Medicine',\n",
              "  'tweet_text': 'Interested in chronic lymphocytic #leukemia research? \\n\\nIf so, don\\'t miss \"Safety Study Supports Acalabrutinib Alone or in Combination for CLL,\" in @OncologyTimes with @EngIPM Member Richard Furman, M.D (@RichardFurmanMD).  #PrecisionMedicine \\n\\nhttps://t.co/bJYMRCfvgu'},\n",
              " '1324591365049626624': {'tweet_author': 'Aloysius Pendergast',\n",
              "  'tweet_text': 'One to rule them all...Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma | Blood | American Society of Hematology https://t.co/TWnhgDFZ2c https://t.co/Pfxw71m0h9'},\n",
              " '1323996044418412545': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044313665537': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044309377024': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044279967751': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044221296642': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044145827842': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323996044057735174': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995920363499520': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995920241893379': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995920153763840': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995920095203330': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919767932929': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919667372034': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919663075334': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919474401281': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919327645698': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995919243763713': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918929141760': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918903975939': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918559965184': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is a treatment option for Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918295814151': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918232920065': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323995918182588423': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A CALQUENCE is for the treatment of Mantle Cell Lymphoma (MCL) in adult patients who have received at least one prior therapy.'},\n",
              " '1323980877773287426': {'tweet_author': 'Toby Eyre',\n",
              "  'tweet_text': 'Long term fup for #acalabrutinib in R/R #mantle cell #lymphoma \\nmedian 2 prior lines\\nd/c 60% due to PD, 11% AEs \\nmDOR 28.6m\\nmPFS 22.0m \\nKi67% or prior lines (1, 2, ≥3) interestingly not predictive of PFS\\nestim 1/3 progression free at 36m #lymsm #ASH2020 https://t.co/xsiBlSzKJJ'},\n",
              " '1323203743006003212': {'tweet_author': 'MEDWAVE',\n",
              "  'tweet_text': 'Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review OrphanPacific’s sakigake-designated hereditary angioedema (HAE) treatment berotralstat, which was de... https://t.co/07SVDclr7q'},\n",
              " '1323158082495676417': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@SeemaAliBhat1, of @OSUCCC_James, discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL\\nhttps://t.co/rTGycOO6dq https://t.co/pmOLtHoc4O'},\n",
              " '1322396884628131840': {'tweet_author': 'Michele Nadeem-Baker',\n",
              "  'tweet_text': 'Many CLL patients are now placed on BTK inhibitors. Learn what they are - and how they work with Dr. Richard Furman. #CLL #Ibrutinib #Acalabrutinib #btkinhibitor @WeillCornell @RichardFurmanMD https://t.co/aGOKuhaL3W'},\n",
              " '1322176564579061760': {'tweet_author': 'Oncology',\n",
              "  'tweet_text': 'Pembrolizumab vs Pembrolizumab and Acalabrutinib in Patients With Platinum-Resistant Metastatic Urothelial Cancer https://t.co/pJ1LSHrSPJ #oncology'},\n",
              " '1321793789640417281': {'tweet_author': 'Urology',\n",
              "  'tweet_text': 'Pembrolizumab Plus Acalabrutinib for Platinum-Resistant Metastatic Urothelial Carcinoma https://t.co/weawnZjQpl #bladdercancer #blcsm'},\n",
              " '1321437143273775104': {'tweet_author': 'Kate Cwynarski',\n",
              "  'tweet_text': 'Excited to open REMoDL-A (CI Andy Davies):trial design allowing HD-MTX prophylaxis if indicated. R-CHOP +/-Acalabrutinib (also likely to provide additional CNS prophylaxis)\\nData from Phase I/II ACCEPT TRIAL promising (ASH 2020)\\nAlso correlative translational work \\n#lymsm #DLBCL https://t.co/GYfudrOTfQ'},\n",
              " '1321433049377218567': {'tweet_author': 'David Henry',\n",
              "  'tweet_text': 'Acalabrutinib, a next-gen BTK inhibitor, provides prolonged progression-free survival and better tolerability, compared w/ standard-of-care regimens for relapsed or refractory CLL, according to final results from the phase 3 ASCEND study https://t.co/lx13hDGcKN https://t.co/CW4GEbEbpQ'},\n",
              " '1321201269336395776': {'tweet_author': 'WCM Lymphoma',\n",
              "  'tweet_text': \"Dr. Richard Furman explains how Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib, acalabrutinib and zanubrutinib can work to treat people w/ #ChronicLymphocyticLeukemia (#CLL), via @PatientPower. https://t.co/6p5BSDjQB7 #leusm #lymsm\"},\n",
              " '1320812920025030661': {'tweet_author': 'とりさん@obsoleted',\n",
              "  'tweet_text': 'Science \"Global trial eliminates drugs, pivots to new ones\" https://t.co/ErZ1BKZIhe\\n\\nremdesivir は有病期間を短縮するが死亡率は改善せずとのこと。BTK inhibitor の acalabrutinib https://t.co/YWghVa35x3、酸性にしないと溶けないのでコカ・コーラに溶かすって草不可避'},\n",
              " '1319946841283330049': {'tweet_author': 'Lymphoma Papers',\n",
              "  'tweet_text': 'ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. #lymphoma #lymsm https://t.co/6GzQ0qrnzC'},\n",
              " '1319934156093059073': {'tweet_author': 'ThePrint Science',\n",
              "  'tweet_text': 'ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial\\n\\n@ChandnaHimani reports\\n\\n#ThePrintHealth\\n\\nhttps://t.co/KgPl3rj52a'},\n",
              " '1319572401735127042': {'tweet_author': 'ThePrint Science',\n",
              "  'tweet_text': 'ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial\\n\\n@ChandnaHimani reports\\n\\n#ThePrintHealth\\n\\nhttps://t.co/KgPl3rj52a'},\n",
              " '1319571544658432000': {'tweet_author': 'Shekhar Gupta',\n",
              "  'tweet_text': 'ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial\\n\\n@ChandnaHimani reports\\n\\n#ThePrintHealth\\n\\nhttps://t.co/NdVT6ta9tw'},\n",
              " '1319564222036992000': {'tweet_author': 'ThePrintIndia',\n",
              "  'tweet_text': 'ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial\\n\\n@ChandnaHimani reports\\n\\n#ThePrintHealth\\n\\nhttps://t.co/N4grQkEfrH'},\n",
              " '1319171710697017349': {'tweet_author': 'univadis',\n",
              "  'tweet_text': 'Acalabrutinib allein oder in Kombination mit Obinutuzumab zeigt im Vergleich zu anderen Frontline-Behandlungen bei Patienten mit chronisch lymphatischer Leukämie (CLL), die für Fludarabin nicht geeignet sind, ein günstiges PFS und OS.\\nhttps://t.co/hADqcRhobL https://t.co/eD0xjqg5Sy'},\n",
              " '1319149050080432130': {'tweet_author': 'Univadis',\n",
              "  'tweet_text': 'Acalabrutinib in monoterapia o in combinazione con obinutuzumab ottiene una sopravvivenza libera da progressione (progression-free survival, PFS) e una sopravvivenza complessiva (overall survival, OS) favorevoli rispetto ad altri trattamenti di prima...\\nhttps://t.co/ea4p641L2W https://t.co/6yaYAfSE8F'},\n",
              " '1318794364861251586': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@SeemaAliBhat1, of @OSUCCC_James, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial #leusm #CLL\\nhttps://t.co/SIWpRKYNgI https://t.co/emB9IkutHU'},\n",
              " '1318696821296869377': {'tweet_author': 'Marty Fecarotta',\n",
              "  'tweet_text': 'Try Calquence it worked for me. Went from 200 white cells to normal in 4 months.'},\n",
              " '1318392610478870529': {'tweet_author': 'Medelis: OncologyCRO',\n",
              "  'tweet_text': 'World Health Organization eyes cancer drug in treating COVID-19 https://t.co/dh0JB34iIK via @ABSCBNNews'},\n",
              " '1318156279097954304': {'tweet_author': 'Medical Dialogues',\n",
              "  'tweet_text': 'Inclusion of cancer drug in WHO Covid Solidarity trial: CDSCO panel asks ICMR to submit more clarification #icmr #who #covid19 #acalabrutinib #cdsco #AstraZeneca #NARI #cancer #remdesivir #dexamethasone #Calquence https://t.co/AOQm5shPsd'},\n",
              " '1318085165546168320': {'tweet_author': 'MEDWAVE',\n",
              "  'tweet_text': 'Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30 A key health ministry panel will review whether to recommend approval for OrphanPacific’s sakigake-d... https://t.co/y341rns4vD'},\n",
              " '1317463633438408706': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': '🔬 How does acalabrutinib compare with current standard of care treatments for R/R CLL? https://t.co/q7jr6aJFZ9 #lymsm #lymphoma https://t.co/KUEjkQcgmD'},\n",
              " '1317274126717980673': {'tweet_author': 'SunStar Cebu',\n",
              "  'tweet_text': 'The anti-cancer drug acalabrutinib has been included in the ongoing solidarity trial of the World Health Organization (WHO) to find a treatment for the coronavirus disease 2019 (Covid-19). https://t.co/27dbLLQrsP'},\n",
              " '1317228798492856320': {'tweet_author': 'ꪀꪖ𝕛᭙ꪖ',\n",
              "  'tweet_text': 'Interferon withdrawn from solidarity. New agent coming.. Acalabrutinib 🤞🏻'},\n",
              " '1317210735425081345': {'tweet_author': 'Mike Thompson, MD, PhD, FASCO',\n",
              "  'tweet_text': 'MT @HemOncToday [Oct 7, 2020] @LLSusa &amp; @AstraZeneca partner on clinical trial of acalabrutinib for patients with blood cancer &amp; #COVID19 -- READ our interview w/ Burd @LLSusa &amp; Byrd @OSUCCC_James https://t.co/vmI12KqLMu #CLLsm #leusm #COVID19 #COVID19nCancer #CCC19 @COVID19nCCC'},\n",
              " '1317159645375496199': {'tweet_author': 'COVID-19 and Cancer Consortium (CCC19) Registry',\n",
              "  'tweet_text': 'n=19 acalabrutinib #COVID19nCancer https://t.co/yyleeHNUEd'},\n",
              " '1317120165541072897': {'tweet_author': 'ENTIRE MARKET INFORMATION',\n",
              "  'tweet_text': 'AstraZeneca Pharma India will launch Calquence in India on Oct 21; stock trades flat https://t.co/7zoV3tSdDW'},\n",
              " '1317110666801475585': {'tweet_author': '日本がん対策新聞',\n",
              "  'tweet_text': '《朗報》\\n【慢性リンパ性白血病】「BTK阻害薬 カルケンス（一般名：アカラブルチニブ）」が30日開催予定の第二部会にて「再発または難治性の慢性リンパ性白血病/小リンパ球性リンパ腫」の適応について審議される予定。\\nhttps://t.co/cForyw4mKP'},\n",
              " '1317060897525927940': {'tweet_author': 'Antibiotic Steward🆔🦠Bassam Ghanem',\n",
              "  'tweet_text': 'New drugs will be Soon added to SOLIDARITY trial :\\nAcalabrutinib \"capsule\" (BTK) inhibitor \"lymphoma drug\" \\nPotential candidates\\nMEDI3506 IV Inj– anti-IL-33 monoclonal antibody\\nBemcentinib Capsule – AXL inhibitor\\nAll these drugs are currently part of UK ACCORD mega trial #COVID19 https://t.co/vVOV1V1Nhx'},\n",
              " '1317060726515769344': {'tweet_author': 'ExpPharma',\n",
              "  'tweet_text': '.@AstraZeneca to launch #oncology drug #Calquence in India https://t.co/IN1FrSyJyR | #pharma #pharmanews'},\n",
              " '1317056063590551553': {'tweet_author': 'Thiago Carvalho',\n",
              "  'tweet_text': 'Acalabrutinib is a BTK inhibitor, used in mantle cell lymphoma. Have to look up the rationale behind this one- as an ex B cell person, I think of Btk as primarily being important for B1 and natural abs https://t.co/mt166J2nJa'},\n",
              " '1317055303301681152': {'tweet_author': 'Julien Potet',\n",
              "  'tweet_text': \"Two major findings in @kakape's piece on the SOLIDARITY trial \\n1) Gilead knew about these negative results two weeks before signing a US$1Bn deal with EU for #remdesivir 😲\\n2) @WHO will now test acalabrutinib (i.e. cancer drug) for #COVID19 https://t.co/bIkImDLTJs\"},\n",
              " '1317039299892826112': {'tweet_author': 'zavingsin',\n",
              "  'tweet_text': 'AstraZeneca Pharma India will launch Calquence in India on Oct 21; stock trades\\xa0flat https://t.co/l2hJDE1bdy'},\n",
              " '1317037820473610240': {'tweet_author': 'CNN Philippines',\n",
              "  'tweet_text': 'Health experts are looking into testing a drug used to treat cancer patients as a possible cure to coronavirus after several drugs tested were found to have no effect on COVID-19 patients. https://t.co/j8lY5H6uz9'},\n",
              " '1317036386134884352': {'tweet_author': 'IIFLMarkets',\n",
              "  'tweet_text': 'AstraZeneca Pharma India will launch Calquence in India on Oct 21; stock trades flat\\nhttps://t.co/wqjckSh6BX'},\n",
              " '1317036259030798337': {'tweet_author': 'TheUemployed',\n",
              "  'tweet_text': 'AstraZeneca Pharma India will launch Calquence in India on Oct 21; stock trades\\xa0flat https://t.co/9UUDRD71U2'},\n",
              " '1317036183491280898': {'tweet_author': 'Doktor Net PH',\n",
              "  'tweet_text': 'Health undersecretary Maria Rosario Vergeire said Friday that the World Health Organization (WHO) has included acalabrutinib in its clinical trial for COVID-19 treatments.\\n#DoktorNews\\nhttps://t.co/EHVDRqZsyS'},\n",
              " '1317017006353215489': {'tweet_author': 'Sun Star Pampanga',\n",
              "  'tweet_text': 'THE anti-cancer drug acalabrutinib has been included in the ongoing solidarity trial of the World Health Organization (WHO) to find a treatment for the coronavirus disease 2019 (Covid-19).  Read | https://t.co/NH6yDo3nYk\\nhttps://t.co/EANej6T3HU'},\n",
              " '1317012407374499841': {'tweet_author': 'ABS-CBN News',\n",
              "  'tweet_text': 'World Health Organization eyes cancer drug in treating #COVID19 https://t.co/hkeonKLOuV'},\n",
              " '1316994786059046912': {'tweet_author': 'ABS-CBN News Channel',\n",
              "  'tweet_text': 'World Health Organization eyes cancer drug in treating #COVID19 https://t.co/0ice5pKzGo'},\n",
              " '1316988433143717888': {'tweet_author': 'Dayco India',\n",
              "  'tweet_text': 'AstraZeneca Pharma India to launch Calquence® in India\\nNews- https://t.co/fIPjmSkl6j\\n💙Follow Us\\n👉Website- https://t.co/v9yQPzh97G\\n👉Facebook- https://t.co/tlTVZ4LpgC\\n👉YouTube-https://t.co/6BEykx8TIS\\n👉Instagram-https://t.co/6P0zay3YIh\\n#India #AstraZenecaPharma #Daycosecurities https://t.co/vMB5Ueasl8'},\n",
              " '1316981342098264064': {'tweet_author': 'Medical Dialogues',\n",
              "  'tweet_text': 'AstraZeneca to launch cancer drug Acalabrutinib under brand name Calquence @AstraZeneca,@AstraZenecaIn #astrazeneca #astrazenecanews #acalabrutinibcapsules #bloodcancer #calquence https://t.co/ggGL9J4pFV'},\n",
              " '1316981325241384960': {'tweet_author': 'Vikas kumar sharma',\n",
              "  'tweet_text': 'HERO MOTO कंपनी ने नई Pleasure स्कूटर लॉन्च की है। इसकी कीमत 60,950 रुपए से शुरू है।\\nASTRAZENECA 21 अक्टूबर को देश में Mantle Cell Lymphoma की दवा Calquence लॉन्च करेगी।\\nPERSISTENT SYSTEMS पर फोकस अमेरिकी कंपनी CAPIOT को 63.4 लाख डॉलर में खरीदेगी।'},\n",
              " '1316962049503711232': {'tweet_author': 'FinReach',\n",
              "  'tweet_text': 'AstraZeneca Pharma will launch Calquence in India on October 21.\\n\\n#stockmarket #stockmarketnews #finance #financenewsdaily #finreach #india'},\n",
              " '1316957880445186049': {'tweet_author': 'MADURAI TRADING ACADEMY',\n",
              "  'tweet_text': '#AstraZeneca Pharma | Company will launch Calquence in India on October 21\\n\\nhttps://t.co/EeFLp9vqjO'},\n",
              " '1316945914582401024': {'tweet_author': '#Enritchansrajpandey',\n",
              "  'tweet_text': '🔆Good Morning All🔆 \\n☀️ Exclusive Morning Market News &amp; Update☀️\\n🔹AstraZeneca Pharma: To launch Calquence in India on October 21. Company had received import and market permission from Drugs Controller General of India on March 12. The... #frontpag'},\n",
              " '1316943282648342531': {'tweet_author': 'K Karthik Raja',\n",
              "  'tweet_text': 'AstraZeneca Pharma | Company will launch Calquence in India on October 21'},\n",
              " '1316942071362736129': {'tweet_author': 'The Hans India',\n",
              "  'tweet_text': \"AstraZeneca Pharma India to launch cancer drug with brand name, 'Calquence' on October 21 #CancerDrug #Calquence https://t.co/Xscn4Z1gJQ\"},\n",
              " '1316938577469722624': {'tweet_author': 'Markets Today',\n",
              "  'tweet_text': \"AstraZeneca\\xa0Pharma:\\xa0Drug firm AstraZeneca Pharma India said it will launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name 'Calquence' in the country on October 21.\"},\n",
              " '1316937017167630339': {'tweet_author': 'Ancient Stock Analysis',\n",
              "  'tweet_text': \"Here are a few #StocksToWatch out for ahead of today's trade. Also watch out for Persistent which is to acquire US-based CAPIOT Software for $6.34 m &amp; AstraZeneca which is to launch Calquence in India, used for lymphoma treatment\\n#... #frontpage_app https://t.co/ZWrZzX1Djd\"},\n",
              " '1316933443519975425': {'tweet_author': 'CNBC-TV18',\n",
              "  'tweet_text': \"Here are a few #StocksToWatch out for ahead of today's trade.\\n\\nAlso watch out for Persistent which is to acquire US-based CAPIOT Software for $6.34 m &amp; AstraZeneca which is to launch Calquence in India, used for lymphoma treatment https://t.co/hpLXR0Dz8r\"},\n",
              " '1316933248635777024': {'tweet_author': 'Markets Today',\n",
              "  'tweet_text': 'AstraZeneca Pharma will launch Calquence in India on October 21.\\nKPMG has resigned as the auditor with effect from October 8 for UPL’s material arm in Mauritius - UPL Corporation.'},\n",
              " '1316914510108774405': {'tweet_author': 'Medscape Pharmacists',\n",
              "  'tweet_text': 'Acalabrutinib, alone or in combo with obinutuzumab, showed favorable PFS and OS in CLL. https://t.co/RstKM0veRD #cllsm https://t.co/mYaBmnDMY8'},\n",
              " '1316881061121454080': {'tweet_author': 'Markets Today',\n",
              "  'tweet_text': 'AstraZeneca Pharma will launch Calquence in India on October 21'},\n",
              " '1316787203075235840': {'tweet_author': 'NEERAJ BAJPAI',\n",
              "  'tweet_text': 'ASTRAZENECA\\nAstraZeneca Pharma India To Launch Calquence In India On October 21, 2020\\nAlert: Calquence Medicine Is Used To Treat Adults With Mantle Cell Lymphoma\\n@CNBC_Awaaz'},\n",
              " '1316772957553745920': {'tweet_author': 'BloombergQuint',\n",
              "  'tweet_text': 'AstraZeneca Pharma to launch its Acalabrutinib 100 milligram capsules, used for treatment of various types of blood cancers.\\nhttps://t.co/EDpJ0uGqlY'},\n",
              " '1316705290381864968': {'tweet_author': 'Redbox India',\n",
              "  'tweet_text': 'ASTRAZENECA PHARMA: CO TO LAUNCH CALQUENCE IN INDIA ON OCT 21 || CALQUENCE IS USED TO TREAT ADULTS WITH MANTLE CELL LYMPHOMA'},\n",
              " '1316703689361379328': {'tweet_author': 'CNBC-TV18',\n",
              "  'tweet_text': 'AstraZeneca Pharma India to Launch Calquence in India on October 21, 2020. Calquence is used to treat adults with mantle cell lymphoma\\n\\n#Pharmaceutical #pharmanews https://t.co/iwBfaCXEhP'},\n",
              " '1316700734059147264': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) for treatment of chronic lymphocytic leukaemia (CLL) https://t.co/mR2qsZwCZX'},\n",
              " '1316696842571182082': {'tweet_author': 'BSE Corporate News',\n",
              "  'tweet_text': 'ASTRAZEN - Launch Of Acalabrutinib 100Mg Capsules (Calquence®) https://t.co/IrmNUfnYKx'},\n",
              " '1316666715413966848': {'tweet_author': 'myupchar',\n",
              "  'tweet_text': \"#COVID19: #Cancer ड्रग 'एकलाब्रुटिनिब' को #CoronaVirus के मरीजों पर आजमाना चाहता है @ICMRDELHI सरकार के पैनल के सामने प्रस्ताव रखा\\n#CoronaUpdates\\n#letsBeatCorona #IndiaFightsCorona @MoHFW_INDIA #coronavirusindia\\nhttps://t.co/RKoQzwYv3j\"},\n",
              " '1316641364013129728': {'tweet_author': 'ITSM - Industrial',\n",
              "  'tweet_text': 'ETIndustryNews: ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment #ETIndustryNews https://t.co/1uJsQRmtsf #YoSoyJabali'},\n",
              " '1316579703981924352': {'tweet_author': 'Teena Thacker',\n",
              "  'tweet_text': 'The \\u2066@ICMRDELHI\\u2069 has sought approval from the govt’s panel of experts for testing cancer drug #acalabrutinib as part of the \\u2066\\u2066@WHOSEARO\\u2069 ‘Solidarity’ trial, which seeks to find an effective treatment for #Covid-19 https://t.co/7fFdSZXi55'},\n",
              " '1316499284720746501': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@SeemaAliBhat1, of @OSUCCC_James, on the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia #leusm #cll\\nhttps://t.co/ie6LhZnlYd https://t.co/1sfFixzTxT'},\n",
              " '1316415135347507200': {'tweet_author': 'PINSIDER NEWS',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid\\xa0treatment https://t.co/I536asvu2M'},\n",
              " '1316377025263751169': {'tweet_author': 'EJ',\n",
              "  'tweet_text': 'Acalabrutinib https://t.co/w4nrJQP09l'},\n",
              " '1316355707801792514': {'tweet_author': '日経メディカル',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibは日本人の再発・難治性CLL/SLL、MCLでも忍容性があり有効性示す【日本血液学会2020】 https://t.co/OJ3YD9Np9w #日経メディカル'},\n",
              " '1316355583046344704': {'tweet_author': 'Guwahati News',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment https://t.co/p6YE2ddZzX https://t.co/gcwXoOtYRh'},\n",
              " '1316355575022837760': {'tweet_author': 'Economic Times',\n",
              "  'tweet_text': 'India’s health research body-Indian Council of Medical Research (#ICMR) has approached government’s panel of experts to approve testing of acalabrutinib, a cancer drug as part of the World Heath Organization’s global ‘Solidarity’ trial.\\n\\nhttps://t.co/kLyePcSs2U'},\n",
              " '1316346614273859584': {'tweet_author': 'がんナビ通信',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibは日本人の再発・難治性CLL/SLL、MCLでも忍容性があり有効性示す【日本血液学会2020】：がんナビ\\n日本でも早く承認されることを願っています。\\n#CLL #SLL #MCL  https://t.co/RWNWKsAMdD'},\n",
              " '1316317828488654851': {'tweet_author': 'Mango News',\n",
              "  'tweet_text': 'ICMR has approached govt’s panel of experts to approve testing of acalabrutinib, a cancer drug as testing drugs to find an effective treatment for Covid-19. \\n\\n#ICMR  #AstraZeneca #Acalabrutinib #NARI # #WorldHeathOrganization #WHO #CoronaVirus #Covid19 #MangoNews https://t.co/u6gyr8ia6U'},\n",
              " '1316308161184235520': {'tweet_author': 'MAJ DR B P SINGH,SG Medallist*(SIACHEN GLACIER*)',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment\\nhttps://t.co/ustquoRhUk\\n- shared via @ETHealthWorld App:'},\n",
              " '1316300589819744257': {'tweet_author': '医学学会ニュース',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibは日本人の再発・難治性CLL/SLL、MCLでも忍容性があり有効性示す【日本血液学会2020】 https://t.co/Po28zFSCrV'},\n",
              " '1316294052422189056': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibは日本人の再発・難治性CLL/SLL、MCLでも忍容性があり有効性示す【日本血液学会2020】 https://t.co/Pw49Sw3LEw'},\n",
              " '1316287310682488832': {'tweet_author': 'JINU JAMES',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment https://t.co/0OsTrcB2jj via @ETHealthWorld'},\n",
              " '1316285058152566784': {'tweet_author': 'ET Industry News',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment #ETIndustryNews https://t.co/LgSxxma0As'},\n",
              " '1316280163470991360': {'tweet_author': 'ETHealthWorld',\n",
              "  'tweet_text': 'ETHealthworld | ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid treatment #ICMR #Dexamethasone #ClinicalTrial #Covid #TheWho #Solidarity #Remdesivir #Acalabrutinib https://t.co/TudMFD6XMy'},\n",
              " '1316274685156495360': {'tweet_author': 'Freddy Pizart, R.N.',\n",
              "  'tweet_text': 'Medscape: Acalabrutinib, alone or in combo with obinutuzumab, showed favorable PFS and OS in CLL. https://t.co/DT86C7w1sq #cllsm https://t.co/GiN0EsJpYz https://t.co/SOsHsM7AG3'},\n",
              " '1316266955712663552': {'tweet_author': 'Aaj Ka Samachar',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug acalabrutinib for Covid\\xa0treatment https://t.co/g9ADAWpoEe'},\n",
              " '1316265694334337024': {'tweet_author': 'Ketan',\n",
              "  'tweet_text': 'ICMR approaches experts panel to approve testing of cancer drug \"acalabrutinib\" for Covid treatment\\n\\nhttps://t.co/20zNUyCdbZ https://t.co/R94tpk6Pl5'},\n",
              " '1316183721939099648': {'tweet_author': '印度孟加拉代购yindu948',\n",
              "  'tweet_text': '阿卡替尼，适应症：用于治疗患有套细胞淋巴瘤（mantlecell lymphoma）且曾接受过至少一次治疗的成人患者。接受Calquence治疗的患者有81%获得了完全缓解或部分缓解 https://t.co/fwc5pvOXXi'},\n",
              " '1316031093783564289': {'tweet_author': 'UroToday.com',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab vs pembrolizumab &amp; acalabrutinib in patients with platinum-resistant #mUC. #BeyondTheAbstract on UroToday &gt; https://t.co/lp7h6gCqrl @AmericanCancer @TiansterZhang @MRHarrisonMD @AlvaAjjai @sonpavde @Daniel_J_George @LenAppleman https://t.co/OMhHGhHVfd'},\n",
              " '1315993866579836928': {'tweet_author': 'V.V. Ganesha',\n",
              "  'tweet_text': '/*\\n\\nICMR seeks govt panel approval to test cancer drug acalabrutinib in WHO’s Solidarity trial\\n\\n*/\\n\\nhttps://t.co/nvHqINP9KD via @ThePrintIndia'},\n",
              " '1315993189329842177': {'tweet_author': 'ThePrint Science',\n",
              "  'tweet_text': \"ICMR seeks govt panel approval to test cancer drug acalabrutinib in WHO’s Solidarity trial\\n\\nThePrint's @ChandnaHimani reports\\n\\nhttps://t.co/8fVKGq0oiO\"},\n",
              " '1315987653494484992': {'tweet_author': 'Medscape',\n",
              "  'tweet_text': 'Acalabrutinib, alone or in combo with obinutuzumab, showed favorable PFS and OS in CLL. https://t.co/kxXbva00S8 #cllsm https://t.co/SI5VixZgXG'},\n",
              " '1315977260176793600': {'tweet_author': 'Himani Chandna',\n",
              "  'tweet_text': 'BREAKING : ICMR seeks govt panel approval to test cancer drug acalabrutinib in WHO’s Solidarity trial. \\n\\nPanel has asked for more clarification &amp; said that “results on Remdesivir from the Solidarity trial may be available in a few weeks.”\\n\\nhttps://t.co/NkxZuGzi95  @ThePrintIndia'},\n",
              " '1315968020410363909': {'tweet_author': 'ThePrintIndia',\n",
              "  'tweet_text': \"ICMR seeks govt panel approval to test cancer drug acalabrutinib in WHO’s Solidarity trial\\n\\nThePrint's @ChandnaHimani reports\\n\\nhttps://t.co/vyihNlMe5C\"},\n",
              " '1315908473662722050': {'tweet_author': '印度🇮🇳孟加拉🇧🇩土耳其🇹🇷药',\n",
              "  'tweet_text': '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。 https://t.co/P9MEjeTKYq'},\n",
              " '1315902825528877057': {'tweet_author': '印度孟加拉土耳其进口药',\n",
              "  'tweet_text': '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。 https://t.co/hnJFVuZOjo'},\n",
              " '1315902692829536256': {'tweet_author': '印度孟加拉土耳其靶向药',\n",
              "  'tweet_text': '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。 https://t.co/WFYCvmUUC9'},\n",
              " '1315835399944785920': {'tweet_author': 'MDEdge',\n",
              "  'tweet_text': 'Acalabrutinib use alone or with obinutuzumab shows positive results for CLL. https://t.co/mpaCAFP9AC #lymphomahub https://t.co/ElKX1bM4dL'},\n",
              " '1315590650079907841': {'tweet_author': 'www.zdravezpravy.cz',\n",
              "  'tweet_text': 'Najít účinnou léčbu medikamenty pro onemocnění covid-19 pomohou i čeští odborníci. \\n\\n#SolidarityTrial #WHO @WHO_Europe @muni_cz #CZECRIN #lecbacovidu #SUKL #remdesivir #acalabrutinib #interferon \\n\\nhttps://t.co/6KgnvRzcxE'},\n",
              " '1315555409713934337': {'tweet_author': 'AGD Biomedicals',\n",
              "  'tweet_text': 'From Medscape Hematology-Oncology Headlines&gt;&gt;https://t.co/SQxKiNIH6X: Acalabrutinib Bests Other Frontline CLL Therapies'},\n",
              " '1314996874097692673': {'tweet_author': 'Medscape Oncology',\n",
              "  'tweet_text': 'Acalabrutinib, alone or in combo with obinutuzumab, showed favorable PFS and OS in CLL. https://t.co/c9pMEKl05F #cllsm https://t.co/MMi4lHpGE6'},\n",
              " '1314929430540808192': {'tweet_author': 'MDedge Hematology & Oncology',\n",
              "  'tweet_text': 'Acalabrutinib use alone or with obinutuzumab shows positive results for CLL. https://t.co/LXOdJKXFoP #lymphomahub https://t.co/x01M51QIyN'},\n",
              " '1314869165195317248': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New article: Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis. https://t.co/QSLki6TK9G #CLL #leusm #hematology'},\n",
              " '1314670170703495168': {'tweet_author': 'eDNA',\n",
              "  'tweet_text': '#NCCNhem20 CLL sequencing\\n⚠️Phase III RCTs 1st line: Only RESONATE-2 &amp; E1912 show OS benefit\\n🤨ELEVATE-TN: does obinutuzumab add much to acalabrutinib?\\n🧐Acalabrutinib vs ibrutinib: bleeding ↔️, maybe ⬇️ fatigue, rash\\n💡Venetoclax \"consolidation\" ⏩ U-MRD? \\n💡BCL2 + BTK (+CD20)?'},\n",
              " '1314564583332491264': {'tweet_author': 'ClinicalTrialsData',\n",
              "  'tweet_text': '$AZN Phase 2 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.…NCT04346199. Estimated Primary Completion Date -  11/2020'},\n",
              " '1314564094213656579': {'tweet_author': 'ClinicalTrialsData',\n",
              "  'tweet_text': '$AZN Phase 2 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.…NCT04380688. Estimated Primary Completion Date -  11/2020'},\n",
              " '1314563851011186689': {'tweet_author': 'ClinicalTrialsData',\n",
              "  'tweet_text': '$AZN Phase 1 A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects…NCT04488016. Estimated Primary Completion Date -  11/2020'},\n",
              " '1314492448626880512': {'tweet_author': 'MEDWAVE',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請 \\u3000BTK阻害薬acalabrutinibを、アストラゼネカが再発または難治性の慢性リンパ性白血病/小リンパ球性リンパ腫（CLL/SLL）を対象に日本で申請していたことがこのほど明らかとなった。同社の国内開発リストに掲載された。 https://t.co/ai0n94E15s'},\n",
              " '1314161509367345154': {'tweet_author': 'がんナビ通信',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請：がんナビ\\n#白血病 #慢性リンパ性白血病 #CLL  https://t.co/dMFVZYmLpH'},\n",
              " '1313985213781819393': {'tweet_author': '日経メディカル',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請 https://t.co/nTWqM75ogw #日経メディカル'},\n",
              " '1313916008697004032': {'tweet_author': 'abe dental',\n",
              "  'tweet_text': 'あべ歯科医療ニュースｐｉｃｋUP★BTK阻害薬acalabrutinibがCLL/SLLを対象に申請 https://t.co/hqUQdCWO3S ★福岡市東区・歯周病・インプラント・あべ歯科クリニック\\u3000https://t.co/mV2i8CMpzY'},\n",
              " '1313912979218456581': {'tweet_author': 'Taan Pacheco',\n",
              "  'tweet_text': 'El Instituto Nacional del Cáncer analizó que tratamiento con acalabrutinib  puede ser efectivo para ayudar a combatir el COVID-19. #COVID19 #Salud \\n\\nInformación sobre el estudio en @Notimex  \\n\\nhttps://t.co/KPU0VylrqU'},\n",
              " '1313902031132864513': {'tweet_author': 'HemOnc Today',\n",
              "  'tweet_text': '.@LLSusa &amp; @AstraZeneca partner on clinical trial of acalabrutinib for patients with blood cancer and #COVID19 -- READ our interview with Amy Burd, PhD @LLSusa &amp; John C. Byrd, MD @OSUCCC_James https://t.co/tFRyVg3ttJ https://t.co/VTmZtFac6s'},\n",
              " '1313891099681775616': {'tweet_author': 'Cancer Review',\n",
              "  'tweet_text': 'Trial to test acalabrutinib for patients with blood cancer, COVID-19 - Healio https://t.co/7YiaGaByiS'},\n",
              " '1313891093826605056': {'tweet_author': 'Cancer Update',\n",
              "  'tweet_text': 'Trial to test acalabrutinib for patients with blood cancer, COVID-19 - Healio https://t.co/1oHiaow5BJ'},\n",
              " '1313888025726914566': {'tweet_author': 'Cancer Research News',\n",
              "  'tweet_text': 'Trial to test acalabrutinib for patients with blood cancer, COVID-19 https://t.co/t5VXYnDZvw'},\n",
              " '1313869595556687874': {'tweet_author': '医学学会ニュース',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請 https://t.co/XCgZedw9bP'},\n",
              " '1313863668665204736': {'tweet_author': '前田静吾｜海外情報活用コンサルタント\\u3000Insights4 Pharma編集長',\n",
              "  'tweet_text': 'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請 https://t.co/DCHQ3IePRZ'},\n",
              " '1313572577881870336': {'tweet_author': 'DrugPatentWatch',\n",
              "  'tweet_text': 'CALQUENCE Drug Profile, 2020 https://t.co/6yRGCHVChS'},\n",
              " '1313472506989338628': {'tweet_author': 'INDoximity 🇮🇳',\n",
              "  'tweet_text': 'Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis https://t.co/7voMKNFUWA #ClinicalTherapeutics #Physicians'},\n",
              " '1313215648961503232': {'tweet_author': 'clinicaltherapeutics',\n",
              "  'tweet_text': 'Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis https://t.co/6n9yKIcEc8'},\n",
              " '1312943306783981568': {'tweet_author': 'Vasanthi Ilangovan',\n",
              "  'tweet_text': 'acalabrutinib drug is blocking BTK (Briton Tyrosine Kinase) protein. This helps to control cytokines and improve oxygenation in severe cases. This is cancer drug. P'},\n",
              " '1312417098535243776': {'tweet_author': 'Sherry',\n",
              "  'tweet_text': 'Can anyone get this info to \\n@realDonaldTrump @FLOTUS @EricTrump @DonaldJTrumpJr @IvankaTrump? #WeLoveTrump \\nAcalabrutinib #Calquence for #COVID19 -19 https://t.co/Modq5LHN8F via @OncNursingNews'},\n",
              " '1312138838295236608': {'tweet_author': 'Sid Murlidhar',\n",
              "  'tweet_text': 'Hydroxychloroquine. Remdesivir. Calquence. Jakafi. Olumiant. Kineret. Ilaris. Mavrilimumab.\\n\\nWhy do all these possible Covid-19 treatments sound like definite Decepticon school dropouts?'},\n",
              " '1311018032144277505': {'tweet_author': 'UroToday.com',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab vs pembrolizumab &amp; acalabrutinib in patients with platinum-resistant #mUC. #BeyondTheAbstract on UroToday &gt; https://t.co/lp7h6gCqrl @AmericanCancer @TiansterZhang @MRHarrisonMD @AlvaAjjai @sonpavde @Daniel_J_George @LenAppleman https://t.co/jfnKiR9h4t'},\n",
              " '1310884787754852354': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Check out Acalabrutinib in patients with relapsed or refractory chronic lymphocytic l... https://t.co/gL8tkhWkIC via @medivizor #Leukemia'},\n",
              " '1310698861069967360': {'tweet_author': 'Oncology Tube',\n",
              "  'tweet_text': 'Phase III ASCEND: Randomized Trial of Acalabrutinib - Paolo Ghia, MD, Ph.D. @MyUniSR #RRCLL #CLL \\n\\nLink To Full Video:\\nhttps://t.co/bBc6586xCS https://t.co/8AFSuKY8jg'},\n",
              " '1310685885940330498': {'tweet_author': 'dtw Research, Inc',\n",
              "  'tweet_text': 'During Q2, AstraZeneca highlighted Caluquence\\'s \"Keep Inspiring\" campaign!🎨🖌️\\n\\n#AstraZeneca #calwuence #acalabrutinib #keepinspiring #newcampagintheme #calendar #oncology #leukemia #antineoplastics #interestingmarketing #q2 #q22020 #leukemiamarket #dtwmarkethighlight https://t.co/Rx91b30XOG'},\n",
              " '1310658055688851457': {'tweet_author': 'Cancer Discovery',\n",
              "  'tweet_text': 'September is #Leukemia and #Lymphoma AwarenessMonth. \\nICYMI: Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic #leukemia. \\n@OhioState #CLL #ClinicalTrial \\nhttps://t.co/2yESjAXHVU https://t.co/uax2lg2xqr'},\n",
              " '1310574743284637701': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma https://t.co/a8IQxO0iOR #MCL #lymsm #hematology'},\n",
              " '1310381587750703107': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) for treatment of chronic lymphocytic leukaemia (CLL) https://t.co/mR2qsZwCZX'},\n",
              " '1309580546973065216': {'tweet_author': 'Tian Zhang, MD, MHS',\n",
              "  'tweet_text': 'Pembrolizumab vs pembrolizumab-acalabrutinib for metastatic #bladddercancer is fully published! @JournalCancer @DukeGUCancer @sonpavde @AlvaAjjai #PeterODonnell @Daniel_J_George @MRHarrisonMD @MattMilowsky https://t.co/0ytSMFpav1'},\n",
              " '1309463299067699200': {'tweet_author': 'OncLive SOSS',\n",
              "  'tweet_text': '.@ErleneSeymour, of @karmanoscancer, on the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia #leusm\\nhttps://t.co/chHTusi7xb https://t.co/mDAq9WvYr4'},\n",
              " '1309448697923555329': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of… https://t.co/YJ2oBIQHXw #MCL #lymsm #hematology'},\n",
              " '1309198145507790849': {'tweet_author': 'Occupandi Temporis',\n",
              "  'tweet_text': 'This hypothesis is already in clinical trial with oral oncolytic agents such #Acalabrutinib https://t.co/QeF7wfFahY'},\n",
              " '1308473523954839552': {'tweet_author': 'Oncology Tube',\n",
              "  'tweet_text': 'Paolo Ghia, MD, Ph.D. @MyUniSR #RRCLL #CLL ASCEND: Phase III, Randomized Trial of Acalabrutinib https://t.co/kIjnP9UMSX https://t.co/VWRqfy7HCn'},\n",
              " '1308310817306222594': {'tweet_author': 'AustralianPrescriber',\n",
              "  'tweet_text': 'https://t.co/R5Dzg4rZR8'},\n",
              " '1308020588146044929': {'tweet_author': 'TAP Clinical Trial Network',\n",
              "  'tweet_text': '📌STELLAR UPDATE📌Welcome to @KingsCollegeNHS &amp; @UHSFT who recently opened to this study of #acalabrutinib, in combination with CHOP-R, in patients with newly diagnosed #RichtersSyndrome. 11/16 planned sites are now open to recruitment.\\n\\n@AnnaSchuh3 @tobyeyre82 @CRCTU @CCH_Bham'},\n",
              " '1307748783976050694': {'tweet_author': 'filippo masini',\n",
              "  'tweet_text': 'Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia ... https://t.co/NVTHDy8sej'},\n",
              " '1307744042147549191': {'tweet_author': 'filippo masini',\n",
              "  'tweet_text': 'Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on ... https://t.co/f1ksnRFLUe'},\n",
              " '1307735915796652041': {'tweet_author': 'Oncology Tube',\n",
              "  'tweet_text': 'Michael Wang, MD @michaelwangmd @MDAndersonNews Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma https://t.co/lKytGYpKko https://t.co/JYjOzLDs1h'},\n",
              " '1307656133625221121': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: Acalabrutinib (Calquence) for treatment of chronic lymphocytic leukaemia (CLL) https://t.co/mR2qsZwCZX'},\n",
              " '1306545959145541634': {'tweet_author': 'TAP Clinical Trial Network',\n",
              "  'tweet_text': '📌STELLAR UPDATE📌Congratulations @CRUK_BI on registering your 1st patient. 9 patients are now part of this study of #acalabrutinib, in combination with CHOP-R, in patients with newly diagnosed #RichtersSyndrome. Thank you Anna, Nicole, Dr Rafferty and the team\\n@CRCTU @AnnaSchuh3'},\n",
              " '1306107613885665282': {'tweet_author': 'BioMassSpec',\n",
              "  'tweet_text': 'Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study #JPBA  https://t.co/xftxi4xax4'},\n",
              " '1305888828851396610': {'tweet_author': 'CALQUENCE® (acalabrutinib)',\n",
              "  'tweet_text': 'https://t.co/W83AqpUk5A Learn more about CALQUENCE for adult patients with chronic lymphocytic leukemia (CLL). #bloodcancerawarenessmonth'},\n",
              " '1305793572361441280': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'WATCH: Jennifer Woyach, MD, of @OSUCCC_James, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia. #leusm https://t.co/L4CjQXFtaE'},\n",
              " '1305775309518639106': {'tweet_author': 'KOLKATA RAVI SPECIALITIES PHARMA PVT.LTD.,',\n",
              "  'tweet_text': 'CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer. https://t.co/v8pU4xU2wz'},\n",
              " '1305770094794956803': {'tweet_author': 'delhi-ravi worldwide medicines',\n",
              "  'tweet_text': 'CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer. https://t.co/LQnpqdJCLd'},\n",
              " '1305718000335675392': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Acalabrutinib sustained superiority in terms of extended progression-free survival with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, which was inclusive of patients with high-risk features...\\nhttps://t.co/Lh0EI8x7CS #leusm'},\n",
              " '1305655277606375425': {'tweet_author': 'CureHuntr',\n",
              "  'tweet_text': '#clinicaltrial LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas https://t.co/dayd0bwvco'},\n",
              " '1305561121227767809': {'tweet_author': 'TrialBulletin',\n",
              "  'tweet_text': 'LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas: Status: Not yet recruiting, \\nCondition Summary: Lymphoma https://t.co/eiyyrlg8tz'},\n",
              " '1305465325387874306': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) https://t.co/MDkb3bPfYJ #DLBCL #lymsm #hematology'},\n",
              " '1305431201663127554': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib continued to show prolonged progression-free survival with a favorable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia. @MyUniSR #leusm https://t.co/dhTw2bqXAV'},\n",
              " '1305402391903301633': {'tweet_author': 'Helen Ong',\n",
              "  'tweet_text': 'Once a highly promising #BTK inhibitor in pre-clinical studies, Acalabrutinib lacks OS benefit in #CLL trial\\n▪️Relevant to (and wondering about) $APTO #GC’806 currently under a similar study https://t.co/kaWeBGNS38'},\n",
              " '1305385858045022209': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'WATCH: Paolo Ghia, MD, PhD, of @MyUniSR, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial. #leusm https://t.co/NlNYC0mzNT'},\n",
              " '1305234842536366081': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Paolo Ghia, MD, PhD, of @MyUniSR, highlights the safety profile of acalabrutinib in CLL. #leusm https://t.co/iQWHdUJULF'},\n",
              " '1305051986132426752': {'tweet_author': 'Stem Cells in the News',\n",
              "  'tweet_text': 'Acalabrutinib Demonstrates Superior PFS Over Standard-0f-Care in Relapsed/Refractory CLL https://t.co/06uyS5ZwuT'},\n",
              " '1304902544196591616': {'tweet_author': 'chadi nabhan MD, MBA, FACP',\n",
              "  'tweet_text': 'Nice quick editorial on BTKi in #CLL\\nToo many of them but will be interesting to see the 3rd generation.\\nAlso, await the results of the trial comparing acalabrutinib to ibrutinib, sometime in 2021. @ASCO_pubs https://t.co/hestcJW66q'},\n",
              " '1304854172651544576': {'tweet_author': 'Stem cell Watch',\n",
              "  'tweet_text': 'Acalabrutinib Demonstrates Superior PFS Over Standard-0f-Care in Relapsed/Refractory CLL - Targeted Oncology https://t.co/u36hU1DHye'},\n",
              " '1304689538447683584': {'tweet_author': 'Stem Cells in the News',\n",
              "  'tweet_text': 'Acalabrutinib Shows Sustained Superiority Over Standard-of-Care Regimens in Relapsed … https://t.co/hHUh73vKLr'},\n",
              " '1304612834035167232': {'tweet_author': 'Oncology News Update',\n",
              "  'tweet_text': 'Dr. Woyach on the Role of Acalabrutinib in CLL https://t.co/uq0qTyN2qL'},\n",
              " '1304568953067507713': {'tweet_author': 'Gabriel Chinchilla',\n",
              "  'tweet_text': 'SOHO2020 - Calquence Prescribing Information https://t.co/JVs94PRQT3'},\n",
              " '1304555391251034113': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'WATCH: Jennifer Woyach, MD, of @OSUCCC_James, discusses the role of acalabrutinib in chronic lymphocytic leukemia. #leusm https://t.co/fl212IqOcz'},\n",
              " '1304510082328268801': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'Acalabrutinib Shows Sustained Superiority Over Standard-of-Care Regimens in Relapsed/Refractory CLL @MyUniSR #leusm https://t.co/wbr1vSrDee'},\n",
              " '1304463847982592002': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'CONGRESS | #SOHO2020 | @MorieGertz from @MayoClinic discussed therapy options for #WM. Bortezomib and carfilzomib has demonstrated fast and deep responses, acalabrutinib showed high response rates with low risk of bleeding. #lymsm https://t.co/a18Y9JBNDR'},\n",
              " '1304454606714535936': {'tweet_author': 'HemOnc Today',\n",
              "  'tweet_text': 'NEWS from @SocietyofHemOnc #SOHO2020 - Patients treated with acalabrutinib (@AstraZeneca) had longer progression-free survival than with standard regimens https://t.co/uoX0MRYqJT data presented by Paolo Ghia, MD, PhD @SanRaffaeleMI https://t.co/A5sBgzYv6R'},\n",
              " '1304224404801499138': {'tweet_author': 'Seema Ali Bhat',\n",
              "  'tweet_text': 'This debate\\n#CLL\\nWill CLL17 answer it?\\nWish the single agent BTKi could be acalabrutinib in the CLL17 Study https://t.co/YPqECnvhjj'},\n",
              " '1304180287413407744': {'tweet_author': 'TeamHaem',\n",
              "  'tweet_text': 'Our patient with TP53 undisrupted CLL has been commenced in acalabrutinib. He has some concerns as his WCC has increased  from 60 to 102 and he is getting recurrent headaches. What would you advise? #Teamhaem'},\n",
              " '1304166804118474753': {'tweet_author': 'Lymphoma Hub',\n",
              "  'tweet_text': 'The ASCEND trial presented again at #SOHO2020 by P Ghia of @MyUniSR \\n \\n📢 Acalabrutinib received recently the CHMP positive opinion to be approved for patients with CLL: https://t.co/ITPxMPovyt https://t.co/655HzVrhcq'},\n",
              " '1303450074794598400': {'tweet_author': 'Ronald M. Chavin',\n",
              "  'tweet_text': '9-8-2020:  \"Trials in China have been carried out on IL-6 blocker tocilizumab, trials in Italy for IL-1 blocker anakinra, and trials in the U.S. for IL-1 blocker acalabrutinib, all with positive outcomes:\"\\nhttps://t.co/rKNHJglLoE\\nhttps://t.co/dQynNz1qh5\\nhttps://t.co/8JwlIjB71F'},\n",
              " '1303423744678014978': {'tweet_author': 'Dr. Luis Villela',\n",
              "  'tweet_text': 'Mantle cell lymphoma , M 56 y/o bulky mediastinum (11.4x6cm) &amp; abdomen (8.4x16cm). Spectacular response with RCHOP/RDHAP (PET/CT negative, Deauville 1 residual). Pathology: p53 positive and FISH p53 +ve,43%. Next step ASCT vs allo? Maintenance rituximab vs. Acalabrutinib?(off-la)'},\n",
              " '1303181289114292224': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Dr. Woyach discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/5pwMeDrN3q #leukemia #leusm'},\n",
              " '1303063004343394308': {'tweet_author': 'Steven Artandi, MD, PhD',\n",
              "  'tweet_text': 'SCI member Steve Coutre and colleagues found that acalabrutinib with or without obinutuzumab significantly improved progression-free survival in a #clinicaltrial for treatment-naive chronic lymphocytic #leukemia. https://t.co/9kJAESitFP #cll'},\n",
              " '1301963795456294912': {'tweet_author': 'Mahmoud Aljurf',\n",
              "  'tweet_text': 'Phase III, Randomized Trial of Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: Acalabrutinib significantly improved PFS compared with I-R or B-R &amp; has an acceptable safety profile in pts with R/R CLL https://t.co/LBrETUKMwD'},\n",
              " '1301822552428417025': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Dr. Woyach discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/5pwMeDrN3q #cllsm #leusm'},\n",
              " '1301559874778574848': {'tweet_author': 'MD Anderson Leukemia',\n",
              "  'tweet_text': 'New #clinicaltrial #2019-1141\\nAcalabrutinib + Obinutuzumab in TX naive #CLL | PI: Jan Burger, M.D., Ph.D. of @MDAndersonNews #Leukemia | NCT04505254 | https://t.co/wsJdLD94fP| #endcancer #leusm'},\n",
              " '1301515287649378305': {'tweet_author': 'The ASCO Post',\n",
              "  'tweet_text': 'Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL https://t.co/6kJX4zGOck #leusm #hematology'},\n",
              " '1301339174952464386': {'tweet_author': 'Targeted Oncology',\n",
              "  'tweet_text': 'Dr. Woyach discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/5pwMeDrN3q #leusm #leukemia'},\n",
              " '1301167496133775360': {'tweet_author': 'The ASCO Post',\n",
              "  'tweet_text': 'Drs Seema Bhat &amp; Jennifer Woyach: Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL https://t.co/X5UOif7o7l #leusm #hematology @OSUCCC_James https://t.co/NzO7hydLA4'},\n",
              " '1300731411419201536': {'tweet_author': '7NEWS Sydney',\n",
              "  'tweet_text': \"1600 Australians battling blood cancer will get some financial relief with today's PBS listing of a drug called Calquence, used against a form of chronic leukaemia. https://t.co/TWh1KQycs4 #7NEWS https://t.co/MWFagm5L7m\"},\n",
              " '1300697841325670405': {'tweet_author': '7NEWS Sydney',\n",
              "  'tweet_text': 'More than 1,000 cancer patients could benefit from a new drug treatment being listed on the Pharmaceutical Benefits Scheme. Calquence is now available for patients with a form of chronic leukaemia. https://t.co/TWh1KQycs4 #7NEWS https://t.co/JpkiylDW8i'},\n",
              " '1300689487270346752': {'tweet_author': 'Lymphoma Australia',\n",
              "  'tweet_text': 'Federal Health Minister @GregHuntMP announced that from September 1 Keytruda is now reimbursed on PBS for relapsed/refractory PMBCL &amp; Calquence (Acalabrutinib) is approved for CLL &amp; SLL. Great news for lymphoma patients\\n#lime4lymphoma #lymphomaawarenessmonth @MSD_Aus @AstraZeneca https://t.co/9GGUBmApjs'},\n",
              " '1300626282913263621': {'tweet_author': 'Rozalina Sarkezians',\n",
              "  'tweet_text': 'To mark World Lymphoma Awareness month, @AstraZeneca Calquence is now reimbursed for certain Australian patients with chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL).\\n#BloodCancerAwarenessMonth #lymphoma #leukemia \\n@lymphomaOz \\nhttps://t.co/lmoXmENIsy'},\n",
              " '1300564206425571329': {'tweet_author': 'haemdoc',\n",
              "  'tweet_text': 'Acalabrutinib PBS listing; P2Y12 Inhibitors in Australian comparitive study; Pre-operative anaemia screening pays off https://t.co/kbt8F44TZ9'},\n",
              " '1300538962671534081': {'tweet_author': 'Specialty Pharmacy Continuum',\n",
              "  'tweet_text': 'Cancer drugs may dampen #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/sED87kMI7a #calquence #BTKinhibitors'},\n",
              " '1300479710523203584': {'tweet_author': 'Tom Henry, MBA, RPh, CPh',\n",
              "  'tweet_text': 'Acalabrutinib a Second-Generation BTKi https://t.co/tRVC0a5lcr'},\n",
              " '1300243285147934720': {'tweet_author': 'Leukaemia Foundation',\n",
              "  'tweet_text': 'Brilliant news for people living w/ #bloodcancer - @healthgovau added #Calquence to the #PBS ensuring more people are able to access better treatments &amp; improve outcomes! https://t.co/R1LDo3H4xe'},\n",
              " '1300184376769220612': {'tweet_author': 'Narinder Grewal, MD',\n",
              "  'tweet_text': 'BTK inhibitors might combat the #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/NpogHWRyGO \\nIDSE_Online LLSusa sloan_kettering DanaFarber LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1300171441929846792': {'tweet_author': 'Anesthesiology News',\n",
              "  'tweet_text': 'BTK inhibitors might combat the #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/qbRob09zvm \\n@IDSE_Online @LLSusa @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1299920226264526848': {'tweet_author': 'MW Gunter',\n",
              "  'tweet_text': 'Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19. https://t.co/n2sBRUKDa3 https://t.co/bS0clMH3yb'},\n",
              " '1299879846873632773': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Check out: Acalabrutinib in patients with relapsed or refractory chronic lymphocytic ... https://t.co/gL8tkhWkIC via @medivizor #Leukemia'},\n",
              " '1299618067081650176': {'tweet_author': 'Greg Hunt',\n",
              "  'tweet_text': 'On September 1, Calquence will be listed on the PBS for the first time for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma. \\n\\nVideo: @10NewsFirst https://t.co/5OLAFU8yYv'},\n",
              " '1299413488490688514': {'tweet_author': 'filippo masini',\n",
              "  'tweet_text': 'ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia https://t.co/LNnOjhOFj5'},\n",
              " '1299384099103277058': {'tweet_author': 'Narinder Grewal, MD',\n",
              "  'tweet_text': 'BTK inhibitors might combat the #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/NpogHWRyGO \\nIDSE_Online LLSusa sloan_kettering DanaFarber LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1299371174233886720': {'tweet_author': 'Anesthesiology News',\n",
              "  'tweet_text': 'BTK inhibitors might combat the #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/qbRob09zvm \\n@IDSE_Online @LLSusa @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1299301838269734912': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB Subtype DLBCL (ACE-LY-312) https://t.co/u250pWG3ZL #DLBCL #lymsm #hematology'},\n",
              " '1299104829034369025': {'tweet_author': 'CancerNetwork®, Home of the Journal ONCOLOGY®',\n",
              "  'tweet_text': '#ICYMI: Both the phase 2 ACE-CL-001 trial and the pivotal phase 3 ASCEND trial showed the long-term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/pDysrG92ZC'},\n",
              " '1298410653405904896': {'tweet_author': 'Jasdeep Sandhu',\n",
              "  'tweet_text': \"I know my phone is listening to me and targeting ads to me, but if it could save the Calquence and Brukinsa ads during office hours I'd appreciate it .\\n\\nThank you.\"},\n",
              " '1298345744718606343': {'tweet_author': 'Specialty Pharmacy Continuum',\n",
              "  'tweet_text': 'Cancer drugs may dampen #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/sED87kMI7a @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1298293575848022017': {'tweet_author': 'Dr. Iván R. González',\n",
              "  'tweet_text': 'A randomized #phase2trial of #pembrolizumab vs pembrolizumab and #acalabrutinib in patients with platinum-resistant metastatic #UrothelialCancer\\nhttps://t.co/gkBDbUbfNo\\n@OncoAlert @KatsuakiMaehara @PGrivasMDPhD\\n@crisbergerot @VivekSubbiah @DrYukselUrun https://t.co/X1JNjpukbd https://t.co/XrWQCCSzgI'},\n",
              " '1298145823746863104': {'tweet_author': 'Ignacio Duran',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resist… https://t.co/t3NNS60FWc'},\n",
              " '1297928009467539456': {'tweet_author': 'ACS Journal Cancer',\n",
              "  'tweet_text': 'US FDA approval of the BTK inhibitor acalabrutinib for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) represents several concerning patterns in trial design and drug approvals in BTK inhibitors. https://t.co/hc5fikstQ9 @VPrasadMDMPH https://t.co/LQY8LNE1qR'},\n",
              " '1297919537220923394': {'tweet_author': 'Medicine Matters oncology',\n",
              "  'tweet_text': 'News: Adding acalabrutinib to pembrolizumab in patients with metastatic #UrothelialCancer does not improve outcomes, report @TiansterZhang @Daniel_J_George et al in @JournalCancer w/ accompanying editorial by @PGrivasMDPhD @uroupdate @WileyNews @DukeCancer https://t.co/w5VcLsCn6l'},\n",
              " '1297238004990435329': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia from @medivizor: https://t.co/gL8tkhWkIC #Leukemia'},\n",
              " '1297218236866531328': {'tweet_author': 'CancerNetwork®, Home of the Journal ONCOLOGY®',\n",
              "  'tweet_text': '#ICYMI: Both the phase 2 ACE-CL-001 trial and the pivotal phase 3 ASCEND trial showed the long-term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/RZPyIWgYyH'},\n",
              " '1297078692448002048': {'tweet_author': 'CureHuntr',\n",
              "  'tweet_text': '#clinicaltrial REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) https://t.co/OG362S7KoB'},\n",
              " '1297075104334188545': {'tweet_author': 'TrialBulletin',\n",
              "  'tweet_text': 'REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL): Status: Not yet recruiting, \\nCondition Summary: CLL/SLL https://t.co/6nYRRENC79'},\n",
              " '1296885193425465344': {'tweet_author': 'OncologyNurseAdvisor',\n",
              "  'tweet_text': 'The addition of acalabrutinib to pembrolizumab failed to improve objective response rate, progression-free survival, and overall survival (OS) among patients with platinum-resistant metastatic urothelial cancer, according to the results of a phase 2 study.\\nhttps://t.co/ppkhetW0EB'},\n",
              " '1296835102220181504': {'tweet_author': 'Fondation ARC',\n",
              "  'tweet_text': \"Suivi à long terme d'une thérapie ciblée pour les patients atteints de leucémie lymphoïde chronique. Près de 100% de réponse après 4 ans de traitement.\\n#acalabrutinib #LLC \\nhttps://t.co/sVBXwVqjkv\"},\n",
              " '1296762985600266242': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) https://t.co/VQtrqcKabw #CLL #leusm #hematology'},\n",
              " '1296472069690003456': {'tweet_author': 'Renal & Urology News',\n",
              "  'tweet_text': 'Acalabrutinib plus pembrolizumab failed to improve outcomes in relapsed mUC https://t.co/2qOFgtT8NQ'},\n",
              " '1296466076977500161': {'tweet_author': 'Hematology Advisor',\n",
              "  'tweet_text': 'Nurse-led approaches for facilitating patient adherence to treatment with acalabrutinib for relapsed/refractory #MCL were described in the Clinical Journal of #Oncology Nursing, which center on educating patients and monitoring treatment adherence and AEs. https://t.co/tW0wCSbOpt'},\n",
              " '1296160361943629826': {'tweet_author': 'CancerTherapyAdvisor',\n",
              "  'tweet_text': 'Nurse-led approaches for facilitating patient adherence to treatment with acalabrutinib for relapsed/refractory mantle cell #lymphoma (MCL) described in a new report published in the Clinical Journal of Oncology Nursing– https://t.co/0mBT8SJyqT'},\n",
              " '1296070230582624256': {'tweet_author': 'CONQUER the patient voice',\n",
              "  'tweet_text': 'The treatment of patients with #CLL has changed dramatically with the introduction of drugs that target the B-cell antigen receptor pathway. Learn more about the first-line treatment with Calquence, and its long-term responses: https://t.co/VfRNEMaCBZ'},\n",
              " '1295843322540498944': {'tweet_author': 'Amer. Urol. Assn.',\n",
              "  'tweet_text': 'Acalabrutinib Plus Pembrolizumab Failed to Improve Outcomes in Relapsed mUC https://t.co/DTC9nUiYq1'},\n",
              " '1295843187228057601': {'tweet_author': 'OncologyNurseAdvisor',\n",
              "  'tweet_text': 'A new report presents a review of strategies that facilitate AE management and medication adherence among patients receiving acalabrutinib to treat mantle cell lymphoma. https://t.co/iHQfe4XEof #lymphoma'},\n",
              " '1295752755643129858': {'tweet_author': 'OncologyNurseAdvisor',\n",
              "  'tweet_text': 'A new report presents a review of strategies that facilitate AE management and medication adherence among patients receiving acalabrutinib to treat MCL. https://t.co/iHQfe4XEof #lymphoma'},\n",
              " '1295707356559441922': {'tweet_author': 'univadis',\n",
              "  'tweet_text': '75 Patienten mit platinrefraktärem metastasiertem Urothelkarzinom wurden randomisiert Pembrolizumab mit oder ohne Acalabrutinib zugeteilt.\\nhttps://t.co/Z8AiVSL2TG https://t.co/P99r6YJV1S'},\n",
              " '1295556062255423500': {'tweet_author': 'OncLive.com',\n",
              "  'tweet_text': 'WATCH: Ian Flinn, MD, of @SarahCannonDocs; Tycel Jovelle Phillips, MD, of @UMich; Bijal Shah, MD, of @MoffittNews; and Javier Munoz, MD, FACP, of @MayoClinic, discuss the use of acalabrutinib in R/R mantle cell lymphoma. #lymsm https://t.co/JkII75IUXL https://t.co/HUyH7gHJJV'},\n",
              " '1295382409660293120': {'tweet_author': 'CancerTherapyAdvisor',\n",
              "  'tweet_text': 'Acalabrutinib plus pembrolizumab failed to improve outcomes in relapsed metastatic urothelial cancer.  https://t.co/eFbLJBJI3m #cancer'},\n",
              " '1295123438730752000': {'tweet_author': 'TekCrispy',\n",
              "  'tweet_text': 'Estudio revela que el medicamento acalabrutinib, aprobado por la FDA, puede calmar la tormenta de citoquinas en pacientes con coronavirus. https://t.co/7v1Ycwc6So https://t.co/vDJE6pLiOp'},\n",
              " '1294715870288261121': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia https://t.co/fZ4hYFhTO4'},\n",
              " '1294397143923470339': {'tweet_author': 'CURE Magazine',\n",
              "  'tweet_text': 'Follow-up data further support the use of Calquence in patients with relapsed or refractory chronic lymphocytic leukemia. https://t.co/KEoj5C0DHR'},\n",
              " '1294320940449443842': {'tweet_author': 'garvs',\n",
              "  'tweet_text': 'They’re just rolling in now! \\n\\nThis is an ad for Acalabrutinib, which is a cancer drug of unknown effectiveness that @AstraZeneca charges over $14,000/month for \\n\\nIn 2010, AZ paid half a billion dollars for using paid shills to sell a drug to patients it wasn’t meant for https://t.co/ok68flYykp'},\n",
              " '1293633585992347650': {'tweet_author': 'Alejandro de Bary',\n",
              "  'tweet_text': 'Hay 10 ensayos clínicos en Perú relacionados al Covid.\\nLos tratamientos en prueba son:\\nPlasma (3)\\nIvermectina\\nMavrilimumab\\nRuxolitinib\\nAcalabrutinib\\nHidroxicloroquina\\nTocilzumab\\nSolidaridad (OMS - 4 fármacos)\\n\\nResultados habrá recién en unos meses'},\n",
              " '1292806412003717120': {'tweet_author': 'Paperbirds_Hematology',\n",
              "  'tweet_text': 'New clinical trial: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia https://t.co/idy1UePkfC #CLL #leusm #hematology'},\n",
              " '1292510991834591238': {'tweet_author': 'Specialty Pharmacy Continuum',\n",
              "  'tweet_text': 'Cancer drugs may dampen #cytokinestorm that occurs in patients with severe #COVID19. https://t.co/sED87kMI7a @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1292234300805570561': {'tweet_author': 'CancerNetwork®, Home of the Journal ONCOLOGY®',\n",
              "  'tweet_text': '#ICYMI: Both the phase 2 ACE-CL-001 trial and the pivotal phase 3 ASCEND trial showed the long-term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia.\\nhttps://t.co/pDysrG92ZC'},\n",
              " '1292211091737661440': {'tweet_author': 'PharmacyPhunQuiz',\n",
              "  'tweet_text': 'This is your Name Game—Real or Fake edition. Here are four “Bruton Tyrosine Kinase (BTK) inhibitors.” Only three are real. Can you ID the FAKE?\\n\\nA. Ibrutinib\\nB. Zanubrutinib\\nC. Oceabrutinib\\nD. Acalabrutinib\\n\\nThe answer is in the thread'},\n",
              " '1292153028326428673': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'Learn more: Acalabrutinib in patients with relapsed or refractory chronic lymphocy... https://t.co/gL8tkhWkIC #Leukemia (via @medivizor)'},\n",
              " '1291863572201353217': {'tweet_author': 'ImmunotherapyPapers',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. https://t.co/41WW4RQ5mt'},\n",
              " '1291844542472347649': {'tweet_author': 'Maria Badillo, MSN RN OCN CCRP',\n",
              "  'tweet_text': 'Our article is finally published @OncologyNursing #ONSCJON from our colleagues @MDAndersonNews with @michaelwangmd. So happy to share how we manage our #MCL patients taking #acalabrutinib. @AstraZeneca @AstraZenecaUS @CarolPorterDNP https://t.co/2N9FomgO0Q'},\n",
              " '1291840309563985923': {'tweet_author': 'CURE Magazine',\n",
              "  'tweet_text': 'Follow-up data further support the use of Calquence versus standard-of-care regimens in patients with relapsed or refractory chronic lymphocytic leukemia. https://t.co/OCrWbq0hxY'},\n",
              " '1291809850398130178': {'tweet_author': 'Immuno-Oncology',\n",
              "  'tweet_text': 'A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. https://t.co/DAD2kOReUG https://t.co/4LskC12bqj'},\n",
              " '1291180941621317632': {'tweet_author': 'オンコロ',\n",
              "  'tweet_text': '#慢性リンパ性 #白血病 に対して #Calquence（#アカラブルチニブ）が欧州医薬品評価委員会より製造販売承認を取得\\n#英アストラゼネカ社\\nhttps://t.co/jqgOOkZPUU'},\n",
              " '1291164002299584514': {'tweet_author': 'Guru Sonpavde, MD',\n",
              "  'tweet_text': 'Acalabrutinib (BTK inhibitors deplete MDSCs) + pembro did not improve outcomes vs. pembro in a randomized phase II trial of unselected post-platinum metastatic #UrothelialCarcinoma: need greater role for better patient selection informed by preclinical / early clinical data? https://t.co/poff08nz5P'},\n",
              " '1291046687226691584': {'tweet_author': 'Trip Database',\n",
              "  'tweet_text': 'New2Trip: ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia https://t.co/fZ4hYFhTO4'},\n",
              " '1291046627281719301': {'tweet_author': 'Nash Peters',\n",
              "  'tweet_text': 'https://t.co/9ZsAzXbeaS Phase I: Acalabrutinib (CALQUENCE® by @AstraZeneca) suspension via nasogastric co-administered with a PPI, in the treatment of #COVID19 Calquence\\xa0is a selective BTK inhibitor currently approved in the US for treatment of certain haematological malignancies'},\n",
              " '1291044327104196608': {'tweet_author': 'Ali Khaki',\n",
              "  'tweet_text': 'Just published in @JournalCancer an editorial @neerajaiims @montypal @PGrivasMDPhD and I wrote reviewing RAPID CHECK phase 2 trial of acalabrutinib and pembrolizumab led by @TiansterZhang.\\n\\nWe review the trial and the broader IO trial landscape for aUC\\n\\nhttps://t.co/PvkAgmNWLZ'},\n",
              " '1291037572437770241': {'tweet_author': 'ACS Journal Cancer',\n",
              "  'tweet_text': 'Available via #OpenAccess | A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer https://t.co/1oRQIihY5m\\n\\nAccompanying editorial 👉 https://t.co/13efSsgXZd https://t.co/71ELqDZbHT'},\n",
              " '1290681419245727745': {'tweet_author': 'InfectiousDiseaseAdv',\n",
              "  'tweet_text': 'In this study, #emergency, unregistered use of acalabrutinib was available to patients hospitalized with advanced #COVID-19 in accordance with the #WHO MEURI guidelines. #IDATwitter https://t.co/om3lk6Wic1'},\n",
              " '1290679648876220425': {'tweet_author': 'LymphomaAction',\n",
              "  'tweet_text': 'The European Medicines Agency has approved a new drug called acalabrutinib for people with chronic lymphocytic leukaemia (CLL). Read more here &gt; https://t.co/KHiApCvoYx @EMA_News #Lymphoma #LymphomaMatters https://t.co/3fcyHwPR2s'},\n",
              " '1290583670345084928': {'tweet_author': 'Hématologie',\n",
              "  'tweet_text': 'Acalabrutinib : une véritable avancée pour la prise en charge de la leucémie lymphoïde chronique en rechute ou réfractaire ? https://t.co/VDhZyzoMcx\\n#ActusHemato par Laly Nsiala et Cécile Tomowiak https://t.co/iod5JLQkpV'},\n",
              " '1290439030518304771': {'tweet_author': 'いきいき健康村',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 https://t.co/HUtIogI822 @PRTIMES_JPより'},\n",
              " '1290349681323589634': {'tweet_author': 'ゆめびと',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 https://t.co/mV65g3AHBR @PRTIMES_JPより'},\n",
              " '1290279615768825856': {'tweet_author': 'MD Anderson Leukemia',\n",
              "  'tweet_text': 'New #clinicaltrial #2019-0565\\nPhase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Pts w/ Chronic Lymphocytic #Leukemia (#CLL) | PI: @wwierda of @MDAndersonNews #Leukemia | NCT04169737 | https://t.co/sTeip1cuWp | #endcancer #leusm'},\n",
              " '1290260604091949056': {'tweet_author': 'ダビデ🧬Aqoursドームツアー成功祈願🐳',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、新型コロナウイルス感染症19例の入院患者さんの大多数において有望な臨床効果を示す https://t.co/HNMj3RvIb5 @PRTIMES_JPから'},\n",
              " '1290259572108570624': {'tweet_author': 'ダビデ🧬Aqoursドームツアー成功祈願🐳',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 https://t.co/DNN1X8krFo @PRTIMES_JPから\\n\\nこれコロナ治療薬としても期待されてるのに日本では未承認なんだよな、早く治験開始してくれや'},\n",
              " '1290179751718432768': {'tweet_author': 'NEWSRELEA.SE',\n",
              "  'tweet_text': 'アストラゼネカ株式会社、アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 https://t.co/vA3dbNbhMx'},\n",
              " '1290147919228592128': {'tweet_author': 'JPubb 日本企業 リリース 医薬品',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として、欧州医薬品評価委員会より承認勧告を取得 〔08/03 アストラゼネカ〕 https://t.co/OmGT3ytdvY'},\n",
              " '1290115396184367105': {'tweet_author': 'PR TIMESビジネス',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認... https://t.co/b7yZnhKtSV'},\n",
              " '1290107690266423297': {'tweet_author': '薬剤師ニュース配信くん',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 - PR TIMES\\nhttps://t.co/u2CCPbRCoi'},\n",
              " '1290107560561803264': {'tweet_author': 'PR TIMESニュース',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認... https://t.co/MF82C2FUsV'},\n",
              " '1290105747829747712': {'tweet_author': 'WMR Tokyo - スタートアップ',\n",
              "  'tweet_text': 'アストラゼネカのアカラブルチニブ（Calquence）、慢性リンパ性白血病の治療薬として欧州医薬品評価委員会より承認勧告を取得 https://t.co/BRxYuFm6Vz'},\n",
              " '1290018340069617671': {'tweet_author': 'Specialty Pharmacy Continuum',\n",
              "  'tweet_text': 'Cancer drugs tapped for #COVID19 to dampen #cytokinestorm that occurs in patients with severe COVID-19.\\nhttps://t.co/iHzza2HhCZ @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1289939453646053376': {'tweet_author': 'InfectiousDiseaseSE',\n",
              "  'tweet_text': 'Cancer drugs tapped for #COVID19 to dampen #cytokinestorm that occurs in patients with severe COVID-19. https://t.co/uKPNFJ6OGY @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1289668517730689027': {'tweet_author': 'ClinicalOncologyNews',\n",
              "  'tweet_text': 'Myriad trials are testing immunomodulating blood cancer agents to combat cytokine storm in patients with severe COVID-19. https://t.co/9DRadaTVFz \\n@AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #COVID19 #calquence #BTKinhibitors'},\n",
              " '1289580473065201664': {'tweet_author': 'Pharmacy Practice News',\n",
              "  'tweet_text': 'Cancer drugs tapped for #COVID19 to dampen #cytokinestorm that occurs in patients with severe COVID-19.\\nhttps://t.co/VieMlD8zkL @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1289568571010375680': {'tweet_author': 'COTA, Inc.',\n",
              "  'tweet_text': 'Researchers are exploring #BTK inhibitors &amp; other blood #cancer drugs for COVID-19. A study found the BTK inhibitor acalabrutinib showed benefit in a small uncontrolled case series of hospitalized patients with severe #COVID-19. Learn more: https://t.co/fBkHoxQGIm @PharmPracNews'},\n",
              " '1288989406246785024': {'tweet_author': 'Pete Afrasiabi',\n",
              "  'tweet_text': '#CNNTownHall \\nAcalabrutinib showing 80 percent improvement in patients on oxygen and 50 percent improvement for those on ventilators, all being discharged in a small off-label study. Can FDA do an EUA for small studies similar to this one?'},\n",
              " '1288885957400432640': {'tweet_author': 'Pharmacy Practice News',\n",
              "  'tweet_text': 'Cancer drugs tapped for #COVID19 to dampen #cytokinestorm that occurs in patients with severe COVID-19.\\nhttps://t.co/VieMlCQYtd @AstraZeneca @LLSusa @DrDonaldHarvey @theNCI @sloan_kettering @DanaFarber @LeedsHospitals #calquence #BTKinhibitors'},\n",
              " '1288871993530515456': {'tweet_author': 'ESMO - Eur. Oncology',\n",
              "  'tweet_text': 'EMA Recommends Marketing Authorisation for Acalabrutinib, a Bruton #tyrosinekinaseinhibitor, intended for the treatment of chronic lymphocytic #leukaemia https://t.co/9CsrnveQrh #leusm https://t.co/EMJmTEX6oY'},\n",
              " '1288821559512182787': {'tweet_author': 'Ärzte Zeitung',\n",
              "  'tweet_text': 'Acalabrutinib zur Zulassung als CLL-Arznei empfohlen\\nEin wesentlicher Treiber der chronisch lymphatischen Leukämie ist der B-Zell-Rezeptor-Signalweg, in dem die Bruton-Tyrosinkinase (BTK) eine zentrale Position einnimmt. Acalabrutinib hemmt die BTK.\\nhttps://t.co/KbuuknkMd8 https://t.co/gDm17XsgCK'},\n",
              " '1288719649320980480': {'tweet_author': 'Medivizor',\n",
              "  'tweet_text': 'New by @Medivizor: Acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https://t.co/gL8tkhWkIC #Leukemia'},\n",
              " '1288686006607249408': {'tweet_author': 'AGD Biomedicals',\n",
              "  'tweet_text': 'From Medscape Hematology-Oncology Headlines&gt;&gt;https://t.co/Hl1ujxcSVu Green Light for Avapritinib for GIST, Acalabrutinib for CLL'},\n",
              " '1288637051412156416': {'tweet_author': 'Ronald M. Chavin',\n",
              "  'tweet_text': \"7-29-2020:  Both AstraZeneca's acalabrutinib and Janssen/Pharmacyclic's ibrutinib are BTK-inhibiting cancer drugs being tested against mid-stage COVID-19 in separate clinical trials:\\nhttps://t.co/F5vuINapKS\\nhttps://t.co/uu2e3JxXwJ\\nhttps://t.co/8JwlIjSHTd\\nhttps://t.co/B4marO45lv\"},\n",
              " ...}"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "temp='tweet_author'\n",
        "lst1 = [val[temp] for key, val in df.items() if temp in val]\n",
        "\n",
        "temp1='tweet_text'\n",
        "lst2 = [val[temp1] for key, val in df.items() if temp1 in val]\n",
        "\n",
        "#Dropping id as it is of no use\n",
        "data = pd.DataFrame(list(zip(lst1, lst2)),\n",
        "               columns =['tweet_author', 'tweet_text'])\n",
        "\n",
        "#For use in objective 2 making a copy of data\n",
        "data_copy=data.copy()\n",
        "     "
      ],
      "metadata": {
        "id": "-3x7XoykHE0S"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "XwQkYEoLHOVC",
        "outputId": "c1d14928-614d-449f-b6e8-2a03db1b3873"
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...\n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...\n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...\n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...\n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...\n",
              "...                   ...                                                ...\n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...\n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...\n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...\n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...\n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...\n",
              "\n",
              "[43347 rows x 2 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-be57c29d-adf2-43c4-859c-830fb18b8864\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 2 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-be57c29d-adf2-43c4-859c-830fb18b8864')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-be57c29d-adf2-43c4-859c-830fb18b8864 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-be57c29d-adf2-43c4-859c-830fb18b8864');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_pattern(input_txt, pattern):\n",
        "    r = re.findall(pattern, input_txt)\n",
        "    for i in r:\n",
        "        input_txt = re.sub(i, '', input_txt)\n",
        "    return input_txt"
      ],
      "metadata": {
        "id": "KSZ9jjiIHPmj"
      },
      "execution_count": 12,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install Translator"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lEAImXpYHSWk",
        "outputId": "3f4aea76-cdd4-47cb-83f7-4100e4296c2d"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting Translator\n",
            "  Downloading translator-0.0.9-py3-none-any.whl (5.3 kB)\n",
            "Requirement already satisfied: beautifulsoup4>=4.0 in /usr/local/lib/python3.8/dist-packages (from Translator) (4.6.3)\n",
            "Installing collected packages: Translator\n",
            "Successfully installed Translator-0.0.9\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from googletrans import Translator\n"
      ],
      "metadata": {
        "id": "hwbiGicCHV6S"
      },
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Converting Tweets into English\n",
        "\n",
        "#Function for translating the tweets into English\n",
        "translator = Translator(service_urls=[\n",
        "      'translate.google.com',\n",
        "      'translate.google.co.kr',\n",
        "    ])\n",
        "data['tweet_text'].astype(str)\n",
        "data = data.loc[data['tweet_text'] != '']\n",
        "\n",
        "#Replacing '.' with '. ' for Data translation issue\n",
        "data['tweet_text'] = data['tweet_text'].str.replace('.', '. ',regex=True)\n",
        " \n",
        "#Some tweets are in japanese so converting it into english\n",
        "#data['tweet_text']=data['tweet_text'].apply(translator.translate, src='ja', dest='en').apply(getattr, args=('text',))\n",
        "# data['clean_tweet']=data['clean_tweet'].apply(translator.translate, src='hi', dest='en').apply(getattr, args=('text',))"
      ],
      "metadata": {
        "id": "ja972epXHYQj"
      },
      "execution_count": 15,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "vip1oAD8HbBC",
        "outputId": "9bbbfbe8-8809-40e1-d414-934ac0cfc42a"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...\n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...\n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...\n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...\n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...\n",
              "...                   ...                                                ...\n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...\n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...\n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...\n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...\n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...\n",
              "\n",
              "[43347 rows x 2 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ab668fba-eab1-4415-aa91-2ffe913526a0\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 2 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ab668fba-eab1-4415-aa91-2ffe913526a0')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-ab668fba-eab1-4415-aa91-2ffe913526a0 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-ab668fba-eab1-4415-aa91-2ffe913526a0');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#removing hashtags (word starting with #)\n",
        "data['clean_tweet'] = np.vectorize(remove_pattern)(data['tweet_text'], \"#[\\w]*\")\n",
        "\n",
        "#removing hashtags (word starting with https)\n",
        "data['clean_tweet'] = np.vectorize(remove_pattern)(data['clean_tweet'], \"https[\\w]*\")\n",
        "\n",
        "#remove user, https, and RT\n",
        "data['clean_tweet'] = np.vectorize(remove_pattern)(data['clean_tweet'], \"https|RT|@[\\w]*\")\n",
        "\n",
        "#remove punctuations\n",
        "data['clean_tweet'] = data['clean_tweet'].str.replace(\"[^a-zA-Z#]\", \" \")\n",
        "\n",
        "#lowering string\n",
        "data['clean_tweet'] = data['clean_tweet'].str.lower()\n",
        "\n",
        "#remove stop words\n",
        "stop_words = set(stopwords.words('english')) \n",
        "\n",
        "\n",
        "# #remove words with len < 2\n",
        "data['clean_tweet'] = data['clean_tweet'].apply(lambda x: ' '.join([w for w in x.split() if len(w)>2]))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "TMppgOlpHdUC",
        "outputId": "7c518e44-1606-43cc-dc0c-6aca14539333"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-17-3828b6d18eac>:11: FutureWarning: The default value of regex will change from True to False in a future version.\n",
            "  data['clean_tweet'] = data['clean_tweet'].str.replace(\"[^a-zA-Z#]\", \" \")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Creating a list of clean tweets \n",
        "data['clean_tweet'] = [' '.join([w for w in x.lower().split() if w not in stop_words]) \n",
        "    for x in data['clean_tweet'].tolist()]"
      ],
      "metadata": {
        "id": "EhV_-gkwHgpC"
      },
      "execution_count": 18,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "XPKLh2xXHlWC",
        "outputId": "ee098587-6cc1-4445-a3ed-c3bfd4dd119d"
      },
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text  \\\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...   \n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...   \n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...   \n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...   \n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...   \n",
              "...                   ...                                                ...   \n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...   \n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...   \n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...   \n",
              "\n",
              "                                             clean_tweet  \n",
              "0      scientists conducted phase study acalabrutinib...  \n",
              "1      phase acalabrutinib venetoclax trial still rec...  \n",
              "2                                          backs lpdogra  \n",
              "3      valuable option pts intolerant valuable data h...  \n",
              "4      nice recommended use acalabrutinib patients tr...  \n",
              "...                                                  ...  \n",
              "43342                    hanging friends http pdleww bbb  \n",
              "43343                     hanging friends http gynchdnul  \n",
              "43344  zusatznutzen von ist weder noch refrakt res fo...  \n",
              "43345  ptk expression immunochemotherapy outcome chro...  \n",
              "43346  mutations tlr myd pathway identify subset youn...  \n",
              "\n",
              "[43347 rows x 3 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-64437e0d-ee22-410d-a6e3-6f7cac81cab5\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "      <th>clean_tweet</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "      <td>scientists conducted phase study acalabrutinib...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "      <td>phase acalabrutinib venetoclax trial still rec...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "      <td>backs lpdogra</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "      <td>valuable option pts intolerant valuable data h...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "      <td>nice recommended use acalabrutinib patients tr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http pdleww bbb</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http gynchdnul</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "      <td>zusatznutzen von ist weder noch refrakt res fo...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "      <td>ptk expression immunochemotherapy outcome chro...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "      <td>mutations tlr myd pathway identify subset youn...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 3 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-64437e0d-ee22-410d-a6e3-6f7cac81cab5')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-64437e0d-ee22-410d-a6e3-6f7cac81cab5 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-64437e0d-ee22-410d-a6e3-6f7cac81cab5');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 19
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "print(data['tweet_text'][0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "UXumorXGHnJk",
        "outputId": "dce21aca-25a5-40b5-aedb-a2ccdcc180e6"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "⚕️ Scientists conducted a Phase II study of acalabrutinib in patients with relapsed/refractory #CLL who were ibrutinib-intolerant, and found an overall response rate of 73%.  \n",
            "https://t. co/eJ6m4QpC5P https://t. co/kuZz6ZO47r\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(data[\"clean_tweet\"][0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gO4shR_4Hsxy",
        "outputId": "27480e70-23e3-4739-8bce-63bd806a368d"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "scientists conducted phase study acalabrutinib patients relapsed refractory ibrutinib intolerant found overall response rate qpc kuzz\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from textblob import TextBlob\n",
        "wiki = TextBlob('Pink Pearl Apples are tasty but Empire Apples are not.')# checking polarity of given sentence\n",
        "wiki.noun_phrases\n",
        "     "
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "WpnyEKMcHvuh",
        "outputId": "81f37fdc-68e2-4c0e-80be-b9c23d436694"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "WordList(['pink pearl apples', 'apples'])"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def blob(text):\n",
        "  return TextBlob(text).noun_phrases\n",
        "\n",
        "Entities = data['clean_tweet'].apply(blob)\n",
        "data[\"entities\"]=Entities"
      ],
      "metadata": {
        "id": "SYIrHzC1Hy32"
      },
      "execution_count": 23,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "4XI4BXgjH23i",
        "outputId": "6ffa7e5e-35e1-4c1e-867f-2090a7027d7d"
      },
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text  \\\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...   \n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...   \n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...   \n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...   \n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...   \n",
              "...                   ...                                                ...   \n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...   \n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...   \n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...   \n",
              "\n",
              "                                             clean_tweet  \\\n",
              "0      scientists conducted phase study acalabrutinib...   \n",
              "1      phase acalabrutinib venetoclax trial still rec...   \n",
              "2                                          backs lpdogra   \n",
              "3      valuable option pts intolerant valuable data h...   \n",
              "4      nice recommended use acalabrutinib patients tr...   \n",
              "...                                                  ...   \n",
              "43342                    hanging friends http pdleww bbb   \n",
              "43343                     hanging friends http gynchdnul   \n",
              "43344  zusatznutzen von ist weder noch refrakt res fo...   \n",
              "43345  ptk expression immunochemotherapy outcome chro...   \n",
              "43346  mutations tlr myd pathway identify subset youn...   \n",
              "\n",
              "                                                entities  \n",
              "0      [phase study acalabrutinib patients, refractor...  \n",
              "1      [phase acalabrutinib venetoclax trial, recruit...  \n",
              "2                                        [backs lpdogra]  \n",
              "3      [valuable option pts intolerant, valuable data...  \n",
              "4      [acalabrutinib patients treatment chronic lymp...  \n",
              "...                                                  ...  \n",
              "43342                          [friends http pdleww bbb]  \n",
              "43343                           [friends http gynchdnul]  \n",
              "43344  [zusatznutzen von ist weder noch refrakt res f...  \n",
              "43345  [ptk expression immunochemotherapy outcome chr...  \n",
              "43346  [mutations tlr myd pathway identify subset, yo...  \n",
              "\n",
              "[43347 rows x 4 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-99654ccf-295a-4ace-8a19-49094ab0fd2a\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "      <th>clean_tweet</th>\n",
              "      <th>entities</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "      <td>scientists conducted phase study acalabrutinib...</td>\n",
              "      <td>[phase study acalabrutinib patients, refractor...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "      <td>phase acalabrutinib venetoclax trial still rec...</td>\n",
              "      <td>[phase acalabrutinib venetoclax trial, recruit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "      <td>backs lpdogra</td>\n",
              "      <td>[backs lpdogra]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "      <td>valuable option pts intolerant valuable data h...</td>\n",
              "      <td>[valuable option pts intolerant, valuable data...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "      <td>nice recommended use acalabrutinib patients tr...</td>\n",
              "      <td>[acalabrutinib patients treatment chronic lymp...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http pdleww bbb</td>\n",
              "      <td>[friends http pdleww bbb]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http gynchdnul</td>\n",
              "      <td>[friends http gynchdnul]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "      <td>zusatznutzen von ist weder noch refrakt res fo...</td>\n",
              "      <td>[zusatznutzen von ist weder noch refrakt res f...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "      <td>ptk expression immunochemotherapy outcome chro...</td>\n",
              "      <td>[ptk expression immunochemotherapy outcome chr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "      <td>mutations tlr myd pathway identify subset youn...</td>\n",
              "      <td>[mutations tlr myd pathway identify subset, yo...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 4 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-99654ccf-295a-4ace-8a19-49094ab0fd2a')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-99654ccf-295a-4ace-8a19-49094ab0fd2a button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-99654ccf-295a-4ace-8a19-49094ab0fd2a');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# from functools import reduce\n",
        "# l = reduce(lambda x, y: list(x)+list(y), zip(tokenized_tweet))\n",
        "l=data[\"entities\"]\n",
        "\n",
        "#Counting the most repeated entity\n",
        "flatten = [item for sublist in l for item in sublist]\n",
        "counts = Counter(flatten).most_common()\n",
        "     "
      ],
      "metadata": {
        "id": "wkDiT6gJH8pD"
      },
      "execution_count": 25,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Creating a dataframe\n",
        "entity_df = pd.DataFrame.from_records(counts, columns=['entity', 'frequency'])\n",
        "entity_df['entity']= entity_df['entity'].apply(lambda x: ''.join([w for w in x]))"
      ],
      "metadata": {
        "id": "WUWJZWCRIAoD"
      },
      "execution_count": 26,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "entity_df.head(10)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 363
        },
        "id": "LlF7B-KQIDvS",
        "outputId": "c7d92dcb-010a-42c0-acb5-188a83418e28"
      },
      "execution_count": 27,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                    entity  frequency\n",
              "0             chronic lymphocytic leukemia       1102\n",
              "1                        cancer adults amp        373\n",
              "2                              new article        284\n",
              "3                                new trial        250\n",
              "4  refractory chronic lymphocytic leukemia        216\n",
              "5         chronic lymphocytic leukemia cll        177\n",
              "6                                high risk        163\n",
              "7            powerful new kind cancer drug        162\n",
              "8                             fda approves        159\n",
              "9                        available placebo        155"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-4ec1e3e2-bebc-4c3e-9b7c-f32087cf55cf\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity</th>\n",
              "      <th>frequency</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>chronic lymphocytic leukemia</td>\n",
              "      <td>1102</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>cancer adults amp</td>\n",
              "      <td>373</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>new article</td>\n",
              "      <td>284</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>new trial</td>\n",
              "      <td>250</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>refractory chronic lymphocytic leukemia</td>\n",
              "      <td>216</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>chronic lymphocytic leukemia cll</td>\n",
              "      <td>177</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>high risk</td>\n",
              "      <td>163</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>powerful new kind cancer drug</td>\n",
              "      <td>162</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>fda approves</td>\n",
              "      <td>159</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>available placebo</td>\n",
              "      <td>155</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-4ec1e3e2-bebc-4c3e-9b7c-f32087cf55cf')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-4ec1e3e2-bebc-4c3e-9b7c-f32087cf55cf button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-4ec1e3e2-bebc-4c3e-9b7c-f32087cf55cf');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 27
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Data Visualization with bar graph\n",
        "df_new=entity_df.copy()\n",
        "\n",
        "df_new = df_new.nlargest(columns=\"frequency\", n = 10) \n",
        "plt.figure(figsize=(30,15))\n",
        "ax = sns.barplot(data=df_new, x= \"entity\", y = \"frequency\")\n",
        "ax.set(ylabel = 'frequency')\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 877
        },
        "id": "fgc1KW_CIFgC",
        "outputId": "4bd3fd7f-0fc5-4e68-efd3-303460bbf3fc"
      },
      "execution_count": 48,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2160x1080 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from wordcloud import WordCloud\n"
      ],
      "metadata": {
        "id": "0-6txOHsKS7z"
      },
      "execution_count": 52,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "all_words = ' '.join([text for text in df['clean_tweet']])\n",
        "#Wc = wordcloud(width=800, height=500, random_state=21, max_font_size=110)\n",
        "wc = WordCloud(background_color='white',mode=\"RGB\", width=800 , height=500, max_font_size=110).generate(all_words)\n",
        "\n",
        "plt.figure(figsize=(10, 7))\n",
        "plt.imshow(wc, interpolation='bilinear')\n",
        "plt.axis('off')\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 380
        },
        "id": "M_4rtJLtJ4r9",
        "outputId": "5a1e7c3d-6e4d-46a8-97c6-48d96b5f2b6b"
      },
      "execution_count": 53,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x504 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "entity=entity_df[\"entity\"]\n",
        "entity[0]\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "rB5Cnl1bIJbC",
        "outputId": "4ef54a66-9361-4c05-8d6d-7d9f3e66a095"
      },
      "execution_count": 30,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'chronic lymphocytic leukemia'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 30
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "frequency=entity_df[\"frequency\"]\n",
        "frequency[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "D38biBqLIQ4S",
        "outputId": "858f70f4-36ae-4b9d-aeb2-1b61d9d3568d"
      },
      "execution_count": 31,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1102"
            ]
          },
          "metadata": {},
          "execution_count": 31
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "entity_df.to_csv(\"Objective1.csv\")\n"
      ],
      "metadata": {
        "id": "ui3jUk1RITHy"
      },
      "execution_count": 33,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df=data.copy()"
      ],
      "metadata": {
        "id": "UHPdV1QSIVDy"
      },
      "execution_count": 34,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "_2NA2YngIfII",
        "outputId": "465e5a2b-658d-4ed4-a356-d98395ec251d"
      },
      "execution_count": 35,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text  \\\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...   \n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...   \n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...   \n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...   \n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...   \n",
              "...                   ...                                                ...   \n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...   \n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...   \n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...   \n",
              "\n",
              "                                             clean_tweet  \\\n",
              "0      scientists conducted phase study acalabrutinib...   \n",
              "1      phase acalabrutinib venetoclax trial still rec...   \n",
              "2                                          backs lpdogra   \n",
              "3      valuable option pts intolerant valuable data h...   \n",
              "4      nice recommended use acalabrutinib patients tr...   \n",
              "...                                                  ...   \n",
              "43342                    hanging friends http pdleww bbb   \n",
              "43343                     hanging friends http gynchdnul   \n",
              "43344  zusatznutzen von ist weder noch refrakt res fo...   \n",
              "43345  ptk expression immunochemotherapy outcome chro...   \n",
              "43346  mutations tlr myd pathway identify subset youn...   \n",
              "\n",
              "                                                entities  \n",
              "0      [phase study acalabrutinib patients, refractor...  \n",
              "1      [phase acalabrutinib venetoclax trial, recruit...  \n",
              "2                                        [backs lpdogra]  \n",
              "3      [valuable option pts intolerant, valuable data...  \n",
              "4      [acalabrutinib patients treatment chronic lymp...  \n",
              "...                                                  ...  \n",
              "43342                          [friends http pdleww bbb]  \n",
              "43343                           [friends http gynchdnul]  \n",
              "43344  [zusatznutzen von ist weder noch refrakt res f...  \n",
              "43345  [ptk expression immunochemotherapy outcome chr...  \n",
              "43346  [mutations tlr myd pathway identify subset, yo...  \n",
              "\n",
              "[43347 rows x 4 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d27d7ed2-1896-43b0-a222-41c64118a50f\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "      <th>clean_tweet</th>\n",
              "      <th>entities</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "      <td>scientists conducted phase study acalabrutinib...</td>\n",
              "      <td>[phase study acalabrutinib patients, refractor...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "      <td>phase acalabrutinib venetoclax trial still rec...</td>\n",
              "      <td>[phase acalabrutinib venetoclax trial, recruit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "      <td>backs lpdogra</td>\n",
              "      <td>[backs lpdogra]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "      <td>valuable option pts intolerant valuable data h...</td>\n",
              "      <td>[valuable option pts intolerant, valuable data...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "      <td>nice recommended use acalabrutinib patients tr...</td>\n",
              "      <td>[acalabrutinib patients treatment chronic lymp...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http pdleww bbb</td>\n",
              "      <td>[friends http pdleww bbb]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>hanging friends http gynchdnul</td>\n",
              "      <td>[friends http gynchdnul]</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "      <td>zusatznutzen von ist weder noch refrakt res fo...</td>\n",
              "      <td>[zusatznutzen von ist weder noch refrakt res f...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "      <td>ptk expression immunochemotherapy outcome chro...</td>\n",
              "      <td>[ptk expression immunochemotherapy outcome chr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "      <td>mutations tlr myd pathway identify subset youn...</td>\n",
              "      <td>[mutations tlr myd pathway identify subset, yo...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 4 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d27d7ed2-1896-43b0-a222-41c64118a50f')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-d27d7ed2-1896-43b0-a222-41c64118a50f button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-d27d7ed2-1896-43b0-a222-41c64118a50f');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 35
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Importing required library\n",
        "import pandas as pd\n",
        "import re\n",
        "import plotly.express as px\n",
        "import nltk\n",
        "import spacy"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KmFYaLQ3IgLi",
        "outputId": "a272b4f5-8fcd-409a-f574-7f4c91de2bf9"
      },
      "execution_count": 36,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.8/dist-packages/torch/cuda/__init__.py:497: UserWarning: Can't initialize NVML\n",
            "  warnings.warn(\"Can't initialize NVML\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp = spacy.load('en_core_web_sm')\n"
      ],
      "metadata": {
        "id": "GjZsm4GrIoTS"
      },
      "execution_count": 37,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install vaderSentiment\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pzyZpu1QIr3B",
        "outputId": "29b5bb3b-945d-4583-d9bd-c05f158464a1"
      },
      "execution_count": 38,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting vaderSentiment\n",
            "  Downloading vaderSentiment-3.3.2-py2.py3-none-any.whl (125 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m126.0/126.0 KB\u001b[0m \u001b[31m3.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: requests in /usr/local/lib/python3.8/dist-packages (from vaderSentiment) (2.25.1)\n",
            "Requirement already satisfied: chardet<5,>=3.0.2 in /usr/local/lib/python3.8/dist-packages (from requests->vaderSentiment) (3.0.4)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.8/dist-packages (from requests->vaderSentiment) (2.10)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.8/dist-packages (from requests->vaderSentiment) (2022.12.7)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.8/dist-packages (from requests->vaderSentiment) (1.24.3)\n",
            "Installing collected packages: vaderSentiment\n",
            "Successfully installed vaderSentiment-3.3.2\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Importing the library\n",
        "from vaderSentiment.vaderSentiment import SentimentIntensityAnalyzer\n",
        "from nltk.sentiment.util import *\n",
        "\n",
        "#Sentiment Analysis\n",
        "SIA = SentimentIntensityAnalyzer()\n",
        "\n",
        "df[\"clean_tweet\"]= df[\"entities\"].astype(str)\n",
        "# Applying Model, Variable Creation\n",
        "df['Polarity Score']=df[\"entities\"].apply(lambda x:SIA.polarity_scores(x)['compound'])\n",
        "df['Neutral Score']=df[\"entities\"].apply(lambda x:SIA.polarity_scores(x)['neu'])\n",
        "df['Negative Score']=df[\"entities\"].apply(lambda x:SIA.polarity_scores(x)['neg'])\n",
        "df['Positive Score']=df[\"entities\"].apply(lambda x:SIA.polarity_scores(x)['pos'])\n",
        "\n",
        "\n",
        "# Converting 0 to 1 Decimal Score to a Categorical Variable\n",
        "df['overall polarity']=''\n",
        "df.loc[df['Polarity Score']>0,'overall polarity']='Positive'\n",
        "df.loc[df['Polarity Score']==0,'overall polarity']='Neutral'\n",
        "df.loc[df['Polarity Score']<0,'overall polarity']='Negative'\n",
        "df[:5]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "YxTAMFkCIv5S",
        "outputId": "ffcc1813-2330-4534-b8b4-beb7666f5228"
      },
      "execution_count": 39,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         tweet_author                                         tweet_text  \\\n",
              "0  Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...   \n",
              "1    Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...   \n",
              "2         1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...   \n",
              "3           Toby Eyre  #acalabrutinib is a valuable option in pts int...   \n",
              "4        Lymphoma Hub  NICE has recommended the use of acalabrutinib ...   \n",
              "\n",
              "                                         clean_tweet  \\\n",
              "0  ['phase study acalabrutinib patients', 'refrac...   \n",
              "1  ['phase acalabrutinib venetoclax trial', 'recr...   \n",
              "2                                  ['backs lpdogra']   \n",
              "3  ['valuable option pts intolerant', 'valuable d...   \n",
              "4  ['acalabrutinib patients treatment chronic lym...   \n",
              "\n",
              "                                            entities  Polarity Score  \\\n",
              "0  [phase study acalabrutinib patients, refractor...          0.0000   \n",
              "1  [phase acalabrutinib venetoclax trial, recruit...          0.0000   \n",
              "2                                    [backs lpdogra]         -0.0516   \n",
              "3  [valuable option pts intolerant, valuable data...          0.4767   \n",
              "4  [acalabrutinib patients treatment chronic lymp...          0.0000   \n",
              "\n",
              "   Neutral Score  Negative Score  Positive Score overall polarity  \n",
              "0          1.000           0.000           0.000          Neutral  \n",
              "1          1.000           0.000           0.000          Neutral  \n",
              "2          0.455           0.545           0.000         Negative  \n",
              "3          0.693           0.000           0.307         Positive  \n",
              "4          1.000           0.000           0.000          Neutral  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-db2c886d-8511-485f-be55-fdbce137fb3b\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "      <th>clean_tweet</th>\n",
              "      <th>entities</th>\n",
              "      <th>Polarity Score</th>\n",
              "      <th>Neutral Score</th>\n",
              "      <th>Negative Score</th>\n",
              "      <th>Positive Score</th>\n",
              "      <th>overall polarity</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "      <td>['phase study acalabrutinib patients', 'refrac...</td>\n",
              "      <td>[phase study acalabrutinib patients, refractor...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "      <td>['phase acalabrutinib venetoclax trial', 'recr...</td>\n",
              "      <td>[phase acalabrutinib venetoclax trial, recruit...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "      <td>['backs lpdogra']</td>\n",
              "      <td>[backs lpdogra]</td>\n",
              "      <td>-0.0516</td>\n",
              "      <td>0.455</td>\n",
              "      <td>0.545</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Negative</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "      <td>['valuable option pts intolerant', 'valuable d...</td>\n",
              "      <td>[valuable option pts intolerant, valuable data...</td>\n",
              "      <td>0.4767</td>\n",
              "      <td>0.693</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.307</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "      <td>['acalabrutinib patients treatment chronic lym...</td>\n",
              "      <td>[acalabrutinib patients treatment chronic lymp...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-db2c886d-8511-485f-be55-fdbce137fb3b')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-db2c886d-8511-485f-be55-fdbce137fb3b button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-db2c886d-8511-485f-be55-fdbce137fb3b');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 39
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df2=df.copy()\n",
        "df2"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 537
        },
        "id": "17q56sQjIzLy",
        "outputId": "7ecc3903-7fdd-4044-e271-cecb6db9c9df"
      },
      "execution_count": 40,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                         tweet_text  \\\n",
              "0      Hematopoiesis News  ⚕️ Scientists conducted a Phase II study of ac...   \n",
              "1        Michael Wang, MD  This phase 2 Acalabrutinib-Venetoclax (AV) tri...   \n",
              "2             1stOncology  #NICE backs #AstraZenecas #Calquence for #CLL ...   \n",
              "3               Toby Eyre  #acalabrutinib is a valuable option in pts int...   \n",
              "4            Lymphoma Hub  NICE has recommended the use of acalabrutinib ...   \n",
              "...                   ...                                                ...   \n",
              "43342  Joy is a Lifestyle  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹  Hanging out with Friends! :) #FF #CLL #Happine...   \n",
              "43344               IQWiG  Zusatznutzen von #Idelalisib ist weder für #CL...   \n",
              "43345           Medibooks  #Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...   \n",
              "43346           Medibooks  #Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...   \n",
              "\n",
              "                                             clean_tweet  \\\n",
              "0      ['phase study acalabrutinib patients', 'refrac...   \n",
              "1      ['phase acalabrutinib venetoclax trial', 'recr...   \n",
              "2                                      ['backs lpdogra']   \n",
              "3      ['valuable option pts intolerant', 'valuable d...   \n",
              "4      ['acalabrutinib patients treatment chronic lym...   \n",
              "...                                                  ...   \n",
              "43342                        ['friends http pdleww bbb']   \n",
              "43343                         ['friends http gynchdnul']   \n",
              "43344  ['zusatznutzen von ist weder noch refrakt res ...   \n",
              "43345  ['ptk expression immunochemotherapy outcome ch...   \n",
              "43346  ['mutations tlr myd pathway identify subset', ...   \n",
              "\n",
              "                                                entities  Polarity Score  \\\n",
              "0      [phase study acalabrutinib patients, refractor...          0.0000   \n",
              "1      [phase acalabrutinib venetoclax trial, recruit...          0.0000   \n",
              "2                                        [backs lpdogra]         -0.0516   \n",
              "3      [valuable option pts intolerant, valuable data...          0.4767   \n",
              "4      [acalabrutinib patients treatment chronic lymp...          0.0000   \n",
              "...                                                  ...             ...   \n",
              "43342                          [friends http pdleww bbb]          0.4767   \n",
              "43343                           [friends http gynchdnul]          0.4767   \n",
              "43344  [zusatznutzen von ist weder noch refrakt res f...          0.0000   \n",
              "43345  [ptk expression immunochemotherapy outcome chr...          0.0000   \n",
              "43346  [mutations tlr myd pathway identify subset, yo...          0.0000   \n",
              "\n",
              "       Neutral Score  Negative Score  Positive Score overall polarity  \n",
              "0              1.000           0.000           0.000          Neutral  \n",
              "1              1.000           0.000           0.000          Neutral  \n",
              "2              0.455           0.545           0.000         Negative  \n",
              "3              0.693           0.000           0.307         Positive  \n",
              "4              1.000           0.000           0.000          Neutral  \n",
              "...              ...             ...             ...              ...  \n",
              "43342          0.492           0.000           0.508         Positive  \n",
              "43343          0.392           0.000           0.608         Positive  \n",
              "43344          1.000           0.000           0.000          Neutral  \n",
              "43345          1.000           0.000           0.000          Neutral  \n",
              "43346          1.000           0.000           0.000          Neutral  \n",
              "\n",
              "[43347 rows x 9 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-06abc955-6761-42aa-ad58-8b26e0c561d3\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>tweet_text</th>\n",
              "      <th>clean_tweet</th>\n",
              "      <th>entities</th>\n",
              "      <th>Polarity Score</th>\n",
              "      <th>Neutral Score</th>\n",
              "      <th>Negative Score</th>\n",
              "      <th>Positive Score</th>\n",
              "      <th>overall polarity</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>⚕️ Scientists conducted a Phase II study of ac...</td>\n",
              "      <td>['phase study acalabrutinib patients', 'refrac...</td>\n",
              "      <td>[phase study acalabrutinib patients, refractor...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>This phase 2 Acalabrutinib-Venetoclax (AV) tri...</td>\n",
              "      <td>['phase acalabrutinib venetoclax trial', 'recr...</td>\n",
              "      <td>[phase acalabrutinib venetoclax trial, recruit...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>#NICE backs #AstraZenecas #Calquence for #CLL ...</td>\n",
              "      <td>['backs lpdogra']</td>\n",
              "      <td>[backs lpdogra]</td>\n",
              "      <td>-0.0516</td>\n",
              "      <td>0.455</td>\n",
              "      <td>0.545</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Negative</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>#acalabrutinib is a valuable option in pts int...</td>\n",
              "      <td>['valuable option pts intolerant', 'valuable d...</td>\n",
              "      <td>[valuable option pts intolerant, valuable data...</td>\n",
              "      <td>0.4767</td>\n",
              "      <td>0.693</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.307</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>NICE has recommended the use of acalabrutinib ...</td>\n",
              "      <td>['acalabrutinib patients treatment chronic lym...</td>\n",
              "      <td>[acalabrutinib patients treatment chronic lymp...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>['friends http pdleww bbb']</td>\n",
              "      <td>[friends http pdleww bbb]</td>\n",
              "      <td>0.4767</td>\n",
              "      <td>0.492</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.508</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Hanging out with Friends! :) #FF #CLL #Happine...</td>\n",
              "      <td>['friends http gynchdnul']</td>\n",
              "      <td>[friends http gynchdnul]</td>\n",
              "      <td>0.4767</td>\n",
              "      <td>0.392</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.608</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Zusatznutzen von #Idelalisib ist weder für #CL...</td>\n",
              "      <td>['zusatznutzen von ist weder noch refrakt res ...</td>\n",
              "      <td>[zusatznutzen von ist weder noch refrakt res f...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología PTK2 EXPRESSION AND IMMUNOCHEMOTH...</td>\n",
              "      <td>['ptk expression immunochemotherapy outcome ch...</td>\n",
              "      <td>[ptk expression immunochemotherapy outcome chr...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>#Hematología MUTATIONS IN TLR/MYD88 PATHWAY ID...</td>\n",
              "      <td>['mutations tlr myd pathway identify subset', ...</td>\n",
              "      <td>[mutations tlr myd pathway identify subset, yo...</td>\n",
              "      <td>0.0000</td>\n",
              "      <td>1.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>0.000</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 9 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-06abc955-6761-42aa-ad58-8b26e0c561d3')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-06abc955-6761-42aa-ad58-8b26e0c561d3 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-06abc955-6761-42aa-ad58-8b26e0c561d3');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 40
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Dropping the excess columns\n",
        "df2=df2.drop(['tweet_text',\t'clean_tweet',\t'Polarity Score',\t'Neutral Score',\t'Negative Score',\t'Positive Score'], axis=1)"
      ],
      "metadata": {
        "id": "yv5R_2mBI51i"
      },
      "execution_count": 41,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Making the entites along with author sentiments on it as a list\n",
        "df2['entities'] = [','.join([''.join(y) for y in x]) for x in data['entities']]"
      ],
      "metadata": {
        "id": "7kas-TLeI9ai"
      },
      "execution_count": 42,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df2"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "Rd-ez94ZI_3i",
        "outputId": "be24ea1c-8235-4b73-a761-03443ea65b3d"
      },
      "execution_count": 43,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "             tweet_author                                           entities  \\\n",
              "0      Hematopoiesis News  phase study acalabrutinib patients,refractory ...   \n",
              "1        Michael Wang, MD  phase acalabrutinib venetoclax trial,recruitme...   \n",
              "2             1stOncology                                      backs lpdogra   \n",
              "3               Toby Eyre  valuable option pts intolerant,valuable data,d...   \n",
              "4            Lymphoma Hub  acalabrutinib patients treatment chronic lymph...   \n",
              "...                   ...                                                ...   \n",
              "43342  Joy is a Lifestyle                            friends http pdleww bbb   \n",
              "43343       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹                             friends http gynchdnul   \n",
              "43344               IQWiG  zusatznutzen von ist weder noch refrakt res fo...   \n",
              "43345           Medibooks  ptk expression immunochemotherapy outcome chro...   \n",
              "43346           Medibooks  mutations tlr myd pathway identify subset,youn...   \n",
              "\n",
              "      overall polarity  \n",
              "0              Neutral  \n",
              "1              Neutral  \n",
              "2             Negative  \n",
              "3             Positive  \n",
              "4              Neutral  \n",
              "...                ...  \n",
              "43342         Positive  \n",
              "43343         Positive  \n",
              "43344          Neutral  \n",
              "43345          Neutral  \n",
              "43346          Neutral  \n",
              "\n",
              "[43347 rows x 3 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-7aa4d129-f403-4774-9db8-e7061808de67\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>tweet_author</th>\n",
              "      <th>entities</th>\n",
              "      <th>overall polarity</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>phase study acalabrutinib patients,refractory ...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>phase acalabrutinib venetoclax trial,recruitme...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1stOncology</td>\n",
              "      <td>backs lpdogra</td>\n",
              "      <td>Negative</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>valuable option pts intolerant,valuable data,d...</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>acalabrutinib patients treatment chronic lymph...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>friends http pdleww bbb</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>friends http gynchdnul</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>IQWiG</td>\n",
              "      <td>zusatznutzen von ist weder noch refrakt res fo...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>ptk expression immunochemotherapy outcome chro...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>Medibooks</td>\n",
              "      <td>mutations tlr myd pathway identify subset,youn...</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 3 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-7aa4d129-f403-4774-9db8-e7061808de67')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-7aa4d129-f403-4774-9db8-e7061808de67 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-7aa4d129-f403-4774-9db8-e7061808de67');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 43
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Changing the format \n",
        "df2=df2[['entities','tweet_author','overall polarity']]\n",
        "     "
      ],
      "metadata": {
        "id": "_AS2Tdq8JDvy"
      },
      "execution_count": 44,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df2.rename(columns = {'entities':'entity','tweet_author':'author'}, inplace = True)\n"
      ],
      "metadata": {
        "id": "Q_eTClh8JIMy"
      },
      "execution_count": 45,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df2"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "TH3_Ft-RJLnx",
        "outputId": "1d44bd5d-bb49-40aa-f749-a4ef5b68c093"
      },
      "execution_count": 46,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                  entity              author  \\\n",
              "0      phase study acalabrutinib patients,refractory ...  Hematopoiesis News   \n",
              "1      phase acalabrutinib venetoclax trial,recruitme...    Michael Wang, MD   \n",
              "2                                          backs lpdogra         1stOncology   \n",
              "3      valuable option pts intolerant,valuable data,d...           Toby Eyre   \n",
              "4      acalabrutinib patients treatment chronic lymph...        Lymphoma Hub   \n",
              "...                                                  ...                 ...   \n",
              "43342                            friends http pdleww bbb  Joy is a Lifestyle   \n",
              "43343                             friends http gynchdnul       𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹   \n",
              "43344  zusatznutzen von ist weder noch refrakt res fo...               IQWiG   \n",
              "43345  ptk expression immunochemotherapy outcome chro...           Medibooks   \n",
              "43346  mutations tlr myd pathway identify subset,youn...           Medibooks   \n",
              "\n",
              "      overall polarity  \n",
              "0              Neutral  \n",
              "1              Neutral  \n",
              "2             Negative  \n",
              "3             Positive  \n",
              "4              Neutral  \n",
              "...                ...  \n",
              "43342         Positive  \n",
              "43343         Positive  \n",
              "43344          Neutral  \n",
              "43345          Neutral  \n",
              "43346          Neutral  \n",
              "\n",
              "[43347 rows x 3 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-fd59f8f7-643b-48d2-bb8f-c2d441532fc8\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity</th>\n",
              "      <th>author</th>\n",
              "      <th>overall polarity</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>phase study acalabrutinib patients,refractory ...</td>\n",
              "      <td>Hematopoiesis News</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>phase acalabrutinib venetoclax trial,recruitme...</td>\n",
              "      <td>Michael Wang, MD</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>backs lpdogra</td>\n",
              "      <td>1stOncology</td>\n",
              "      <td>Negative</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>valuable option pts intolerant,valuable data,d...</td>\n",
              "      <td>Toby Eyre</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>acalabrutinib patients treatment chronic lymph...</td>\n",
              "      <td>Lymphoma Hub</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43342</th>\n",
              "      <td>friends http pdleww bbb</td>\n",
              "      <td>Joy is a Lifestyle</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43343</th>\n",
              "      <td>friends http gynchdnul</td>\n",
              "      <td>𝓒𝓻𝓲𝔃𝔃𝔂 𝓟𝓮𝓻𝓻𝔂🌹</td>\n",
              "      <td>Positive</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43344</th>\n",
              "      <td>zusatznutzen von ist weder noch refrakt res fo...</td>\n",
              "      <td>IQWiG</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43345</th>\n",
              "      <td>ptk expression immunochemotherapy outcome chro...</td>\n",
              "      <td>Medibooks</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43346</th>\n",
              "      <td>mutations tlr myd pathway identify subset,youn...</td>\n",
              "      <td>Medibooks</td>\n",
              "      <td>Neutral</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>43347 rows × 3 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-fd59f8f7-643b-48d2-bb8f-c2d441532fc8')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-fd59f8f7-643b-48d2-bb8f-c2d441532fc8 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-fd59f8f7-643b-48d2-bb8f-c2d441532fc8');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 46
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df2.to_csv(\"Objective2.csv\")\n"
      ],
      "metadata": {
        "id": "sz6zIa3yJNXS"
      },
      "execution_count": 47,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "IWkRLlH8JT8S"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}